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INTRODUCTION
 INTRODUCTION 
Siddha is a holistic medical system that gives importance to mental as well as 
physical well beings of a patient. The word siddha means "established truth". The word 
siddha comes from the word siddhi that means an object to be attained such as 
perfection in life or heavenly bliss. 
           Medicine is all about preventing and treating ailments thus postponing death. As 
interesting aspect of siddha medicine is its view about death. Thirumoolar defines the 
ailment of the body and mind as diseases. In the same breath he defines death as disease 
and hence could be prevented. 
     "¯¼õÀ¡ø «Æ¢Â¢ü ¯Â¢Ã¡ ÄÆ¢Å÷
     ¾¢¼õÀ¼ ¦Áö»¡Éõ §ºÃ×õ Á¡ð¼¡÷
     ¯¼õ¨À ÅÇ÷ìÌõ ¯À¡Âõ «È¢ó§¾
     ¯¼õ¨À ÅÇ÷ò§¾ý ¯Â¢÷ ÅÇ÷ò§¾§É". 
                                                                         
-   ¾¢ÕãÄ÷.
           Siddhars not only defines death as disease, but they also earnestly tried to 
prevent death by advocating life style modification and developing new drugs. Siddha 
drugs are derived from natural sources such as plants, animals and minerals. Plant drugs 
are its mainstay. The standing instruction of siddhars to medical practitioners is to use 
herbal drugs first in any ailment, if herbal drugs are ineffective then only advised to go 
herbomineral preparations.    
          "«ñ¼ò¾¢ÖûÇ§¾ À¢ñ¼õ 
           À¢ñ¼ò¾¢ÖûÇ§¾ «ñ¼õ." 
                         
           "What exists in the world exists in Man". Siddha propounds that the physical 
structures of the universe and man are basically made up of same stuff, namely five 
elements. They are nilam (earth), neer (water), thee (fire), kaatru (air) and vin (sky). 
These five elements are present in different proportions in all living and nonliving 
things including drugs and diet articles. Various tissues of the body are the combination 
of these five elements in different proportions. 
           The physical function of the body is mediated and maintained by three forces. 
They are vali, Azhal and iyam. In normal state they are called three forces or three 
thathu that sustain and nourish the body. In disease state when the three forces are 
vitiated they are called mukkutrams. When these three forces are in balance one is 
healthy. When vitiated singly or combination bring about disease. 
           Seven pillars or fundamental tissues called thathus supporting every living body. 
When the three forces are vitiated the tissues, disease will occur.  
           Various siddhars classified disease, one of is Yugi munivar. Yugi munivar 
classifies disease based on clinical signs and symptoms along with humoral pathology. 
Yugi classified vatha diseases in to 80 types in "Yugivaithiya chinthamani". Uthiravatha 
suronithan is one of them.  
           The disease Uthiravatha suronitham has a very close relevance to Rheumatoid 
arthritis. The disease Uthiravatha suronitham involving multiple system of the body 
especially musculoskeletal system affected first and then other systems are affected 
depends upon their immunology.  Single and herbal drug therapies are not much useful 
to cure the disease. So only the author selected herbomineral drug for internal medicine. 
           
Anupoga vaithiya navaneetham said that the Rasapralaya chenthuram is good 
for vatha diseases and Theraiyar thylavarukka surukkam describes the Navanatha 
siddhar thylam is useful to reduce inflammatory conditions of vatha diseases. The 
principle drugs Rasapralaya chenthuram which is useful in chronic musculoskeletal 
disorder and Navanatha siddhar thylam is an external application reducing 
inflammatory condition because of its contents has effective anti-inflammatory action.  
           All the above drugs are found very effective in Uthiravatha suronitham, which I 
selected for dissertation. This is a small effort on my part in this regard. Further, study 
in this regard has to be continued in the course of time with Almighty’grace. 
AIM AND OBJECTIVES 
AIM AND OBJECTIVES 
          The knowledge of preserving one’s health sound and thus prolonging life is said 
to have descended in this modern technological world.  The prolonged and uncertain 
course of the disease “Udhira Vatha Suronitham” calls for special emphasis and 
intended the author to bring an ideal treatment for the disease.  
       Medicine, as everyone knows is not a mere science, but is an art as well. It is the 
only want of men with such knowledge of science and its practical practice with 
efficacious cures on hand. 
x The principal aim of the present study is to estimate the efficacy of the siddha 
drugs Rasapralaya chenthuram and Navanatha siddhar thylam.
x To ensue a new approach in diagnosis for the disease. 
x To know whether the drug has any side- effects or not. 
OBJECTIVES: 
@ The main objective of the present study is to create awareness about the siddha 
sciences and to highlight the efficacy of siddha drugs among the public. 
@ To collect various informations about “Uthiravatha Suronitham” and to expound 
the characteristics of etiology, premonitory symptoms, signs and pathogenesis 
based on both siddha and modern aspects. 
@ To access the prevalence of the disease with reference to age, sex, diet habits, 
socio economic status, family history etc. 
@ To highlight the siddha diagnostic principles in diagnosing the disease. 
@ To conduct a thorough study on Uthiravatha suronitham with Rheumatoid 
arthritis. 
@  To make a clinical trial with necessary investigations. 
@ To have a complete study of the disease Uthiravatha suronitham, under the 
headings of  
 (a) Pori Pulangal   (b) Mukkutram  
 (c) Udal Kattugal           (d) Ennvagai thervugal  etc. 
@ To evaluate the pharmacological study on the trial drug. 
@ To study the bio-chemical and chemical analysis on the trial drug.  
@ To evaluate the efficacy of the trial medicine on Antimicrobial activity by in 
vitro studies. 
@ To conduct a clinical trial with a well defined proforma on identified patients of 
Uthiravathasuronitham. 
REVIEW
OF
LITERATURE
SIDDHA ASPECT 
SIDDHA ASPECT 
          The things exist in the universe also exist in the human beings. Any adverse 
changes of these two, even a minute change will be reflecting on the other.  
           In siddha system of medicine, the physiological function in human system is 
mediated by three substances viz, Vatham (vali + veli), Pitham (thee), Kabham (neer + 
man). These three humors maintain the upkeep of the human body through their 
combined functioning. When deranged, they bring about diseases peculiar to their 
influence. Uthiravatha suronitham the disease taken for study is one of the vatha 
diseases described by Yugi vaithya chinthamani. 
DEFINITION OF VATHAM:
           Vatham is a clinical condition characterized by pain, swelling, pricking sensation 
and loss of function due to vitiated vatha, which is the principle humour of the body. 
‘nghw;wh kiuahd; Gidnka; auz;fhf;Fk; 
 nghw;wh kiuahd; Gfy;tnjd;  nghw;whk; 
 tstpdpNy ahf;Fuk;ig kd;ndd;d kd;d 
 tstpdpNy ahf;Fk; tsp.”
                  - Njiuah; akf ntz;gh. 
Vatham is being hailed as the king, who rules the fort (Body) and enables the 
dwelling of the citizen (Uyir) in the fort.  Hence Theraiyar lauds Vatham as the prime 
force in normal state. 
AETIOLOGY: (Neha; tUk;top)
According to Yugi Vaidhya chinthamani the disease is caused by various factors. 
'vd;dNt thjk;jh ndz;gjhFk; 
 ,fj;jpNy kdpjh;fSf; nfa;AkhW 
gpd;dNt nghd;jidNa NrhuQ; nra;J
 nghpNahh;fs; gpuhkziu J~dpj;Jk;  
td;dNj tw;nrhj;jp NrhuQ; nra;J 
 khjh gpjh FUit kwe;j Ngh;f;Fk; 
fd;dNt Ntjj;ij epe;ij nra;jhy; 
 fhaj;jpw; fye;jpLNk thje; jhNd 
jhd; vd;w frg;NghL Jth;g;G iwg;G 
 rhjfkha; neQ;RfpDQ; rikj;j tz;zk; 
Mdd;w thwpdJ nghrpj;jyhYk; 
 Mfhaj; NjwsJ Fbj;j yhYk; 
ghndd;w gfYf;f kpuh tpopg;G 
 gl;bdpNa kpftWjy; ghunka;jy; 
Njndd;w nkhopahh; Nkw; rpe;ij ahjy; 
 rPf;fpukha; thjkJ nrdpf;Fk; jhNd." 
 - A+fp itj;jpa rpe;jhkzp. 
          Excessive sexual indulgence, over consumption of bitter, astringent and salty-
tasted foods, alcoholism, and daytime sleep, night time over work, starvation and lifting 
over weight will aggravates Vatham.
Pararasasekaram describes the factors for vitiation of vatham: 
'njhopy; ngW ifg;G fhh;j;jy; Jth;j;jy; tpQ;RfpDQ; NrhWk; 
gioajhk; tuF kw;iwa ige;jpid aUe;jpdhYk; 
vopy;ngwg; gfYwq;fp ,utpdp Ywq;fhjjhYk; 
kio epfh; FoypdhNs thjk; Nfhgpf;Fk; fhNz." 
            Consumption of excessive bitters, astringents, salty tasted foods, rancid foods, 
Daytime sleep and lacking of night sleep vitiates Vatham. 
According to Sabapathy Kaiyedu: 
\tspjU fha;fp oq;F 
tiutpyh japyy; Nfhio 
Gspjaph; Nghd;kp Ff;F 
Kiwapyh mz;b Nfly; 
Fsph;jU Kaf;fk; ngw;Nwhh; 
fbnray; fUtpahkhy;.|| 
tspf;Fw;wj;ijj; J}z;Lk; czTfshfpa thiof;fha;> fpoq;F> Gsp> japh;> 
Nghd;wtw;iw mjpfkhf cz;gjhYk; Fsphpy; cyty;> ngz;bh; kaf;fk; 
Kjypatw;whYk; thjNeha; tUk;. 
thjk; th;j;jpf;Fk; fhyk;: 
\thjth;j; jidfhy NkNjh ntd;dpy; 
kUTfpd;w Mdpfw; flf khFk; 
Mjitg; grpNahL fhh;j;jpif jd;dpy; 
mlUNk kw;wkh jq;f ld;dpy; 
NghjNt rkpf;fpd;w fhy khFk|;. 
  tspf;Fw;wk; Mdp> Mbapy; jd;dpiy tsh;r;rpAk;> Ig;grp fhh;j;jpifapy; 
gpuNfhgKk; milAk;. kw;w khjq;fspy; jd;dpiy milAk;. 
Mbahjp aha; Ig;grp <wha; 
mdpykjw; Nfhuurpay; fhyk.;| 
~flfKjy; Jyhk; tiuapy; thjkhFk; 
fz;zhb iag;grpA kJNt ahFk;.| 
                                 - rjfehb. 
CHARACTERISTICS OF VATHA DISEASE: 
'thjtPW md;dkpwq;fhJ fLg;Gz;lhk; tz;zKz;lhk; 
NkhJfl;L Nuhfk; RuKz;lh kpUkYkh Kwq;fhnjd;Wk; 
XJ#hpa thj kdyhF eLf;f Kz;lhk; nghUs;fsha;j; 
jPjdNt euk;gprpj;J re;Jfs; NjhWq; fLf;Fe; jpdKk;jhNd" 
                                       - Njud;thflk.; 
           Loss of appetite, pain and redness, fever, cough, insomnia, shivering and pain in 
all over the joints. 
're;jputhjKld; Fsph;e;njOe;Nj eLf;Fe; rPjtha;thk; 
Ke;jpa Fj;jp rpthe; re;Jfs; NjhWk; File;J nkhspfs; tPq;Fk; 
te;jpa njhe;jthjk; tPf;f Kz;lh Klypw;wp uz;lhNk" 
- Njud;thflk;. 
           Chillness of the body, rigor, spasm, pain and tenderness over the joints and 
swelling of the joints. 
"fhzg;gh thjkPwpy; fhy;iffs; ngUj;J NehTk; 
G+zg;gh Fly; Gul;Lk; kyryk; nghUkpf;  fl;Lk; 
Czg;gh FspUq; fha;r;ry; clk;ngy;yhk; Fj;J tha;T 
tPzg;gh FjkpWf;Fk; tpah;itAk; Nth;f;Fk; jhNd."    
                    - mfj;jpah; itj;jpa fhtpak; 1500. 
"Nktpa thjQ; nra;Ak; Fze;jid tpsk;gf; Nfsha; 
jhtpNa tapW ke;jQ; re;Jfs; nghUe;J NehthQ; 
rPtpa jhJ ehrQ; nrWj;Jld; rpWePh; tPOq; 
fhtpaq; fz;zpdhNs kykJ fUfp tPOk;”.
                               - mfj;jpah; MAs; Ntjk;. 
"vwpa ey;thj nkwpf;Fq; Fzq;NfS 
Fwpnad iffhy; Fisr;R tpyhr;re;J 
gwpnad nehe;Jlw; gr;irg; Gz;zhFNk 
Gz;zha; typf;Fk; ngUFk; FlNyhbj; 
jz;zh kyj;ijj; jk;gpf;Fk; Nghf;fhJ 
xz;zhd Mrdk;  cwNt ruf;fpLk; 
gz;zhh; Fsph;rPjk; gUj;jpLk; thjNk”.
                            - jpU%yh; itj;jparhuk;. 
‘thjk; te;Jw;w NghJ tapwJ nghUkpf; nfhs;Sk;
 jhjtpo;e;jpLg;G iffhy; re;Jfs; fLg;Gj; Njhd;Wk; 
 rPnjhU kyK ePUe; rpWj;jJld; fLj;J tpo 
 khjtkiu Nky; te;j thjj;jpd; FzkpjhNk.”
      - A+fp Kdpth; ngUE}y; itj;jpa fhtpak; 1000. 
           From the above poetic versions, it is clear that the major characters of vatha 
diseases are joint pain, swelling present over the joints, difficulty in walking, 
constipation, burning micturition, oliguria, dyspnoea, flatulence, fever, fatigue, 
giddiness and nerve weakness etc. 
SURONITHA NOI: 
     RNuhzpj Neha; vd;gjw;F T.V. rhk;grptk;gps;is mth;fs; khjtplha; 
rk;ge;jkhf Vw;gLk; Neha; vd;W $wpAs;shh;. 
           Suronitha Vatham is a disorder of menstruation in women characterized by 
affection in chest and limbs, extreme sensibility to pain, dryness in the skin, pain in 
nerves accompanied by intense bodily pain. 
VATHA SURONITHAM:
Yugi Vaidhya Chinthamani classified Vatha suronitham into 7 types. They are: 
1. Vatha Suronitham 
2. Uthiravatha Suronitham 
3. Sithuvatha Suronitham 
4. Vaikithavatha Suronitham 
5. Paithiyavatha Suronitham 
6. Slethuma vatha Suronitham 
7. Udharavatha Suronitham 
1. VATHA SURONITHAM: 
'mwpe;jpl;l mq;fnky;yh nkypT khfp 
mirthd jt;tplq;fs; tPf;fkhfp 
ewpe;jplp;l eilnfhlh jhdpUj;jy; 
typahfp nkhop nkhopa tPf;fkhfr; 
nrhwpe;jpl;l Njfnkq;F kirT fhzy; 
Nrhw;wpd;Nky; dpidtpd;wpj; J}f;fkhjy; 
twpe;jpl;l thajdp dPh;jh D}wy; 
thj RNuhzpjj; jhYk; tFj;j thNu" 
Emaciation, swelling of joints, restricted movement, pain, tenderness, 
discomfort, loss of appetite and excessive salivation. 
2. UTHIRAVATHA SURONITHAM: 
'itfpjkha;f; fizf;fhY Koq;fhy; jhDk; 
kw;flQ; re;J Gw tbAk; tPq;fpr; 
nra;fpjkha; rpWtpuy;fs; kpfTk; nehe;J 
rpe;ij jLkhwpNa rypg;Gz;lhFk; 
igfpjkhk; gapj;jpaj; jpy;yhj kpQ;rpg; 
ghukha; cw;gtpj;J moYz;lhFk; 
ca;fpjkhk; mrdkJ jhDk; Ntz;lh 
cjputhjr; RNuhzpjj;jp Dzh;r;rpahNk" 
           
  Pain and swelling in ankle joints, knee joints and all small joints of the hands 
and toes. 
3. PAITHIYAVATHA SURONITHAM: 
'czh;r;rpaha;r; RNuhzpje;jhd; kpfnt Jk;gp 
Cf;fkha;j; Njfnkq;F kpfNt nehe;J 
Kzh;r;rpaha; Koq;fhy;fs; Koq;if nahf;f 
Kidahd rpWtpuy;fs; fd;dk; new;wp 
jzh;r;rpaha;r; re;JrU thq;f nkq;Fk; 
jhl;bf kha;f;File;J RuK Kz;lhk; 
gzhr;rpaha;g; ghz;lJNghd; Nkdp ahFk; 
gapj;jpath jRNuhzpjj;jpd; gz;G jhNd" 
            Pain in all over the body, pain in elbow joints, knee joints, fingers, cheek, 
forehead, hyper pyrexia, and anemia. 
4. SLETHUMAVATHA SURONITHAM: 
'ghz;ghf Tly;Fsph;e;J VW tPq;fpg; 
gijg;ghd tple;njhl;lhw; ghu Nehthk; 
jpz;ghd rpuRnew;wp Nehf;fh Lz;lhk; 
rpNyl;Lkkha;f; NfhionahL Rthr khFk; 
kz;ghf kaf;fnkhL fdT Kz;lhk; 
tha;tuz;L Urpapy;yh tUj;j khFk; 
ez;ghf ehbANk glg lf;Fk; 
ew;Nrl;g RNuhzpjkhk; ehLq; fhNy" 
            Chillness of the body, headache, cough with dyspnoea, disturbed sleep, dryness 
of the mouth, tastelessness and palpitation. 
5. UTHARAVATHA SURONITHAM: 
'ehLNk Ruk;te;J eLf;f Yz;lhk; 
ehtuz;L jiynehe;J clk; gOe;jp 
thLNk Njfnky;yh kdpr;rk; g+g;Nghy; 
kfhtUj;j Kz;lhfp kaf;f khFk; 
rhLNk abf;fbjhd; Ngjp jhDk; 
jtpf;FNk jz;zPh;jh dhl;l khfpj; 
NjLNk Nrhw;wpd;Nky; epidT jhDk; 
nra;Tju thjRNuh zpje;jh ndd;Nd." 
            Fever with rigor, dryness of the mouth, headache and analgia, giddiness, passing 
loose stools, thirst and excessive appetite. 
6. SITHUVATHA SURONITHAM: 
'thwhd rhPunky;yh jpiwe;J Cjy; 
khrw;w Njhy;jhDk; jpiue;J NghFk; 
ehwhd ehWNghy; euk;G Rf;Fk; 
ehf;Fj;jhd; totoj;Jf; Nfhio ahFk; 
J}whd neUg;Gj;jhd; gl;lhw;Nghy 
nehe;JNk rlnky;yhq; nfhg;g spf;Fk; 
tPwhd Thpe;Jgpd;id ntJk; gPq;Fk; 
kpf;frpj;J thjRNuh zpj khNk" 
           Wrinkled skin, accumulation of phlegm in the throat, vesicles presents all over 
the body, exfoliation and anasarca. 
7. VAIKITHA VATHAM: 
'Mnkd;w tPq;fpdNjhh; tplj;jpy; uj;jk; 
mOj;jkha;j; jpuz;LNk vq;Fk; gha;e;J 
Xnkd;W xl;bNa jpuz;bUf;Fk; 
cWjpaha;j; njhl;LlNd nkj;njd;whFk; 
Njnkd;w Njfnkq; fZK Rf;Fk; 
rPwpaNjh hpUknyhL fha;r;rYz;lhFk; 
ghnkd;w gle;jdpNy jpkpUz; lhFk; 
ghukha; itfpjkhk; thje; jhNd" 
 Swelling, hematomas, cough, hyperpyrexia, numbness in soles and pain in all over the 
body. 
DHANVANTHRI VAITHYAM QUOTES THE CLINICAL FEATURE OF 
SONITHA VATHA ROGAM AS: 
'fhZNk vyptplk; Nghy; fdg;Gld; jbg;Gkhfp 
g+Zlk; GisAk; Fj;Jk; nrhwp fdg;Gld; 
NjhzpUe; Jbg;Gj; Njfk; fps;spdhw; NrhjpaJ 
khdpy Kiyaha; RNuhzpj thjkhNk" 
'ifapdpw; fwz;il jz;zPh; fl;LQ; rijNjhy; tPq;F 
ikaW fUik nrk;ik ngaHj; njwpe;joYk; tPf;fk; 
nka;apidg; gpsf;Fk; thjk; tpahgpf;Fk; clk;gjhf;F 
ikayh; clk;G jk;gpf;Fk; thjRnuhzpj kpnjd;Nd." 
            Pyrexia and swelling of the body as in rat poison intoxication, pain and 
tenderness, twitching of muscles, loss of sensation, swelling of wrist and phalanges, 
black and redness of swelling due to vascular failure and hyperaemia. 
PARARASA SEKARAM CLASSIFIES VATHA SURONITHAM INTO FIVE 
HEADINGS. 
Pararasa Sekaram describes Suronitham as, 
'tpo;ngW RNuhzpje;jhd; kpfTld; nkypTkhfpj; 
jho;tpy; re;JfNs tPq;fpj; jif ngw eil nfhlhky; 
tho;TW ifAq;fhYk; trkpd;wp aod;W Nehthk; 
gho;ngW kzq;fpdhNs gaDwg; gfh;e;Jl;NlhNk" 
           Debility in raktha thathu (anaemia), swelling of peripheral joints, deformed 
movement of joints, pain in upper and lower limbs. 
UTHIRA VATHAM IN PARARASA SEKARAM: 
'gf;fKk; khh;Gk; $lg;gw;wpNa ,Oj;Jf; nfhz;L 
njhf;fpNa khh;gpisj;J Nehjha; euk;gpOj;J 
xf;fNt rapj;jpaq;fs; cah;e;Jld; NkYk; fhyk; 
kpf;FNk cjputhjk; vd;wpJ tpsk;gyhNk" 
           Pain and tenderness of chest and axilla, emaciation, pain and swelling of upper 
and lower limbs. 
            
CLINICAL FEATURES OF VATHASURONITHAM: 
'gfh;e;jpLk; thje; jd;dpw; RNuhzpjk; gfUk; fhiyg;  
GFe;Jlnyq;Fk; nehe;J NghjNt Njhy; jpiue;J 
Gife;jpL neUg;G gl;lhw; NghyNt nfhg;gspj;J 
kpFe;jpl nthpe;J gpd;id ntJk;gpNa tPf;fkhFk;." 
           Pain and tenderness, exfoliation, eruption as in burns and swelling in joints. 
     'tPq;fpa tplj;jpw;jhNd kpfj;jpuz;Nlfp Kl;b 
Mq;fij tpuyhw; njhl;Nl aOj;jpw; nkj;njd;wpUf;Fk; 
Xq;fpa typg;G Kz;lh Klypdpw; fLg;G Kz;lhk; 
Nfhq;nfY KiyapdhNs $wpa Fzq; fNlNu." 
           Soft swelling on touch and pricking nature of pain. 
CLINICAL FEATURES OF SEETHAVATHA SURONITHAM: 
'nrhw;rPj Tjuthj RNuhzpj Koq;fhy; jhDk; 
nghw;fidf; fhYk; re;Jk; Gwtb jhDk; tPq;fp 
ew;NfhZ tpuy;fs; nehe;J eLigj;jpa thjj;jpy; 
cw;gt FzKz;lh %W E}ypy; nrhd;djhNk." 
            Swelling of the knee joint, ankle joint and feet, pain and swelling over the 
phalanges. 
CLINICAL FEATURES OF PAITHIYAVATHA SURONITHAM: 
'nrhd;dNjhh; gapj;jpa thj RNuhzpjk; ntJk;gpr; rhh;e;J 
tpd;dkha; File;J kpd;Nd tpuy;fsp dpiwfnsy;yhk; 
jd;dpfg; nghUe;J NehFQ; re;Jfnsy;yhk; tPq;Fk; 
kd;dpa jiyA nehe;J tphptpop newpAe; Njhd;Wk;." 
           Pain and swelling of the metacarpo phalangeal joints and proximal 
interphalangeal joints and headache. 
CLINICAL FEATURES OF SILETHUMAVATHA SURONITHAM: 
'Nehw;wpa Nrw;gthj RNuhzpj Kly; Fsph;e;Nj 
Vw;wkha; tPq;fpae;j tple;njhl;lhd; kpfr; rpf;nfd;Wk; 
khw;Wwg; nghUe;Jr; rpf;Fk; tphptpop kley;yhNs 
rhw;wpa ey;Nyhh; Ntjj;jpdpDiuj; jpl;lthNu." 
           Chillness of the body, tenderness and swelling of the joints. 
CLINICAL FEATURES OF UTHARAVATHA SURONITHAM: 
'ciungW cjuthj RNuhzpj Kiwf;Fk; fhiyj; 
jiungW thjj;J}w;Nw RNuhzpj FzKk;jf;f 
tphpTW gypj;Jthj RNuhzpjf; FzKkpf;f 
RiungW cjuthj RNuhzpj FzK Kz;lhk;." 
 Vitiation of Vatha aggravates the signs and symptoms of Vatha Suronitham. 
The term suronitha vatha is also mentioned in Aathma Ratchamirtham, Anuboga 
Vaithya deva ragasiyam handled the term Uthiravatha surothinam as Sonitha vatha 
Rogam. 
 Our text book Siddha maruthuvam handle the term Uthiravatha Suronitham as 
Vali Azhal Keelvayu as per Literature Sabhabathi Kaiyedu. 
MUKKUTRA VERUPADUGAL (SIDDHA PATHOLOGY) 
   
   ‘gpzpapDw; gj;jpia NgRtd; gpzpKjy; 
   thjgpj; jq;fg kd; ke;jphp je;jphp 
   tPjkh Alyuz; nka;k;Gu tuR nra; 
   Kiw nrAkhjyhd;.”    
                       - Njiuah; fhg;gpak;.  
(thjk; - murd;> gpj;jk; - ke;jphp> fgk; - Nrdhjpgjp) 
            Which highlights that the main factor in the causation of the disease  
are vatham, pitham and kabham. 
VATHAM: 
 Vatham is the prime force that impacts movement to every living cell in the 
body.  Its dwelling place lies in the bones, muscles, nerves, joints etc.  Hence it is 
responsible for the movement of parts involved in locomotor system.  When vatham is 
affected, the other two pitham and kabham also gets deranged and in turn, they vitiates 
the other structural and functional elements of the living body called seven Udal 
thathus. 
¾ Viyaanan which is responsible for the voluntary and involuntary movements 
and nutrition of the tissue gets affected leading to restriction of movements and 
lassitude. 
¾ Samaanan which neutralizes other vitiated vayus gets affected. Further it is 
needed for normal digestion. So derangement of this vayu produces loss of 
appetite and indigestion. 
¾ Involvement of Abaana Vayu also plays a main role in the manifestation of 
signs and symptoms.  Abaanan which is responsible for distribution and 
assimilation of nutritional factors gets affected leading to symptoms like 
constipation. 
¾ Kirukaran and Thevathathan are also affected because of loss of appetite and 
sleeplessness respectively. 
PITHAM: 
The main function of pitham which represents agni is thermogenesis or heat 
production, metabolism within its limits, process of digestion etc.  Its vitiation 
produces inflammatory changes in joints.  Among the five types of Pitham, the 
following four types get affected in Udhiravatha Suronitham. 
¾ Ranjaga pitham which gives colour to blood.  
¾ Saathaga pitham which is needed to carry out normal activities. 
¾ In few, Anal pitham which is needed for digestion gets affected leading to 
anorexia. 
¾ Prasaga pitham which gives complexion to skin gets affected leading to pallor 
of skin. 
KABAM: 
 The detoriation of the two main kuttram accompany the Kabha kutram whose 
structure is Earth + Water and is concerned with the maintenance of smooth working of 
joints, integration of structural elements of the body into stable structures etc.   
¾ Santhiga kabham which is needed for normal maintenance of synovial fluid 
gets affected.   
¾ Avalambagam which forms the basis for all the other four types of Kabham 
gets affected.  
¾ In few, Kilethagam gets affected leading to loss of appetite. 
Thus disturbance in Mukkutram produces, 
¾ Pain, swelling of joints, joint stiffness, restriction of movements, loss of appetite 
and sleeplessness and constipation due to vatham. 
¾ Inflammatory changes in joints like redness, warmth, loss of appetite and 
anemia due to pitham. 
¾ Erosion of bony margin, osteoporotic changes, increases in the synovial fluid are 
due to disturbed kabham. 
UDALTHATHUKKAL: 
           Disturbances in vatham, pitham and kabham gets reflected on Udal thathus 
leading to change in normalcy of body or predisposition to causing disease.  The seven 
udal thathus that supports the body in their state of equilibrium are as follows. 
1. Saaram  -  Strengthens the body and mind. 
2. Senneer  -  Gives power, knowledge and boldness to the  
                                                mankind. 
3. Oon              -  It gives structure and shape to the body and is  
                                                responsible for movements of the body. 
4. Kozhuppu              -  It lubricates the joints and organs and facilitates  
                                                their functions. 
5. Enbu  -  It protects all the internal organs and forms   
                                                structural framework of the body. 
6. Moolai  -  Resides inside the core of bones.  It strengthens  
                                                and maintains the normal condition of bones. 
7. Sukkilam/  -  Meant for reproduction (Male and Female   
   Suronitham                 respectively). 
In Uthiravatha suronitham, the affected Udal thathus are, 
¾ Saaram            -  Loss of appetite, lassitude. 
¾ Senneer -  Anaemia, presence of RA factor). 
¾ Oon   -  Muscle wasting, swelling. 
¾ Kozhuppu -  Emaciation, restriction of joint movements. 
¾ Enbu  -  Vague pain and swelling of joints and deformity of joints. 
                                                                             DIFFERENTIAL DIAGNOSIS:
             Yugi Munivar in his “Yugi Vaidhya Cinthamani” mentioned about 80 types of 
Vatha diseases.  Among them, the following diseases have joint pain as main clinical 
feature.
1. Oorusthamba vatham. 
2. Malaithakamba vatham. 
3. Santhu vatham. 
4. Paithiya vatha suronitham. 
5. Vatha suronitham. 
1. CU];jk;g thjk; (Oorusthamba vatham):
‘Mnkd;w thjkJ cs;s lq;fp 
  mbj;Jiljhd; Fwq;fpuz;L kstha;g; gw;wpf; 
fhnkd;w iffhypy; tpuYQ; Rw;wpf; 
  fdj;JNk rhzpaJ nghjpe;jhw; Nghyj; 
Njnkd;w rpue;jdpNy ghu Kz;lha;j; 
  Njfnkq;F %jpNa jpkpUz;lhFk; 
ehnkd;w elf;nfhzh nthLf;f khfp 
  eypA+Uj; jk;gkJ eZFq; fhNz.”
            Pain in both the thighs, swelling of fingers and toes, numbness, generalized 
edema of the body and inability to walk are the symptoms of this disease. 
2. kiyj;jfk;g thjk; (Malaithakamba vatham)
‘Fk;gkhq; ifapd;kzpf; fl;L jd;dpw; 
  Ftpe;jiuapy; nkhj;ijNgh Yuj;Jf; fhZe; 
Jk;gkh kq;fq;fs; Jbg;g jhFe; 
  Jtz;LNk fhy; ifA eLf;f khFk; 
mk;gkh kiuf;Ff;fPo; jpkpUz; lhFk; 
  mjuNk kpff;fWj;J ntbg;Gz; lhFk; 
tk;gkhk; thAe;jhd; gupA ehw;wk; 
  tUkiyj;j fk;gj;jpd; khh;f;fkhNk.”
 Congestion of wrist joint, twitching, tremors in upper and lower extremities, 
numbness below the hip joint, fissured lips and passing foul flatus will be seen. 
3. re;J thjk; (Santhu vatham):
‘nra;ifjhd; re;JfS kpfj; jpkpu;e;J  
  rlnkq;F nehe;JNk kpft ow;wp 
ieifaha; eYj;JNk kapu;f; $r;rypl;L 
  ehzpNa Kd;Nghy; eil nfhlhJ 
ikifjhd; kaf;fnkhL tha;ePUWk; 
  tuz;bLNk ehTjh dbf;f bf;Ff; 
iffhy;jhd; juzpjdpw; wupf; nfhzhJ 
  rQ;rupf;FQ; re;Jthk; thjq; NfNs.”
 Pain in joints, body pain, pilo erection, inability to walk, giddiness, dryness of 
the tongue, excessive salivation and unable to keep the limbs in floor are the features of 
this disease. 
4. gapj;jpathj RNuhzpjk; (Paithyavatha suronitham)
‘czu;r;rpaha;r; RNuhzpje;jhd; kpfnt Jk;gp 
  Cf;fkha;j; Njfnkq;F kpfNt nehe;J 
Kzu;r;rpaha; Koq;fhy;fs; Koq;if nahf;f 
  Kidahd rpWtpuy;fs; fd;dk; new;wp 
jzu;r;rpaha;r; re;JrU thq;f nkq;Fk; 
  jhl;bf kha;f;File;J RuK Kz;lhk; 
gzu;r;rpaha; ghz;lJNghy; Nkdp ahFk; 
  gapj;jpa thjRNuhzpjj;jpd; gz;GjhNd.”
 Generalised body pain, severe pain in the knee joint, elbow joint, minor joints, 
temporo mandibular joint and all other joints, fever and anemia are the features of this 
disease. 
5. thj RNuhzpjk; (Vatha suronitham)
‘mwpe;jpl;l tq;fnkyh nkypTkhfp 
 mirthd jt;tplq;fs; tPf;fkhfp 
 ewpe;jpl;l eilnfhlh jhdp Uj;jy; 
 eypahfp nkhop nkhopa tPf;fkhfr; 
 nrwpe;jpl;L Njfnkq;F kirT fhzy; 
  Nrhw;wpd;Nk dpidtpd;wpj; J}f;fkhjy; 
 mwpe;jpl;l thajdp dPh;jh D}wy; 
 thjRNuh zpje;jhDk; tFj;jthNw.”
Emaciation, swelling in movable joints, inability to walk, tremors, anorexia, 
increased sleep and excessive salivation are the features of this disease. 
                                                   
DIFFERENTIAL DIAGNOSIS (NOI NITHANAM) 
Uthiravatha suronitham is differentiating from other types of vatha suronitham as 
follows: 
S.NO 
        DISEASES 
         SIGNS AND SYMPTOMS 
Uthiravatha suronitham 
x Swelling of ankle joints, hip joints and 
knee joints. 
x Pain and tenderness of minor joints 
especially phalanges. 
x Depression. 
x Loss of appetite. 
x Increased vatha and pitha. 
                                   DIFFERENTIAL DIAGNOSIS 
1. Vatha suronitham 
x Emaciation. 
x Swelling of joints. 
x Restricted movements. 
x Joint pain. 
x Discomfort. 
x Excessive salivation. 
x Loss of appetite. 
2. Sithuvatha suronitham 
x Anasarca. 
x Wrinkles. 
x Neural pain. 
x Glossy tongue. 
x Sialorrhoea. 
x Bullous eruption as in burn. 
x Exfoliation, swelling and warmthness. 
3. Vaikithavatha suronitham 
x Swelling with hyperemia. 
x Soft on touch.  
x Cough with pyrexia. 
x Irritability. 
4. Paithiyavatha suronitham 
x Hyperemia. 
x Tenderness in knee, elbow and smaller 
joints. 
x Poly arthralgia. 
x Pyrexia. 
x Anemia. 
5. Slethumavatha suronitham 
x Chillness with abdominal distension. 
x Severe pain and headache. 
x Syncope and hallucination. 
x Dryness of mouth and anorexia. 
x Tachycardia. 
6. Utharavatha suronitham 
x Fever with rigor. 
x Dryness of mouth. 
x Pain in all over the joints. 
x Headache, Giddiness. 
x Diarrhoea. 
x Excessive thirst. 
x Hungry. 
    
NAADI PATHOLOGY: 
‘jpUj;jkhk; thjj; NjhNl jPq;nfhL gpj;jQ;Nrupy; 
 nghUe;Jfs; NjhWk; nehe;J”.
- Fzthflk; Nehapd; rhuk;. 
            ‘fhzg;gh thjkPwpy; 
 fhy;iffs; nghUe;jp NehFk;.”
- fhtpa ehb. 
Vitiation of vatham and pitham produces joint pain. 
‘thjj;jpd; FzNk jd;dpy; 
tapwJ nghUkpf; nfhs;Sk; 
jhjj;jpy; Nkdp iffhy; 
  re;JNk fLg;G Njhd;Wk.;”
                    - Fwpailahs ehb. 
              Increases vatham results abdominal distension and pain in the joints. 
‘mwpe;Jghh; thjNk jdpj;jjhdhy; 
md;dk; Nghy; elf;Fkg;gh ehbghU 
rupe;jplNt fhy;Klf;Fk; NghJ fhl;Lk;”
                          - mfj;jpah; uj;jpdr; RUf;fk;. 
              Vitiated vatham causes difficulty in walking and impaired functioning of the 
lower extremities. 
 ‘mwpAk;; thjj;jpy; mLj;j gpj;jkhapd;  
  FwpaJjhd; thAk; FoWk; newpahy; 
  FspUq; fhy;tPq;Fk; Fly;Gwl;Lk; tpk;kpj; 
  njsptpy;iy Gj;jpnadr; nrg;G”
                      - fz;Zrhkpak; vd;Dk; itj;jpa Nrfuk;. 
          
 MODERN ASPECT 
MODERNASPECTS
ANATOMY:
           Articulations or Joints are specialized anatomical structures at which the ends of 
certain bones are joined or the borders of other bones are juxtaposed.  These osseous 
junctions are secured by ligaments, fibrous capsule and other binding tissues, which 
restrict movements or permit varying degrees of movements.  Joints vary widely in their 
structure, frequently presenting unique morphological features, adapted to specific 
functional requirements.  
JOINT CLASSIFICATION: 
 Depending on the morphological characteristics of the joints, they are classified into, 
 Fibrous Joints   -  Many of which are immovable and are  
                                                            united by fibrous tissue (synarthroses). 
 Cartilaginous Joints  -  Slightly movable, the union between  
                                                            the bones occurs via cartilage (amphiarthroses). 
 Synovial Joints  -  Freely movable (diarthroses). 
SYNOVIAL JOINTS:
 Synovial Joints are highly evolved articulations which permit free movements. 
Because the human lower limbs are concerned with locomotion and the upper limbs 
provide a great versatility of movements, it is not surprising that most of the joints are 
of the synovial type.  The integrity of synovial joint results from its ligaments and 
capsule which bind the articulation externally and to some extent from the surrounding 
muscles.  The contiguous bony surfaces are covered with hyaline cartilage and the joint 
cavity is surrounded by a fibrous capsule, the inner surface of which is lined by a 
synovial layer containing cells that are thought to secrete the viscous lubricating 
synovial fluid.  
STRUCTURES:
Articular Cartilage firmly adherent to the articular surfaces of majority of bones.  
They are either innervated or supplied with blood vessels. 
Ligaments are composed mainly of bundles of collagenous fibres.  They are pliant and 
flexible to allow perfect freedom of movement.  
Articular Capsule forms a complete envelope for a freely movable joint and consists 
of external fibrous layer and internal synovial layer.  The fibrous layer gets attached to 
the periosteum along the entire circumference of the articular end of each bone.  Its 
flexibility permits movement, yet its strength protects joint from dislocation. 
Synovial Membrane covers the inner surface of the fibrous capsule, forming a closed 
sac called the synovial cavity.  It is composed of loose connective tissue and it has a 
free surface of finger like projection called the Synovial villi.  The synovial cavity 
contains only enough synovial fluid to moisten and lubricates the synovial surface, but 
in an injured or inflamed joint, the fluid may accumulate in painful amounts.  
PHYSIOLOGY OF JOINTS:
 As joint is a very well engineered structure, frictionless motion is provided by 
the combination of a smooth articular cartilage as well as lubrication of both the 
articular cartilage and the synovial membrane together which make up the entire surface 
area of the inside of the joints.  Shock absorption to the joint is provided by the 
combination of structures, including articular cartilage, subchondral bone and soft tissue 
structures (Joint Capsule and Ligaments).  Because of its re-silent nature and ability to 
compress, articular cartilage in itself is a good shock absorber but its thickness and 
overall volume is far less than bone or soft tissues.  Hence the soft tissues and bones are 
the primary shock absorbers in joint and any disease that affect bones or soft tissue is 
going to interfere with this shock absorption.  Re-silence of the soft tissue is important 
for normal motion as well as shock absorption.  Hyaluronic acid provides lubrication to 
the synovial membrane surface in addition to another protein structure called Lubricin 
and is involved in the lubrication of articular cartilage.  The substance moving over the 
surface of joints is called Boundary Lubrication.  A second mechanism of lubrication of 
cartilage is affected by fluid being squeezed out of the cartilage on to the surface when 
weight bearing occurs. 
RHEUMATOID ARTHRITIS: 
 Rheumatoid arthritis embraces an amazing array of hereditary and acquired 
disorder with a wide variety of clinical features.  Rheumatoid arthritis is a disease of 
unknown cause, and the current thinking is that interplay between genes, infectious 
agent contributes to initiate an autoimmune disease mechanism that results in 
inflammation, dominantly at limb joints, often with destructive features.  The term 
rheumatoid arthritis was first used by sir Archibald Garrod to describe a chronic non-
suppurative inflammatory arthropathy (Rheuma - flux, eidos - resemblance), a condition 
resembling rheumatism. 
 We are all familiar with the saying regarding rheumatic fever, “It licks the joints 
but bites the heart.” Contrarily it can be said of rheumatoid arthritis, “It bites the joints, 
licks all other systems of the body and barks at the treating physician.” 
DEFINITION:
 Rheumatoid arthritis is a highly inflammatory polyarthritis often leading to joint 
destruction, deformity and loss of function.  Additive, symmetric swelling of peripheral 
joints is the hallmark of the disease.  Extra-articular features and systemic symptoms 
can commonly occur and may antedate the onset of joint symptoms.  Chronic pain, 
disability and excess mortality are unfortunate sequelae. 
FREQUENCY: 
 The worldwide incidence of RA is approximately 3 cases per 10,000 population 
and the prevalence rate is approximately 1%.  First degree relatives of patients with RA 
have an increased frequency of disease (2-3 %).  Disease concordance in monozygotic 
twins is approximately 15-20% suggesting that non-genetic factors play an important 
role.   
AETIOLOGY: 
           The cause of rheumatoid arthritis is unknown.  Genetic, environment, 
immunologic, and infectious factors may play significant roles.  Socioeconomic, 
psychological and lifestyle factors may influence disease outcome. 
1. Age: 
 The frequency of RA increases with age and peaks in persons aged 25-50 years.  
Nevertheless, the disease is observed in both elderly persons and children. 
2. Sex: 
Women before menopause are affected 3 times more often than men.  
After the menopause the frequency of onset is similar between the sexes, suggesting an 
etiological role for sex hormones. 
3. Genetic: 
¾ The disease is familial but sporadic. In occasional families it affects several 
generations. 
¾ HLA types: There is strong association between susceptility to RA and certain 
HLA heliotypes. HLA – DR4 which occurs in 50 – 75% of patients. In addition, 
HLA-DR1 also carries this shared epitope and confers risk in certain areas. 
4. Environmental: 
           For many decades, numerous infectious agents have been suggested to induce 
RA.  Among these are Mycoplasma organisms, Ebstein-Barr and Rubella viruses and 
others.
This supposition is further supported indirectly by the following: 
¾ Occasional reports of flulike disorders preceding the stage of arthritis. 
¾ The inducibility of arthritis in experimental animals with different bacteria or 
bacterial products (eg, streptococcal cell walls) 
¾ The presence of bacterial products including bacterial RNA in patient joints. 
¾ The activity of several agents that have antimicrobial effects as disease-
modifying drugs (e.g.  antimalarials).  
5. Immunologic: 
           All of the major immunologic elements play a fundamental role in the initiation, 
propagation and maintenance of the autoimmune process of RA. The exact 
orchestration of the cellular and cytokine events that lead to pathologic consequences, 
such as synovial proliferation and subsequent joint destruction, is complex.  It involves 
T and B Lymphocytes, antigen-presenting cells (e.g. B cells, macrophages, dendritic 
cells) and numerous cytokines.  Aberrant production and regulation of both pro and 
anti-inflammatory cytokines and cytokine pathways are found in RA. 
            T cells are assumed to play a pivotal role in the initiation of RA and the key 
player in this respect is assumed to be the Th1 CD4 cells.  
 These cells may subsequently activate macrophages and other cell populations, 
including synovial fibroblasts.  The latter 2 populations are the main producers of the 
proinflammatory cytokines TNF-alpha and IL-1 that appears to be the major driving 
forces of inflammation. 
 B cells are important in the pathologic process because they may serve as 
antigen-presenting cells and activated T cells produce numerous autoantibodies (e.g. 
RF, Citrullinated proteins) and secrete cytokines.  
6. Onset: 
 Mostly onset is insidious. 
             75 % - insidious onset. 
             15 % - Acute onset. 
             10 % – Sub acute onset. 
IMMUNOPATHOLOGY:
             The pathological hallmark of RA is synovial membrane proliferation outgrowth 
associated with erosion of articular cartilage and subchondral bone.  In early stages, the 
most obvious histological changes are confined to the synovial microvasculature which 
shows evidence of endothelial damage, infilteration by polymorpho nuclear leucocytes 
and obliteration by thrombus.  In chronic phase, polymorpho nuclear leucocytes are less 
obvious but the synovium is infilterated by large number of inflammatory cells 
(macrophages, T&B lymphocytes, dendritic cells, plasma cells).  The plasma cells in 
the subsynovium synthesize large quantities of immunoglobulin, much of which is IgM 
and IgG rheumatoid factor.  They have the ability to form immune complexes that can 
activate complement and is important in either initiating or prolonging local 
inflammation within the joint.  Antigen-Antibody complexes formed within the joint 
cavity can become trapped in hyaline cartilage and fibrocartilage, where they cause 
changes in matrix macro molecules.  Ultimate destruction of cartilage, bone, tendons 
and ligaments probably results from proteolytic enzymes, metallo proteinases.  
CLINICAL FEATURES:
 Patients often present with constitutional complaints including malaise, fever, 
fatigue, weight loss and myalgias.  Most patients with the disease have an insidious 
onset.  It may begin with systemic features, such as fever, malaise, arthralgias and 
weakness, before the appearance of joint inflammation and swelling.   
JOINT FEATURES:
RA is typically a distal, symmetrical, small joint polyarthritis involving 
proximal interphalangeal and metacarpophalangeal joints of the hands, wrist, 
metatarsophalangeal joints, ankles, knees and cervical spine. The shoulders, 
elbows and hips are less frequently involved, but can be a major source of morbidity.  
Any synovial joint in the body may be affected.  In addition periarticular synovial 
structures such as bursae and tendon sheaths are commonly inflammed. 
Most common symptoms described by patients are pain and pronounced 
stiffness.  The later frequently exhibits a diurnal rhythm, worse on rising in the morning 
and then recurring towards the evening, perhaps reflecting the diurnal variation in 
plasma cortisol levels.  The affected joints are frequently tender, swollen and warm 
and there may be limitation of both active and passive movements.  Progressive 
destruction of the articular cartilage, subchondral bone and periarticular soft tissues 
eventually combine to produce the characteristic deformities seen in long standing RA. 
UPPER LIMBS:
Hands and wrists: 
Early in the disease there may be soft tissue swelling around the affected joints.  
Involvement of the proximal interphalangeal joints gives a spindle shaped appearance 
to the fingers and soft tissue swelling can be observed over the ulnar styloid and in the 
2nd and 3rd metacarpophalangeal joints (MCP).  Tenosynovitis of the long flexor 
tendons in the palm of the hand may exacerbate stiffness of the fingers and cause 
“Trigger finger”.  Similar synovitis of the wrist within the flexor retinaculam may cause 
compression of the median nerve with the typical features of Carpal Tunnel 
Syndrome. Persistent synovitis with erosion of the articular surfaces, weakening of the 
joint capsules and muscle weakness, with or without tendon rupture will inevitably lead 
to deformities. 
Ulnar deviation and subluxation of the fingers:
Occurs as a result of instability of the metacarpophalangeal joints.  The fingers 
may tend to drift in an ulnar direction because of the ulnar vector of the action of both 
flexor and extensor finger tendons. 
Swan Neck deformity:
Develops from hyper extension of the proximal interphalangeal joints in 
conjunction with flexion of distal interphalangeal joints with subsequent contracture 
of the intrinsic muscles which become extensors rather than flexors of the proximal 
interphalangeal joints. 
Boutonniere (Button-Hole) deformity:
Results from flexion contractures of proximal interphalangeal joints 
associated with hyper extension of distal interphalangeal joints.  A similar process 
at the carpometacarpal  joint of  the  thumb may  give  rise  to  the   Z-thumb deformity. 
Piano-Key sign: 
Can be detected when weakening of the distal radio ulnar ligament by synovitis 
allows the distal ulna to migrate dorsally so that it overrides the radius.  The ulna can be 
depressed by pressure like a piano key. 
Elbows and Shoulders:
Involvement of the elbows is less common than of the wrist but severe 
destruction may occur, leading to pronounced deformity and disability.  There may be 
inflammation of the subacromial bursae or supraspinatous tendon in addition to 
glenohumeral joint synovitis, producing a typical painful arc syndrome.  
LOWER LIMBS: 
Feet and Ankles:
Active synovitis of the metatarso phalangeal joints leads to spreading of fore foot.  
Subluxation of metatarsal heads into the soles results in cockup and valgus 
deformities causing painful walking and difficulty with foot wear.  Pain arises in the 
ball of foot (metatarsalgia).  .      
                                                                                       
Knee :            
Involvement of knee is an important cause of disability from an early stage of 
disease. Synovial proliferation is usually most obvious in the supra patella pouch and 
there may be pronounced wasting of the quadriceps as a result of reflex muscle 
inhibition.  Synovial effusion typically produces posterior knee pain in the early stages 
by stretching the posterior capsule of the joint.  This may lead to the development of a 
popliteal cyst (Baker’s cyst).  Valgus deformity of the knee is usual consequence of 
loading. 
Hip:
Involvement of hip is uncommon.  Pain is usually present in the groin; buttock 
and abduction of hip are reduced ultimately leading to fixed flexion deformity of the 
joint. 
AXIAL SKELETON:
 Spinal involvement is limited to upper cervical articulation.  Neckpain and 
stiffness are common and leads to erosion of bones and ligaments in cervical spine.  
Vertebral arteries may also be compressed resulting in vertebro basilar insufficiency 
with vertigo or syncope especially on downward gaze.  The risk of cord compression is 
greatest in those with a subluxation exceeding 8mm and there is also vertical 
subluxation of the atlanto axial joint. 
 Symptoms suggestive of atlantoaxial disease include high cervical pain 
radiating to the occiput and temporal regions, exacerbated by neck movements. 
x Brisk tendon jerk. 
x Positive Hoffman sign. 
x Upgoing plantar response. 
x Loss of proprioception. 
x Vibration sense indicates damage to posterior column. 
OTHER JOINTS:
 Hoarseness of the voice may occasionally be caused by effusion within the 
cricoarytenoid joints.  
 Temporomandibular joint disease causes pain on chewing and restricts opening 
of mouth. 
 EXTRA ARTICULAR FEATURES:
 These tend to be more numerous and severe in those with high titers of 
rheumatoid factor in blood. Three major pathological phenomena dominate the disease.  
¾ Inflammation of membranes 
¾ Nodule formation 
¾ Vasculitis. 
A. RHEUMATOID NODULES: 
 Subcutaneous and intracutaneous nodules are the hall mark of the disease in ¼ 
of the patients.  They are firm, non-tender swellings that occur on the extensor surface 
of the fore arm and olecranon sites, where repeated minor trauma could initiate their 
formation.  They may also develop in many other tissues including eye (Scleromalacia), 
pleura, pericardium, parenchyma of lungs and heart. 
B. HAEMATOLOGICAL MANIFESTATION:
Anaemia: 
Moderate normochromic normocytic anaemia is a finding in active RA.  Factors 
that are related to the inflammatory process probably contribute to this anaemia.  There 
may be ineffective erythropoiesis and red blood cell survival is reduced.  Iron binding 
capacity is typically reduced in active rheumatoid arthritis. 
Thrombocytosis, Leukopenia is a finding in patients with Felty’s Syndrome.  
Vasculitis: 
 Intimal hyperplasia of the small terminal digital vessels causes very limited 
cutaneous lesions (Nail fold infarcts, rashes, splinter haemorrhages). In contrast severe 
life threatening tissue infection may develop when there is involvement of large blood 
vessels by leucocytoclastic or necrotizing vasculitis. 
C. LUNG INVOLVEMENT:
1. Pleurisy: 
The fluid has more protein, low glucose; low complement levels and is typically 
positive for RA factor. 
2. Nodules (Caplan syndrome): 
More in upper zone than lower zones.  Cavitation may occasionally lead                                      
to haemoptysis. 
3. Pulmonary fibrosis:
It causes progressive dyspnoea, clubbing of fingers, fine late inspiratory 
crepitations. 
4. Obliterative Bronchiolitis: 
Acute onset of breathlessness. Many patients have evidence of airway 
obstruction. Bronchiectasis also appears to be more common.  
D. CARDIAC INVOLVEMENT: 
Pericardial effusion can be found by ultra-sonography in patients with 
seropositive nodular disease.  Constrictive pericarditis is more common and presents 
with dyspnoea, right side heart failure and peripheral oedema.  
Valvulitis: Granulomatous thickening of the cusps of the aortic valve occurs 
more frequently than in the mitral valve, rarely producing incompetence. 
E. EYE INVOLVEMENT:
Common in RA and may be due to localized tissue involvement. 
Episcleritis: 
Appears as a raised lesion in the anterior sclera with hyperaemia of the deeper 
layers. 
scleritis: 
 Is less common and may leads to progressive thinning of the sclera 
     (Scleromalacia) and even perforation. 
 Keratoconjunctivitis sicca (dry eyes) due to secondary Sjogren’s syndrome. 
 Corneal melting is a rare manifestation.  Clinical features are pain, redness and 
blurred vision with corneal thinning. 
F. PERIPHERAL NERVE INVOLVEMENT:
Peripheral neuropathies can be produced by  proliferating synovium causing 
compression of nerves.  A mild glove and stocking sensory neuropathy is relatively 
common in RA.  
G. MUSCLE INVOLVEMENT:
Is attributed to the reflex inhibition and wasting resulting from severe joint pain. 
H. BONE INVOLVEMENT:
Juxta – articular osteoporosis is an early feature.  A small proportion of patients 
may develop osteomalacia. 
I. FELTY’S SYNDROME:
Lymphadenopathy is common.  It is more obvious in patients with Felty 
syndrome (Rheumatoid arthritis, Splenomegaly, Leucopenia).  Other features include 
anaemia, thrombocytopenia, persistent vasculitic leg ulceration, cutaneous 
pigmentation, weight loss and recurrent infection. 
DIAGNOSIS: 
 The American College of Rheumatology (1988 revised) developed the following 
criteria for the classification of rheumatoid arthritis. 
1. Morning Stiffness: This occurs in and around the joints and lasts at least 1 hour 
before maximal improvement. 
2. Arthritis of 3 or more joint areas: At least 3 joint areas simultaneously have soft 
tissue swelling or fluid (not bony overgrowth) observed by a physician.   
3. Arthritis of hand joints of at least one area swollen in a wrist, MCP, or PIP joint. 
4. Symmetric arthritis with simultaneous involvement of the same joint areas on both 
sides of the body.  Bilateral involvement of PIPs, MCPs, and MTPs is acceptable 
without absolute symmetry. 
5. Rheumatoid nodules: Subcutaneous nodules are present over bony prominences or 
extensor surfaces or in juxta-articular regions.  
6. Serum Rheumatoid Factor: Abnormal amounts of serum RF are demonstrated by 
any method for which the result has been positive in fewer than 5% of healthy control 
subjects.  
7. Radiographic changes typical of RA on posteroanterior hand and wrist radiographs, 
which must include erosions or unequivocal bony decalcification localized in or most 
marked adjacent to the involved joints. Osteoarthritic changes alone do not qualify. 
          A patient can be classified as having RA if 4 of 7 criteria are present. Criteria 1- 4 
must be present for at least 6 weeks, and a physician must observe criteria 2 - 5.  
COMPLICATIONS: 
 RA is not fatal, but complications of the disease may shorten survival by a few 
years in some individuals. In general, RA is progressive and cannot be cured. In some, 
the disease gradually becomes less aggressive and symptoms may even improve. 
However, if bone and ligament destruction and any deformities have occurred, the 
effects are permanent. According to one survey, 70% of patients with RA believe that 
the disease prevents them from living a fully productive life.   
Lymphoma and other cancers:  Alterations in the immune system associated with RA 
may play a role in the higher risk for lymphoma observed in patients with RA. 
Aggressive treatments for RA that suppress the immune system may help preventing 
this cancer, but more research is needed to evaluate this possibility. Other cancers that 
may occur with increased frequency in patients with RA include prostate and lung 
cancers.  
Macrophage Activation Syndrome: This is a life-threatening complication of RA and 
requires immediate treatment. Patients should be aware of symptoms, which include 
persistent fever, weakness, drowsiness, and lethargy. 
PROGNOSIS:
 The following factors at presentation are associated with a poor prognosis. 
¾ Higher baseline disability. 
¾ Female gender. 
¾ Involvement of Metatarsophalangeal joints. 
¾ Positive Rheumatoid Factor. 
¾ Disease duration of over 3 months. 
¾ Disease that remains persistantly acting for more than a year is likely to lead to 
joint deformities and disability around 80%. 
INVESTIGATIONS: 
 No pathognomonic test is available to confirm the diagnosis of RA; instead, the 
diagnosis is made using clinical, laboratory, and imaging features. 
HAEMATOLOGICAL:   
1. Normochromic normocytic anaemia is frequently present in active RA. 
2. The WBC count is usually normal, but a mild leucocytosis may be present. 
3. Eosinophilia when present usually reflects severe systemic disease. 
4. The Erythrocyte Sedimentation Rate is increased in nearly all patients with 
active RA. 
5. The levels of acute phase reactants including Ceruloplasmin and C-reactive 
protein are also elevated. 
6. Increased IgG, IgM, IgA and gamma globulin. 
IMMUNOLOGICAL: 
1. Rheumatoid factor (RF): 
           The presence of rheumatoid factor does not establish the diagnosis of RA, but 
can be of prognostic significance.  RA factor are auto antibodies reactive with the Fc 
position of IgG. Presence of RF can be detected by several tests such as Rose Waaler, 
Latex fixation test and other slide agglutination test.  The test can be employed to 
confirm a diagnosis in individuals with suggestive clinical presentation and if present in 
high titer, to designate patients at risk for severe systemic disease.  Other conditions 
associated with RA are SLE, chronic liver disease, sarcoidosis, interstitial pulmonary 
fibrosis, hepatitis B, tuberculosis, syphilis and malaria.  
2. Antinuclear antibodies:  These are present in approximately 40% of patients 
with RA. 
3. Newer antibodies (anti-CCP): Recent studies of antibodies to cyclic 
citrullinated peptide suggest a sensitivity and specificity equal to Rheumatoid 
factor.
  SYNOVIAL FLUID ANALYSIS:
x Colour   -   Yellow 
x Clarity   -   Cloudt 
x Viscosity  -  Reduced 
x Mucin clot -  Poor 
x WBC   -  > 3000 μL to 50000 μL 
x Total protein - >3 gm.Microscopic feature - RA cell. 
x Polymorpho neuclear leucocyte - >70. 
SYNOVIAL BIOPSY: 
           Villus formation with thickening of synovial layer and infiltration with abnormal 
cells. 
RADIOGRAPHIC EVALUATION: 
¾ Diagnosis is supported by a characteristic pattern of abnormalities including 
tendency towards symmetric involvement. 
¾ Soft tissue changes, juxto-articular osteoporosis may become apparent within 
weeks of onset. 
¾ Loss of articular cartilage and bone erosion develop after months of sustained 
activities.  Joint space changes, alignment, deformities, subluxation, bony 
ankylosis develops in the late stage.  
ARTHROSCOPY: 
In acute RA synovium is edematous, diffusely erythematous and friable. In more 
chronic condition it becomes thickened. 
MRI: Used in patients with abnormalities of the cervical spine.  
SONOGRAPHY:  
This allows recognition of effusions in joints that are not easily accessible. High 
resolution ultrasound images may allow visualization of tendon sheaths, changes and 
degree of vascularization of the synovial membrane and even erosions.  
BONE SCANNING:
Findings may help to distinguish inflammatory from non-inflammatory changes 
in patients with minimal swelling. 
DENSITOMETRY: Findings are useful to diagnose changes in bone mineral density 
indicative of osteoporosis. 
OTHER TESTS:  HLA – DR4 may constitute a helpful marker in early 
undifferentiated arthritis. 
OTHER PROCEDURES:  Joint aspiration and biopsies (skin, nerve, rectum and 
kidney) maybe considered if vasculitis is suggested. 
DIFFERENTIAL DIAGNOSIS:
1. Acute viral arthritis (Rubella, Hepatitis B, Parvovirus) 
2. Bacterial endocarditis 
3. Acute Rheumatic fever 
4. Sarcoidosis
5. Reactive arthritis (Reiter’s disease) 
6. Psoriatic arthritis 
7. Inflammatory bowel disease 
8. Systemic Lupus Erythematous 
9. Sjogren’s syndrome 
10. Polymyositis 
11. Vasculitis syndrome 
12. Polyarticular gout 
13. Calcium pyrophosphate disease 
14. Osteoarthritis. 
Origin of disease (Uthira Vatha Suronitham) 
Dietary Changes                                    Socio economical factor 
Seasonal Changes  Genetic Changes  Immoral Activities 
Stress like factors          Immunological Changes    
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AUTO ANTIBODIES IN RHEUMATOID ARTHRITIS: 
Auto antibodies      Target Possible pathogenic role % positive 
Rheumatoid factor Self IgG Generation of immune 
complex 
   70 
Anti nuclear 
antibodies 
Various nuclear 
components 
Reaction with dead cells   4 - 6 
Antihistones Histones-I-IV Vasculitis and uveitis   10 - 30 
Anti ribinuclear 
protein
Ribonuclear
proteins 
Polyclonal b-cell activation   30 
Antikeratin Keratin Disease severity   95 
Anti cardiocipin Diphosphate dyl 
glycerol 
Effect on PGI2 release, 
platelet aggragation 
 10 
Anti collagen Type II collagen Complement fixation joint   25 
Antigliadin    Intestinal mucosa Intestinal permeability to 
bacterial antigen triggers 
25
          PINIYARI MURAIMAI
Piniyari muraimai is a method of diagnosing a disease. 
                        “Pini” means    =   Disease 
  “Ari” means  = Identify 
  “Muraimiai” means   =   Method 
            This is based upon three main principles and Envagai Thervugal. The three main principles are, 
 Poriyal arithal (Inspection) 
 Pulanal arithal ( Palpation) 
 Vinathal ( Interrogation) 
             Physicians ‘Pori’ and ‘Pulan’ are used as tools for examing the ‘Pori Pulan’ of   the patient. 
The above principles correspond to the methodology of  
 Inspection
 Palpation and
 Interrogation in modern medicine, in arrives a clinical diagnosis of the disease. 
1. Poriyal arithal (Inspection)
            Pori is considered as the five senses of perception namely, 
     1. Nose  
                2. Tongue
                3. Eye    
                4. Skin
                5. Ear 
2. Pulanal arithal (Palpation) 
Pulan are functions of five senses. They are, 
1. Smell 
2. Taste
3. Vision
4. Sensation of Touch 
5. Hearing.
           Examinations of Pori and pulan of the patient by Pori and pulan of the physician. 
 3.       Vinathal (Interrogation)
            Vinathal is asking the information regarding the history of the disease, its clinical feature etc., 
from the patient or his close relatives who are taking care of him. 
msitfs; : (Logics): 
Alavaigal are used in clinical diagnose of a disease. 
“msit fhz;ly; fUjy; ciu mghtk; nghUs; xg;ghnwd;gH 
msit NkYk; xopGz;ik iajpfj; Njhbay; ngd ehd; 
fsit fhz;gH mitapw;wpd; NkYk; miwtH mitnay;yhk; 
msit fhz;ly; fUjy; ciu vd;Dk; %d;wpylq;fpLNk”
  - rptrpj;jpahH msit vz;. 6 
 Alavai is divided into ten types, they are, 
1. Observation    –  fhz;ly;
2. Inference    – fUjy;
3. Authority, literature   – ciu 
4. Preception    – mghtk; 
5. Presumption               – mUj;jg;gj;jp
6. Comparison   – cgkhdk; 
7. Inference by elimination  – ghhpNr\k; 
8. Probability    – rk;gtk;
9. Tradition    – IjPfk;
10. Natural Inference   – ,ay;G 
The above mentioned “ten alavaigal” are included in three alavaigal. They are, 
1. Kaandal ( Inspection by Siddha method):
           Through ‘Kaandal’ the physician can directly see the patient, hear the patients all the complaints 
and at length concludes a diagnosis. 
2. Karuthal (Through Siddha Investigations)
 Through Envagai thervu and Neerkuri as well as Neikuri, we can diagnose a disease by Karuthal. 
3. Urai (Literature evidence of Siddha)
 Comparative study of the signs and symptoms of the patient with the reference books and come to a 
diagnosis. 
Ennvagai  thervuagal (Eight diagnostic tools) 
           Siddhars have developed a unique method of diagnosing the disease by “Ennvagai thervugal”. 
“ehb ];ghprk; eh epwk; nkhop tpop 
 kyk; %j;jpukpit kUj;Jt uhAjk;”
          - rpj;j kUj;Jt Neha;ehly; Neha;Kjy; ehly;  jpul;L. 
Hence the diagnosis is made by the following,
1. Naadi   (Pulse) 
2. Sparisam (Sensation to touch) 
3. Naa (Tongue) 
4. Niram (Colour) 
5. Mozhi (Voice) 
6. Vizhi (Eyes) 
7. Malam (Faeces) 
8. Moothiram (Urine) 
 The specialty of eight tools of diagnosis is mentioned in the following verses also, 
‘njhLf;fYw;w ml;ltpjg; gupl;ir jd;id 
 Jyf;fKWk; gz;bjNu njsp tjhfg; 
   gFf;fupa ehbNa eP gpbj;Jg; ghU 
   gfh;fpd;w thh;j;ij ghh; ehitg; ghU 
   tFf;fhpa Njfnkdj; njhl;Lg; ghU 
   rfpf;fhpa kyj;ijg; ghh; ryj;ijg; ghU 
   rhu;e;j tpopjidg; ghh;j;J njspthaf; fhNz.”
- mfj;jpah; itj;jpa ty;yhjp 600. 
1. Naadi (Pulse): 
          The science of pulse forms a very important branch in the siddha system of medicine. Naadi is 
the seat anchor of energy. It is the binding force between soul and body.  The pulse-waves as felt on 
the radial artery, one inch from the wrist by means of palpation with the tip of index, middle and ring 
finger corresponds to Vatham, Pitham and Kabham.  They exist in the ratio of 1:1/2:1/4 normally.  
Derangement of this ratio leads to various disease entities. 
 In Udhiravatha Suronitham, Vatha pitha naadi, Pitha vatha naadi and Vatha kaba naadi are 
commonly seen.  
2. Sparisam (Skin): 
  Skin examination can be made by inspection and palpation (touch).  It reveals about the 
warmth/chillness, dry/weeping skin, rough/smooth, soft/hard, tenderness, presence of ulcers, fissures, 
swelling, wrinkles etc.
            In Udhiravatha Suronitham, the affected part feels warm with redness, swelling, tenderness and 
subcutaneous nodules can be noticed. 
3. Naa (Tongue examination): 
            The colour, character and condition of tongue change according to changes in mukkutram. 
           In Udhiravatha Suronitham, few cases had coated tongue. In few cases that were anaemic, the 
tongue was pale and some were have glossy. 
4. Niram (Colour): 
            Signs of different complexions in Vatham, Pitham, Kabham and Thontha thegis, cyanosis, 
pallor, yellowish discolouration can be studied by means of niram. 
 In Udhiravatha Suronitham, the patient is of mixed complexion and the affected parts get 
swollen with hyperaemia. 
5. Mozhi (Speech): 
            It constitutes high, low pitched voice, slurring and incoherent speech, nasal speech, hoarseness 
of voice etc. 
            In Udhiravatha Suronitham, the speech is normal in most of the patients. Only two patients had 
horseness of voice. 
6. Vizhi (Eye): 
           Both motor and sensory disturbance of eye are noticed. Burning sensation, redness of eyes, 
paleness, excessive lacrimation, swelling, sunken eyes, corneal ulcers, other diseased conditions 
should be noted. 
           In Udhiravatha Suronitham, if the patient is anaemic, pallor of conjunctiva will be seen. 
7. Malam (Stools): 
Vatha type :  Black coloured stools with constipation. 
Pitha type :  Loose stools with yellowish red colour. 
Kabha type :  White coloured stools with mucus. 
Thontha type :  Stools possess some of the features of  
                            two thodams. 
            In Udhira Vatha Suronitham, constipation is noted in few patients 
8. Moothiram (Urine): 
           It includes Neerkuri and Neikuri. 
Neerkuri:
¾ Niram -  Indicates the colour of urine voided. 
¾ Manan -  Indicates the smell of urine voided. 
¾ Edai -  Indicates the specific gravity of urine voided. 
¾ Nurai -  Indicates the frothy nature of urine voided. 
¾ Enjal -  Indicates the quantity of urine voided. 
            In addition, the frequency of micturation and sedimentations are noted. 
 In Udhiravatha Suronitham, no abnormalities are seen in the above features. 
Neikuri: 
‘mUe;J khwpujKk; mtpNuhjkjha; 
  m/fy; myu;jy; mfhyCz; jtpu;e;jow; 
  Fw;wstUe;jp cwq;fp itfiw 
  Mbf; fyrj; jhtpNa fhJ nga; 
  njhU K$u;j;jf; fiyf;Fl;gL ePupd; 
  epwf;Fwp nea;f;Fwp epUkpj;jy; flNd.    
      - Njiuah;. 
           Prior to the day of urine examination, the patient was advised to take a balanced diet and the 
quantity of food must be proportionate to his appetite and he should have a good sleep. 
After waking up in the morning, urine that is voided first is collected in a glass container and is 
subjected to analysis within one hour. 
A drop of gingelly oil is added without disturbance and neikkuri is noted in direct sunlight. 
Character of Vatha Neer: 
‘muntd ePz;bd/Nj thjk;.”
            When the drop of oil lengthens like a snake, it indicates ‘Vatha Neer’. 
Character of Pitha neer: 
‘MopNghy; gutpd; m/Nj gpj;jk;.”
            When the oil drop spreads like a ring, it indicates ‘Pitha Neer’. 
Character of Kabha Neer: 
‘Kj;njhj;J epw;fpd; nkhoptnjd; fgNk.”
           When the oil drop remains that of pearl, it indicates ‘Kabha Neer’. 
Character of Thontha Neer: 
           Thontha neer appears as the combination of above patterns.
‘mutpyhopAk; Mopapy; muTk; 
mutpd;Kj;Jk; Mopapy; Kj;Jk; 
njhw;wpy; njhe;j Njhlq;fshNk.”
In Uthiravatha suronitham most of the patients had vatha neer and some of had kabha neer.
           Besides Envagai thervugal, a disease can also be diagnosed by means other methods namely 
thinaigal, paruvakalangal, Udal thathukkal, Uyir thathukkal and Pori pulangal. A combination of all 
these diagnostic criteria is helpful to attain a proper diagnosis with complete entity based principles of 
siddha science. 
Thinai (Land and Place): 
 The geographical distribution of land is classified into the five groups. 
 1. Kurinji  -  Mountain and its surroundings 
 2. Mullai  -  Forest and its adjacent areas 
 3. Marutham             -  Field and its surroundings 
 4. Neithal  -  Sea and its surroundings 
 5. Paalai  -  Desert and its surroundings. 
             Each region has its own characters, which influences the inhabitants, physical, mental, 
economical and occupational activities.  In each region, some ailments are endemic based on the 
climatic features of that area. 
           In ‘Udhiravatha Suronitham’ most of the patients comes from Neithal nilam.  Modification in 
lifestyle and food habits can also brings about the disease. 
Paruvakaalam (Seasonal Variations) 
The seasonal variation mainly depends upon the temperature, humidity, air and other climatic 
factors.The whole year is constituted by six seasons. They are, 
S.No Kaalam Kuttram State of Kuttram Suvai 
1. Kaar Kaalam Vatham ĹĹ Vettrunilai Valarchi. Enippu 
(Aavani-Puratasi)  
(Aug16 – Oct 15) 
Pitham Ĺ Thannilai Valarchi Pulippu 
Uppu.
2. Koothir Kaalam 
Iypasi – Karthigai 
(Oct16 – Dec15) 
Vatham (í)
Pitham ĹĹ
Thannilai Adaithal 
Vettrunilai Valarchi. 
Enippu
Kaippu
Thuvarppu
3. Munpani Kaalam 
( Markazhi – Thai) 
(Dec16 – Feb15) 
Pitham (í) Thannilai Adaithal Enippu
Pulippu
Uppu
4. Pinpani Kaalam 
(Masi – Panguni) 
(Feb16 – Apr15) 
Kabam Ĺ Thannilai Valarchi. Enippu 
Pulippu
Thuvarppu
5. Elavenil Kaalam 
(Chithirai – Vaikasi) 
(Apr16 – Jun15) 
Kabam ĹĹ Vettrunilai Valarchi. Kaippu
Karppu
Thuvarppu
6. Mudhuvenil Kaalam 
(Aaani – Aadi) 
(Jun16 – Aug15) 
Vatham Ĺ
Kabam (í)
Thannilai Valarchi 
Thannilai Adaithal Enippu
             According to climatic condition that prevails in every season, changes will occur in the human 
beings which will modify the physiological state and makes them susceptible to certain specific 
disease likely to occur in that season.
 Thus Vatham gets provoked from its normal state in its own location during “Muthuvaenir 
Kaalam”.  This altered vatham spreads to other location in “Kaar Kaalam”.  Altered Vatham subsides 
in “Koothir Kaalam”.  The above three conditions are named as Thannilai Valarchi, Vetrunilai 
Valarchi and Thannilai Adaithal. 
 The incidence of Uthiravatha suronitham more in Kaarkalam and Koothir kaalam. 
MUKKUTRA VERUPADUGAL (SIDDHA PATHOLOGY) 
   ‘gpzpapDw; gj;jpia NgRtd; gpzpKjy; 
   thjgpj; jq;fg kd; ke;jphp je;jphp 
   tPjkh Alyuz; nka;k;Gu tuR nra; 
   Kiw nrAkhjyhd;.”
     - Njiuah; fhg;gpak;.  
(thjk; - murd;> gpj;jk; - ke;jphp> fgk; - Nrdhjpgjp) 
            Which highlights that the main factor in the causation of the disease  
are vatham, pitham and kabham. 
VATHAM: 
 Vatham is the prime force that impacts movement to every living cell in the body.  Its dwelling 
place lies in the bones, muscles, nerves, joints etc.  Hence it is responsible for the movement of parts 
involved in locomotor system.  When vatham is affected, the other two pitham and kabham also gets 
deranged and in turn, they vitiates the other structural and functional elements of the living body called 
seven Udal thathus. 
¾ Viyaanan which is responsible for the voluntary and involuntary movements and nutrition of 
the tissue gets affected leading to restriction of movements and lassitude. 
¾ Samaanan which neutralizes other vitiated vayus gets affected. Further it is needed for normal 
digestion. So derangement of this vayu produces loss of appetite and indigestion. 
¾ Involvement of Abaana Vayu also plays a main role in the manifestation of signs and 
symptoms.  Abaanan which is responsible for distribution and assimilation of nutritional 
factors gets affected leading to symptoms like constipation. 
¾ Kirukaran and Thevathathan are also affected because of loss of appetite and sleeplessness 
respectively. 
PITHAM: 
The main function of pitham which represents agni is thermogenesis or heat production, 
metabolism within its limits, process of digestion etc.  Its vitiation produces inflammatory changes 
in joints.  Among the five types of Pitham, the following four types get affected in Udhiravatha 
Suronitham. 
¾ Ranjaga pitham which gives colour to blood.  
¾ Saathaga pitham which is needed to carry out normal activities. 
¾ In few, Anal pitham which is needed for digestion gets affected leading to anorexia. 
¾ Prasaga pitham which gives complexion to skin gets affected leading to pallor of skin. 
KABAM: 
 The detoriation of the two main kuttram accompany the Kabha kutram whose structure is Earth 
+ Water and is concerned with the maintenance of smooth working of joints, integration of structural 
elements of the body into stable structures etc.   
¾ Santhiga kabham which is needed for normal maintenance of synovial fluid gets affected.
¾ Avalambagam which forms the basis for all the other four types of Kabham gets affected.  
¾ In few, Kilethagam gets affected leading to loss of appetite. 
Thus disturbance in Mukkutram produces, 
¾ Pain, swelling of joints, joint stiffness, restriction of movements, loss of appetite and 
sleeplessness and constipation due to vatham. 
¾ Inflammatory changes in joints like redness, warmth, loss of appetite and anemia due to 
pitham. 
¾ Erosion of bony margin, osteoporotic changes, increases in the synovial fluid are due to 
disturbed kabham. 
UDALTHATHUKKAL: 
           Disturbances in vatham, pitham and kabham gets reflected on Udal thathus leading to change in 
normalcy of body or predisposition to causing disease.  The seven udal thathus that supports the body 
in their state of equilibrium are as follows. 
1. Saaram  -  Strengthens the body and mind. 
2. Senneer  -  Gives power, knowledge and boldness to the  
                                                mankind. 
3. Oon              -  It gives structure and shape to the body and is  
                                                responsible for movements of the body. 
4. Kozhuppu              -  It lubricates the joints and organs and facilitates
                                                their functions. 
5. Enbu  -  It protects all the internal organs and forms   
                                                structural framework of the body. 
6. Moolai  -  Resides inside the core of bones. It strengthens
            and maintains the normal condition of bones. 
7. Sukkilam/  -  Meant for reproduction (Male and Female   
   Suronitham                 respectively). 
In Uthiravatha suronitham, the affected Udal thathus are, 
¾ Saaram            -  Loss of appetite, lassitude. 
¾ Senneer -  Anaemia, presence of RA factor). 
¾ Oon   -  Muscle wasting, swelling. 
¾ Kozhuppu -  Emaciation, restriction of joint movements. 
¾ Enbu  -  Vague pain and swelling of joints and deformity of joints. 
LINE OF TREATMENT: 
Siddha treatment is not only for complete healing but also prevention and rejuvenation.  Saint 
Thiruvalluvar says about physician duty, study the disease, study the cause, treat subsiding way and 
do what is proper and effect. 
“Neha; ehb Neha; Kjy; ehb mJ jzpf;Fk; 
 tha;ehb tha;g;gr; nray;. 
“cw;whd sTk; gzpasTq; fhyKq; 
 fw;whd; fUjpr; nray;.”
               - jpUf;Fws;. 
So it is essential to know the disease, the etiology, the nature of patients, severity of the illness, 
the seasons and the time of occurrence must be observed clearly. 
Line of treatment is as follows. 
¾ Kaappu (Prevention) 
¾ Neekkam (Treatment) 
¾ Niraivu (Restoration). 
1. KAAPPU (Prevention): 
“The curse causeless shall not come” is a proverb.  Knowing the cause there by removing it and 
thus preventing the disease is the main aim of siddha system of medicine.   
Thiruvalluvar depicted,
‘kUe;njd Ntz;lhthk; ahf;iff;F mUe;jpaJ 
 mw;wJ Nghw;wp cz;zpd.;”
This Kural highlights that no medicine is required by the body if food is taken on complete 
digestion on what was taken before.  Thus   change in food habits plays a main role in the causation of 
diseases 
Further, following of Theraiyar Pini Anugaa Vidhi will help in the prevention of diseases.  
The main highlights of Theraiyar Pini Anugaa Vidhi are as follows. 
'jpz;z kpuz;Ls;Ns rpf;f tlf;fhkw; 
ngz;zpd;gh nyhd;iwg; ngUf;fhky; cz;Zq;fhy; 
ePh;RUf;fp Nkhh;ngUf;fp nea;AUf;fp Az;gth;jk; 
NgUiuf;fpw; NghNk gpzp. 
ghYz;Nghk; vz;nza;ngwpd; nte;ePhpw; Fspg;Nghk; 
gfw;GzNuhk; gfw;WapNyhk; gNahjuK%j;j 
VyQ;Nrh; FoypaNuh bsntapYk; tpUk;Nghk; 
,uz;llf;Nfhk; xd;iwtpNlhk; ,lJ ifapw; gLg;Nghk; 
%yQ;Nrh; $wpEfNuhk; %j;japh; cz;Nghk; 
Kjdhypw; rikj;jfwp aKnjzpD kUe;Njhk;
Qhye;jhd; te;jpbDk; grpj;njhopa Tz;Nzhk;... 
kz;guT fpoq;Ffspw; fUizad;wp GrpNahk; 
thioapsk; gpQ;nrhopa fdpaUe;jy; nra;Nahk; 
ez;G ngw Tz;lgpd;G FW eilAq; nfhs;Nthk;.".. 
2. NEEKKAM (Treatment): 
In siddha system the main aim of Pini Neekam is based on the following objectives. 
¾ Accurate diagnosis is essential for the early application of appropriate forms of therapy. 
¾ To bring the three thodams to equilibrium. 
¾ Treatment of the disease and its symptoms by internal medicines, topical application of 
medicated oil (Thokkanam), fomentation (Otradam) in affected region. 
¾ To built up seven body constituents 
¾ Diet and prevention of disease. 
¾ To increase natural immunity. 
¾ Education of patient in maintaining the joint stability by means of Yogasanas. 
‘tpNurdj;jhy; thjk; jhOk; 
 tkdj;jhy; gpj;jk; jhOk; 
      erpa mQ;rdj;jhy; fgk; jhOk;.”
Vatha diseases can be brought down by ‘Viraesanam’.  For this laxatives and purgatives are 
given according to patient’s tolerance to drug.  All the patients were given Merugulli thylam at a dose 
of 10ml with warm water on the first day in the early morning.  They were put in diet allowing only 
taking butter milk.   
‘Ntu;ghU jioghU kpQ;rpdf;fhy; 
nky;y nky;yg; gw;gr; nre;J}uk; ghNu.”
The disease Uthiravatha suronitham involving multiple system of the body especially 
musculoskeletal system affected first and then other systems are affected depends upon their 
immunology.  Single and herbal drug therapies are not much useful to cure the disease. Herbomineral 
drug only can give remarkable improvement in this disease.  
3. NIRAIVU: (RESTORATION) 
Reassurance of disease recovery was given to all patients. All the patients were advised to live in 
good health free from disease. 
Diet: 
“kUe;Nj czT czNt kUe;J”
   - jpU%yH 
“khWghb y;yhj cz;b kWj;Jz;zpd; 
CWgh by;iy capHf;F”
       - jpUf;Fws; 
vd;gjpdhy; cz;Zk; czTg; nghUspYk; ftdk; nrYj;j Ntz;Lk;. FspHe;j 
nghUl;fisj; jtpHf;f Ntz;Lk;.  FspHe;j fhw;W FspHgdpapy; cyhTtij jtpHf;f Ntz;Lk;. 
Anupaanam:
            In siddha system of medicine the adjuvant is one of the most important thing during therapy. 
'mDghdj;jhNy atpo;jk; gypf;Fk; 
,dpjhd Rf;F fd;dy; ,Q;rp - kpD Kjfhy; 
Nfhkak; ghy; Kiyg;ghy; Nfhnea; Njd; ntw;wpiy ePh; 
Mkpijahuha;e;J nra;ayhk;|| 
        - Njud; ntz;gh. 
Pathiyam:
 “Take anything you like” – siddha system does not believe in this dictim.  The system of 
arranging dietary with certain restrictions in diet and physical activities is Pathiyam.  Pathiyam for 
vatha disease as mentioned as Patharthaguna chinthamani is as follows, 
Njhilj; Njd;kpsF ey;nyz;nza; 
jq;F ngUq; fhak; jOjhio vq;nfq;Fk; 
$l;LrpW Kj;J new; Nfhjpy; cSe;jpitfs; 
thl;L kdpyj;ij kjp|| 
Nrh;f;fj;jf;fd:
nrq;fOePh; fpoq;F> Njd;> kpsF> Nfhl;lk;> vs;nea;> nea;> cSe;J> ngUq;fhak;> 
jOjhio. 
ePf;f Ntz;bait: 
cg;G, Gspg;G> Jth;g;G> RitAs;s nghUs;fs;. 
MANAGEMENT OF UTHIRAVATHA SURONITHAM: 
THOKKANAM, OTRADAM: 
          Thokkanam is topical application of medicated oil.  It is the systematic and scientific 
manipulation of body tissues, best performed by hands.  Ottradam is fomentation and is done with the 
use of herbs etc. 
 Both of which produces pain relief and increases the blood flow owing to arteriolar and 
capillary dilatation and reduces joint stiffness. They increase the extensibility of collagen tissues so 
that contractures can be stretched. 
YOGA: 
  Yogasanas are specialized postures of the body and helps in the development of an inner 
awareness and results in deep relaxing and energy conservation. Prescription of these asanas 
which is synchronized with breathing helps in the correction of impairment there by improving the 
musculo-skeletal function and maintaining the state of well being. 
Udhiravatha Suronitham patients were advised to perform, 
1. Savasanam, two times daily for a session of 10 minutes. 
Sava means dead body.  Should lie motionless on the floor in supine
Posture like dead body with a view to secure complete relaxation of all parts of the body and removing 
stress.
2. Deep relaxation techniques once daily for a period of 20 minutes. 
Further the patients were adviced to do Pranayamam in association with Mudras. 
¾ Naadi Sudhi (Using Nasika Mudra) 
¾ Abdominal Breathing (Using Cin Mudra) 
¾ Thoracic Breathing (Using Cinmaya Mudra) 
¾ Full Yogic Breathing (Using Brahma Mudra) 
 Practice of this pranayama relieves stress, tension, anxiety and insomnia there by bringing 
stability to mind. The Mudras preserves the joint movements of fingers. 
3. NIRAIVU (Life style modification): 
 Self help techniques were advised to keep inflammatory process at a minimum, there by 
preserving joint motion. 
Self management techniques:
¾ Rest - reduces the general activities there by avoiding straining of joints and to conserve   the 
quota of vitality.   
¾ Positive mental attitude. 
¾ Use of joint – Patient is told, the value of correct posture and methods of using the joints wisely 
to reduce stress on the painful joints. 
¾ An assistive device – Like splints, walking sticks provides strength and reduces pain and 
inflammation. 
¾ Adequate sleep. 
¾ Relaxation techniques. 
¾ Modification in daily activities like avoiding walking on hard and uneven surfaces, avoiding 
squatting on ground, etc.
PHYSICAL THERAPY: 
Physiotherapy is the application of physical agents and principles to pathological conditions for 
the purpose of producing therapeutic effects. 
Physiotherapy includes:
¾ Active exercise 
¾ Passive joint movement 
¾ Local heat 
¾ Massage
¾ Electrical stimulation of muscle 
¾ Light therapy – UV rays therapy and infra red ray’s therapy. 
DETAILS OF RANGE OF MOTION EXERCISE: 
I. UPPER EXTREMITIES: 
 A.  Neck: 
1. In sitting position twist your head as possible in each direction. 
2. Sit or stand with your hands on the hips. First circle the head clockwise then counter clockwise. 
3. In the sitting position try to touch shoulder with your head. 
4. In the sitting position look behind as for as possible and then look at your toes. 
 B.Shoulder: 
1. Arms at side with elbow straight bring arms forward and upward by ear. 
2. Arms at side with elbow straight take arms sideward and upward. 
3. Arms at side bend elbow to right angle and take hands apart. 
 C.Elbow: 
1. Bend elbow, touching fingers to top of shoulder. 
2. Straighten elbow. 
D.Forearm: 
     Elbow bend, turn palm of the hand and then back of the hand towards face. 
   E.Wrist: 
1. Keeping forearm steady, move the wrist up and down as in waving. 
2. Again hold forearm steady, move the wrist up and down as in hand shaking. 
3. Make circle with hand. 
   F.Hand and Fingers: 
1. Make tight first. 
2. Open fingers as wide as possible. 
3. With the hand open spread fingers away from each other and then together. 
4. Touch tip of the thumb to the tip of the each fingers. 
5. Bend the thumb in toward palms of the hand. 
II.LOWER EXTREMITIES: 
A. Knee: 
Sit with your feet off the floor. Lift the leg and then allow it to return to the bent position 
slowly. 
B. Ankle: 
1. Pull foot up and in, and then push back downward. 
2. Make circle with foot. 
3. Pull foot in toward other foot. 
4. Pull foot to outside. 
C. Toes: 
      Pull up on toes then curl toes under. 
Exercise benefits for individuals with arthritis: 
 Helps to preserve muscle strength and normal mobility of joints. 
 Relieves of pain and stiffness. 
 Prevent further deformities. 
 Improves co-ordination. 
 Return to normal independent life style. 
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ABOUT THE DISEASE:
a)  According to siddha aspect:
In siddha literature the clinical features of Uthiravatha suronitham according to yugi Vaithya 
chinthamani is given below,  
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B) In Modern medicine, clinical features of Rheumatoid arthritis are: 
1. Arthritis of three or more joints including major joints and minor joints. 
2. Arthritis of hand joints – Interphalangeal jts of both hands and feets. 
3. Morning stiffness > 1 hr.     
4. Symmetrical arthritis.                             
5. Fever.
6. Anemia. 
7. Anorexia.
8. Spindled appearance of fingers. 
9. Rheumatoid nodules. 
10. Broadening of the forefoot. 
IV    SAMPLE: 
Patients of Uthiravatha suronitham reporting at OPD – Ayothidoss Pandithar Hospital in 
National institute of siddha, Tambaram sanatorium, Chennai-47. 
SAMPLE SIZE: 
  The trial size will be 40 patients. (20 In patients and 20 Out patients) 
STUDY DESIGN: 
  Clinical trial of cases of Uthiravatha suronitham (Rheumatoid arthritis) by Rasapralaya 
chenthuram (Internal) and Navanatha siddhar thylam (External application) for a period of 20 days. 
V    INCLUSION CRITERIA: 
¾ Age between 25 to 55 years. 
¾ Sex: Both Male and Female. 
¾ Arthritis of three or more joints.  
¾ Symmetrical joint involvement. 
¾ Morning stiffness. 
¾ Positive serum rheumatoid factor. 
¾ Anemia 
¾ Fever 
¾ Anorexia
¾ Spindled shaped appearance of fingers. 
¾ Rheumatoid nodules. 
VI    EXCLUSION CRITERIA: 
¾ Cardiac disease. 
¾ Hypertension 
¾ Diabetes mellitus. 
¾ Use of narcotic drugs. 
¾ Pregnancy and lactation.
¾ Other joint disease. 
¾ History of trauma. 
¾ Neurological disorder. 
VII    TERMINATION CRITERIA:
¾ Development of any adverse drug reaction. 
¾ Occurrence of any serious illness. 
VIII    TRIAL DRUG AND DURATION: 
1. Purgation -   Merugulli thylam   - 10 ml in the morning with hot water (first day of treatment 
only)
2. Internal medicine - Rasapralaya chenthuram 100 mg with Thirikadugu choornam 1 gm with the 
adjuvant of honey, twice a day after food. 
3. External medicine - Navanatha siddhar thylam 10ml local application twice a day. 
4. Trial period – 20 days for each patient. 
IX   STUDY PERIOD: 90 days. 
RECRUITMENT: 
As and when patients reporting in Ayothidoss Pandithar Hospital of National Institute of 
Siddha, satisfying inclusion and exclusion criteria will be eligible for admission to the trail. They will 
be included in the study with the approval of Head of the Department. Informed consent will be 
obtained from the patients before entering into the study. 
IX   TESTS AND ASSESSMENTS: 
A. Clinical Assessment Proforma: 
      B.   Routine investigations: 
x Blood – TC, DC, ESR, Hb, Blood sugar, Serum cholesterol. 
x Kidney function test - Urea, Creatinine. 
x Liver function tests – Serum total Bilirubin, Direct Bilirubin, Indirect Bilirubin, Alkaline 
phosphates, SGOT, SGPT. 
C. Specific investigations: 
CRP, RA factor, ASO titre.
      D.  Urine: 
      Urine sugar, Albumin, Deposits. 
E.   Stool: 
      Ova, Cyst, Occult blood. 
X    ASSESSMENT BY SIDDHA ASPECTS: 
        Envagaithervugal and Mukkutra assessment. 
        SIDDHA ASPECTS (According to yugi vaithya chinthamani): 
¾ Pain and swelling in major joints and minor joints. 
¾ Pain in heels. 
¾ Pain in Interphalangeal joints( hand joints) 
¾ Fever.
¾ Burning sensation. 
¾ Anorexia
X    METHODOLOGY OF TREATMENT:
          Rheumatoid arthritis patients satisfying inclusion and exclusion criteria will be eligible for the 
admission to the trial. Informed consent will be obtained from the patient. Lab test will be carried out 
before treatment. 
         A day before to starting the trial drug treatment, purgation will be given to correct the elevated 
mukkurams. The next day onwards the trail drug will be given to the in patients.  For In patients, the 
trial drug will be given daily by the doctor. The clinical assessment will be made daily and laboratory 
investigations will be done on the first day and 21st day of the treatment.  
         For out patients, the trail drugs will be given in the Out patients Department of our Hospital. The 
patients will be asked to follow regular check up in the Op Department once in 7days regularly. In 
each visit, the clinical assessment will be reported regularly by researchers prescribed proforma. The 
laboratory investigations will be done before and after treatment and recorded in the prescribed format. 
XI      DATA COLLECTION FORMS: 
           Required information will be collected each patients by using forms I, II. 
¾ Form I - Selection proforma – Used at the time of admission of the patient to the study.  
¾ Form II - Assessment proforma - Used after the study period. 
¾ Form III – Daily progress chart – Used during the study period. 
XII    STATISTICAL ANALYSIS:
¾ R.A. Scale for measurement of pain. 
¾ Mean of objective parameters – before and after treatment- paired t test. 
¾ Multivariate analysis will also be performed if applicable. 
UNIVERSAL PAIN ASSEMENTS SCALE: 
                                    No hurt     Hurts little bit   Hurts even more    Hurts whole lot 
 No pain                 -   Patient can able to do day to day life. 
 Mild pain              -     Patient can able to tolerate pain and also able to work. 
 Moderate pain      –     Patient can able to work but pain more interference with         
concentration. 
 Severe pain           –   Difficulty to do basis needs.    
GRADATION OF RESTICTED MOVEMENTS: 
x G I – Able to perform normal duties. 
x G II – Moderate Restiction – Self care is possible. 
x G III – Marked restriction – Limited self care. Some assistance required. 
x G IV – Confirmed to bed or Wheel chair.
                                                                          Mr. DEVA    32/M
MRS. MUNIYAMMA 36/F 
                Mrs. Muniyamma 36 / F 
OBSERVATION
AND
RESULTS
OBSERVATION AND RESULTS 
Results were observed with respect to the following criteria. 
1. Sex distribution. 
2. Age distribution. 
3. Thinai. 
4. Paruvakaalam. 
5. Occupation.
6. Diet reference 
7. Socio-economic status. 
8. Etiological factor. 
9. Mode of onset. 
10. Duration of illness. 
11. Clinical manifestations. 
12. Systemic examination. 
13. Individual joint involvement. 
14. Joint deformity. 
15. Grading of restricted movements. 
16. Disturbance in mukkutrams. 
17. Involvement of Udhal thathukal. 
18. Envagaithervugal.
19. Results. 
1. Sex Distribution: 
Table – 1. Illustrates sex distribution and its relative percentage.
SI. No. Sex 
In -  Patients Out - Patients 
No. of Cases Percentage No. of Cases Percentage 
1 Male 6 30 % 2 10 % 
2 Female 14 70 % 18 90 % 
From the above table, it is clear that the incidence is more in females.
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Sex Distribution
Male
Female
2. Age Distribution: 
Table - 2 illustrates age distribution and its relative percentage:
S.NO AGE 
IN PATIENTS OUT PATIENTS 
No.ofcases Percentage No.ofcases Percentage 
1. 25 - 35 6 30 % 6 30 %
2. 36 - 45 6 30 % 10  50 % 
3. 46 - 55 8 40 % 4     20 % 
The above table shows that the incidence is more in 4th, 5th decades.
Out of 20 In-patients, 30% of the cases were in Vatha Kaalam, 70% of cases were in Pitha 
Kaalam. Out of 20 Out-patients, 30% of the cases were in Vatha Kaalam, 70 % of cases were in Pitha 
kaalam. This shows that majority of the cases were affected in Pitha Kaalam.
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4. Thinai:
Table - 3. Illustrates the distribution with respect to Thinai:
SI. No Thinai 
In -  Patients Out - Patients 
No. of Cases Percentage No. of Cases Percentage 
1 Kurinji - - - - 
2 Mullai - - - - 
3 Marutham 3 15 - - 
4 Neithal 17 85 20 100 
5 Paalai - - - - 
The above table shows, most of the patients were from Neithal Nilam.
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4.Paruva Kaalam: 
Table– 4. Illustrates the incidence of the disease with respect to Kaalam:
SI. No. Paruva Kaalam 
Out -  Patients In - Patients 
No. of Cases Percentage No. of Cases Percentage 
1 Kaar kaalam 12 60  6 30 
2 Koothir kaalam 6 30 12 60 
3 Munpani kaalam 2 10 2 10 
4 Pinpani kaalam - - - - 
5 Elavenir kaalam - - - - 
6 Mudhuvenir kaalam - - - - 
From the above table it is clear that majority of patients were admitted in Kaarkalam and Koothir 
kaalam and some of cases in Munpani kaalam. 
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5. Occupational status:
Since occupational history is closely relates with the exacerbation of the existing condition.
Table - 5 illustrates the Occupational status:
SI.NO  
     Occupation    No. of cases Percentage (%) 
1. Non workers         13     32.5 
2. Office workers           7     17.5 
3.  Teachers           2       5 
4. Coolies          18      45 
5. Total          40     100.0 
  Out of 40 patients 45 % of cases are coolies, 32.5 % of cases are Non workers and 17.5 % are 
Office workers.  
6. Diet reference: 
Table –6. illustrates the Diet: 
SI.NO Food habits No of cases Percentage 
(%) 
1. Vegeterian    2    5 % 
2. Non vegeterian    38    95 % 
3. Total    40    100  
Among 40 cases 95 % of the cases are non vegeterian and 5 % of the cases are vegeterian. It 
indicates non vegeterian diet may prone or aggravate this disease. 
No of cases
Vegeterian
Non vegeterian
7. Socio-Economic status: 
Table – 7. Illustrates the Socio-Economic status.
SI. No 
Socio-Economical 
Status No. of Cases Percentage 
1. High 6 15 % 
2.  Middle 14 35 % 
3.          Poor 20 50 % 
The above table shows, most of the patients affected by this disease belongs to Poor Socio-
Economic status. 
SOCIO ECONOMICAL STATUS
High
Middle
         Poor
8. Mode of Onset: 
Table 8. Illustrates the Mode of onset: 
S.NO Mode of onset In patients Out patients 
No of 
cases 
Percentage No of 
cases 
Percentage 
1 Acute 1 5 4 20 
2 Gradual 19 95 16 80 
Above table shows most of the cases had gradual onset.
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9. Duration of Illness: 
Table – 9. Illustrates the Duration of Illness. 
SI. 
No. 
Duration of 
Illness    No. of Cases Percentage 
1 Below 3 month 5                    12.5 
2 3 - 6  months 6 15 
3 6 - 12 months 11 27.5 
4  1 – 2 yr 10 25 
5  2 – 3 yr 3 7.5 
6  3 – 5 yr 2 5 
7. More than 5 yr 3 5 
   8. Total          40        100 
From the table it is clear that most of the cases were affected in the duration of 6 - 12 months.
Duration of illness
< 3 month
3 - 6  months
6 - 12  months
1 – 2 yr
2 – 3 yr
3 – 5 yr
> 5 yr
10.Clinical Manifestations:
Table – 10. Illustrates the Symptoms of the Disease. 
S.no Symptom Before treatment              After treatment 
No of 
cases 
Perc 
entage 
(%)
Relieved 
(No of 
cases)
Percen
tage 
(%)
Reduc
ed 
(No of 
cases
Percen
tage 
(%)
1 Joint pain 40 100 11 27.5 28 70
2 Major jt swelling 40 100 5 12.5 35 87.5
3 Minor jt swelling 40 100 12 30 28 70
4 Restricted movement 24 60 4 16.6 20 83.3
5 Morning stiffness 40 100 6 15 34 85
6 Sleeplessness 30 75 4 10 26 65
7 Loss of appetite 23 57.5 7 17.5 16 40
Among the 40 cases, before the treatment all the cases had joint pain, major and minor joint 
swelling. 60 % of the case had restricted movement, 75 % of the cases had sleeplessness and 57.5 % of 
cases had loss of appetite. 
After the treatment 
x Joint pain relieved in 27.5 % of cases and reduced in 70% of cases. 
x Major joint swelling relieved in 12.5 % of cases and reduced in 87.5 % of cases. 
x Minor joint swelling relieved in 30 % of cases and reduced in 70 % of cases. 
x Restricted movement relieved i 16.6 % of the cases and reduced in 83.3 % of cases. 
x Morning stiffness relieved in 15 % of cases and reduced in 85 % of cases. 
x Sleeplessness relieved in 10 % of cases and reduced in 65 % of cases. 
x Loss of appetite relieved in 17.5 % of cases and reduces in 40 % of cases. 
11. Systemic Examination (Extra articular features): 
Table – 11. Illustrates the signs of Systemic Examination.  
SI. No Signs 
In -  Patients Out - Patients 
No. of 
Cases
Percentage 
No. of 
Cases
Percentage 
1 Subcutaneous nodules 4 20 - - 
2 Muscle wasting 4 20 3 15 
3 Respiratory 
system(Breathlessnes) 
5 25 3 15 
Horseness of voice - - 2 10 
4 Nervous system 
(Peripheral neuritis) 
3 15 2 10 
Out of 20 In-Patients, 20% of the cases had subcutaneous nodules, 20% of the cases had 
muscle wasting, 15% of the cases had peripheral neuritis and 25 % of the cases had breathlessness. 
Out of 20 Out-Patients 15 % of the cases had muscle wasting, 10% of the cases had central 
nervous system involvement, 10 % of the cases had horseness of voice and 15 % of the cases had 
breathlessness.
12. Individual joints involvement: 
Table – 12. Illustrates the incidence of individual joints involvement.
SI. No. Joints involved 
In -  Patients Out - Patients 
No. of Cases Percentage No. of Cases Percentage
1 Proximal inter phalangeal Joints 20 100 20 100 
2 Metacarpo-phalangeal Joints 20 100 20 100 
3 Wrist Joint 20 100 16 80 
4 Elbow Joint 8 40 9 45 
5 Shoulder Joint 9 45 6 30 
6 Temporomandibular Joint 2 10 1 5 
8 Cervical spine  9 45 6 30 
9 Lumbar spine 4 20 3 15 
10 Hip Joint 2 10 3 15 
11 Knee Joint 18 90 17 85 
12 Ankle Joint 20 100 18 90 
13 Meta-tarso phalangeal Joints 12 60 11 55 
From the above table it is clear that in all the patients’ proximal interphalangeal joints, 
metacarpo-phalangeal joints, wrist joint, ankle joint and knee joint gets more affected.
13. Deformity of Joints: 
Table – 13 illustrates the distribution with respect to Deformity of Joints. 
S. No Deformity 
In-Patients Out-Patients 
No of cases Percentage No of cases Percentage
1 Swan neck deformity 2 10 - - 
2 Z shaped thumb 2 10 - - 
3 Ulnar deviation of fingers 3 15 1 5 
4 Ulnar deviation of toes 3 15 2 10 
5 Hallus valgus 2 10 -         - 
From the table it is clear that in both Out-Patients and In-Patients 
  7.5% of the cases had foot deformity, Swan neck deformity was seen in 10% of cases, Z shaped 
thumb was seen in 10 % ofcases, ulnar deviation of fingers was seen in 10% of Out-patients, Hallus 
valgus seen in 10 % of cases.  
14. Gradation of Pain. 
Table – 14. Illustrates the Grades of Pain in before and after to the treatment: 
S.NO PAIN Before 
treatment 
                   After treatment 
                   (No of Cases) 
No of cases Relieved Reduced No change 
1 Mild 11 8 3 - 
2 Moderate 18 2 10 6 
3 Severe 11 - 7 4 
From the above table, 
Before the treatment 11 cases had mild pain, after the treatment pain relieved in 8 cases, 
reduced in 3 cases.
Before the treatment 18 cases had moderate pain, Out of this after the treatment pain relieved in 
2 cases, reduced in 10 cases and moderate pain still persist in 6 cases. 
Severe pain in 11 cases, after this treatment pain reduced in 7 cases and in 4 cases no changes 
occur.
15. Grading of Restricted movements: 
Table – 15. Illustrates the Grading of Restricted movements. 
SI.
No 
Grading of rheumatoid arthritis 
In -  Patients Out - Patients 
No. of 
Cases
Percentage No. of Cases Percentage 
1 I – no restriction in normal activities 2 10 4 20 
2 II – moderate restriction 10 50 8 40 
3 III – marked restriction 7 35 8 40 
4 IV – confined to bed 1 5 - - 
Most of the cases come under moderate and marked restriction. 
16 Disturbances in Mukkutram: 
Table – 16. Illustrates the disturbances in Mukkutram. 
a. Disturbances in Vatham: 
SI. No Vatham 
In -  Patients Out - Patients 
No. of Cases Percentage No. of Cases Percentage 
1 Praanan             5          25          3        15 
2 Abaanan 12 60 9 45 
3  Viyaanan 20 100 20 100 
4 Udhaanan - - 2 10 
5 Samaanan 20 100 20 100 
6 Naagan - - - - 
7 Koorman - - - - 
8 Kirukaran 17 85              18 90 
9 Devathathan 16 80 14 70 
In all the cases Viyaanan, Samaanan gets affected due to pain, restricted movements and 
difficulty to perform locomotive action. Devathathan affected in most of the cases due to 
sleeplessness and Abaanan were affected in some of the cases due to constipation. Pranan also affected 
in some cases due to breathlessness Uthanan affected in 10 % of out patients due to horseness of voice. 
b. Disturbances in Pitham:
SI. No Pitham 
In - Patients Out - Patients 
No. of 
Cases
Percentage 
No. of 
Cases
Percentage
1 Anal pitham 17 85 18 90 
2 Ranjaga pitham 20 100 20 100 
3  Prasaga pitham 4 20 5 25 
4 Alosaga pitham 5 25 7 35 
5 Saathaga pitham 20 100 20 100 
All the cases get affected with Sathaga pitham and Ranjaga pitham, anal pitham 
affected due to loss of appetite Prasagam affected in some cases due to heat presents over the 
joints. 
c. Disturbances in Kabham: 
 SI. No Kabham In -  Patients Out - Patients 
No. of 
Cases
Percentage No. of 
Cases
Percentage
1 Avalambagam 20 100 20 100 
2 Kilethagam 17 85 18 90 
3  Pothagam  - - - - 
4 Tharpagam 5 25 7 35 
5 Santhigam 20 100 20 100 
Table shows that all the cases get affected with Avalambagam, Kilethagam and 
Santhigam due to pain, swelling, restricted movement and deformity over the joints.
Kilethagam affected due to loss of appetite. Tharpagam affected in some cases due to impaired 
vision.
17. Involvement of Udal Thathukkal:
Table – 17. Illustrates the Involvement of Seven Udal Thathukkal. 
SI. No Udal thathukkal 
In -  Patients Out - Patients 
No. of Cases Percentage No. of Cases Percentage 
1 Saaram 20 100 20 100 
2 Senneer 20 100 20 100 
3  Oon  20 100 20 100 
4  Kozhuppu 20 100 20 100 
5 Enbu 20 100 20 100 
6 Moolai - - - - 
7 Sukkilam/Suronitham 4 20 3 15 
Table shows, in all the cases Saaram, Senneer, Oon, Kozhuppu and Enbu gets affected.
Suronitham affected in some cases due to menstrual irregularity.
Saaram affected due to general debility of the patients, Senneer affected due to ESR, Hb, RA 
factor & CRP variations, Oon affected due to swelling and muscle wasting. Kozhuppu affected due to 
restricted movements. Enbu affected due to deformity and pain over the joints. 
18. Envagai Thervugal:
Table – 18. Illustrates the condition seen in Envagai Thervugal. 
SI. No Envagai thervugal 
In -  Patients Out - Patients 
No. of Cases Percentage No. of Cases Percentage 
1 Naa  
5 25 3 15Pallor of the tongue 
Coated tongue 12 60 9 45 
2 Niram 4 20 5 25 
3  Mozhi - - 2 10 
4 Vizhi  
5 25 3 15Pallor  
Impaired vision 5 25 7 35 
5 Malam 12 60 9 45 
6 Moothiram 
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      Kaba neer
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x Sparisam gets affected in all the patients due to heat and tenderness over the affected area.  In 
all the cases Neerkuri showed straw yellow colour and less frothy. Amoung the 20 out patients 
45 % of the patients showed vatha neer (aravena neelal), 40 % of the patients showed kaba neer 
(aazhipol paraval) and 15 % of the patients showed pitha neer (Muthu othu nitral). 
x Out of 20 in patients 40 % of the patients showed vatha neer, 45 % of the patients showed kaba 
neer and 15 % of the patients showed pitha neer. 
x Out of 20 in patients 60 % of the patients had Vathapitha Naadi and a few had Pithavatha 
Naadi and Vathakabam. 
x Out of 20 out patients 55 % of the patients had vathapitha naadi, 35 % of the patients had Pitha 
vatha naadi and 10 % of the patients had vatha kaba naadi. 
x 25 % of the in patients and 15 % of the Out patients had pallor. 
x Out of 20 out patients 10 % of the patients had horseness of voice. 
x Constipation occurred in 60 % of in patients and 45 % of out patients. 
19. Investigations: 
  A. HB:
       B V A – P < 0.05 – Moderately significant. 
       HB – Before treatment – 10.55 + 1.74 
       HB – After treatment – 11.06 + 1.92    
 In this study, after to the treatment moderate improvement occur in heamoglobin level. 
B. ESR ½ hour: 
       Before treatment – 22.34 + 20.2 
       After treatment – 15.3 + 13.15 
       P < 0.001 – Highly Significant.
    ESR 1 hour: 
       Before treatment – 43.85 + 35.58 
       After treatment – 31.45 + 27.64 
       P < 0.0007 – Highly significant. 
 In this study, after to the treatment moderate improvement occur in ESR level.  
C. Improvement table of RA factor and CRP: 
S.NO Out patients In patients No of 
negative
cases No of cases No of cases 
BT AT BT AT AT 
RA 9 8 8 6 3 
CRP 6 3 12 7 8
 Out of 40 cases 17 cases had RA factor positive and after to the treatment 3 cases only had 
negative result. 
 Out of 40 cases 18 cases had CRP positve and 8 cases had negative result in after the treatment. 
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CRP & RA factor improvement chart
Series1
Series2
Improvement assessed by following assessments: 
1. Pain assessment scale. 
2. Restricted movement assessment grade. 
3. Hb & Erythrocyte sedimentation rate variation. 
4. RA factor & CRP variation.
Over all results. 
SI. No Results 
In -  Patients Out - Patients 
No. of Cases Percentage No. of Cases Percentage 
1 Good  
Improvement 9 45 12 60
2 Moderate 
Improvement 5 30 5 20
3
Mild  
Improvement 4 20 3 15
    4 No Improvement           1            5             -           - 
   5 Deteriorated - - - - 
 Total 20 100 20 100 
Out of 20 In-Patients, 45 % of cases showed good improvement 30 % cases showed moderate 
improvement and 20 % of cases showed mild improvement. Out of 20 out-Patients, 60% of cases 
showed good improvement, 20% of cases showed moderate improvement and 15 % of cases showed 
mild improvement. 5 % of in patient showed no improvement.
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OVERALL IMPROVEMENT FOR OUT PATIENT DEPARTMENT
S.No Op. No Age/Sex Date of 
Treatment
Starting 
 End  
of The
Treatment 
Improvement     Duration 
of illness  
1. A.L.9173    37/F       09.08.08       02.09.08 Good 3 month 
2. A.L.8950    31/F       09.08.08       02.09.08 Good 3 month 
3. A.m.48    55/F       13.08.08       04.09.08 Good > 1 yr 
4. A.m.732    29/F       18.08.08       08.09.09 Mild > 1 yr 
5. A.L.7238    42/F       11.09.08       02.10.08 Mild > 6 month 
6. A.K.271    39/F       17.08.08       08.10.08 Good 3 month 
7. W.368    44/F       20.08.08       11.09.08 Good 1 yr 
8. A.m.22    38/F       13.08.08       04.09.08 Good 1 1/2 yr  
9. A.m.777    33/F       17.08.08       09.09.09 Good > 6 month 
10. A.m.825    29/F       17.08.08       09.09.08 Good > 6 month 
11. A.m.1838    38/F       10.9.08       02.10.08 Moderate 8 month 
12. A.m.4364    46/F        09.09.08       29.09.08 Moderate 3 month 
13. O.5893    32/F        11.09.08       03.10.08 Moderate 6 month 
14. O.2447    40/F        04.09.08       24.09.08 Good > 3 month 
15. A.N.1856    42/F        13.10.08       04.10.08 Good 1 1/2 yr 
16. A.N.1846    55/M        04.10.08       25.10.08 Moderate 1  yr 
17. A.m.191    48/M        14.08.08       05.09.08 Good > 6 month 
18. A.N.1150    38/F        10.10.08       01.11.08 Moderate 4 month 
19. A.N.4353    45/F        11.10.08       02.11.08 Good 5 month 
20. A.N.5285    32/F         22.10.08       13.11.08 Mild 8 month 
OVERALL IMPROVEMENT FOR IN PATIENT DEPARTMENT: 
S.N
o
IP. No Age/S
ex 
Date of 
Admissi
on
Date of 
Discharge 
Treatment 
days in IP Improvement 
Duration of 
illness    
1. 1074  34/F 08.08.08   29.08.08        20       Good < 1 yr 
2. 1103 30/F 21.08.08   12.09.08        20        Mild < 1 yr 
3. 1095 43/F 19.08.08   11.09.08      20      Moderate > 1 yr 
4. 1097 40/F 20.08.08   12.09.08      20       Good > 5 yr 
5. 1631 25/M 16.09.08   29.09.08      12       Good < 3month 
6. 1627 47/M 16.09.08     04.10.08      18       Good < 1 yr 
7. 1675 52/M 04.10.08   13.10.08      08       Good > 6 month 
8. 1195 55/F 29.09.08     10.10.08      10       Good  > 6 month 
9. 1628 32/M 16.09.08    14.10.08      28       Moderate > 4 yr 
10. 1202 50/F 04.10.08     24.10.08      20       Moderate > 2 yr 
11. 1216 36/F 10.10.08   19.10.08      08       Moderate > 3 yr 
12. 1221 48/F 15.10.08    24.10.08      08       Good > 1 yr 
13. 1622 30/M 15.09.08     22.09.08      07       Moderate 2 ½ yr 
14. 1224 36/F 16.10.08   31.10.08      15       Moderate > 4yr 
15. 1205 55/F 06.10.08   31.10.08      24       Moderate > 1 yr 
16. 1211 50/F 07.10.08    31.10.08      22        Mild  < 5 month 
17. 1212 36/F 09.10.08     31.10.08      20        Mild > 5 yr 
18. 1697 36/F 13.10.08  31.10.08      18       Good 1 yr 
19. 1289 40/F 18.11.08    08.12.08      19       Good > 2 yr 
20. 1290 38/F    18.11.08  10.12.08      20        Mild  2 yr 
Ayothidhasar Pandithar Hospital, National Institute of Siddha, Tambaram sanatorium. 
IN PATIENTS SEROLOGICAL IMPROVEMENT REPORT: 
S.NO IP .NO             RA factor                   CRP 
  Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
1. 1103 Pos Pos Pos - 
2. 1095 Pos Pos Pos Neg 
3. 1097 Pos Pos Pos Pos 
4. 1631 Neg Neg Pos Pos 
5. 1195 Pos Neg Pos  Pos 
6. 1202 Pos  Pos Pos  Neg 
7. 1216 Neg Neg Pos  Neg 
8. 1221 Neg Neg Pos  Pos  
9. 1224 Pos  Pos  Pos  Pos  
10. 1205 Pos  Neg  Pos  Pos  
11. 1211 Pos Pos Pos Pos 
12. 1212 Neg Neg Pos  Pos  
13. 1697 Pos  Neg Neg Neg 
14. 1622 Neg Neg Pos Pos 
15. 1289 Pos Pos Pos Pos 
16. 1290 Pos Pos Neg Neg 
Ayothidhasar Pandithar Hospital, National Institute of Siddha, Tambaram sanatorium. 
OUT PATIENTS SEROLOGICAL IMPROVEMENT REPORT: 
S.NO OP .NO             RA factor                   CRP 
  Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
1. AL.9173 Pos Pos Neg Neg 
2. Am.732 Pos Pos Pos Pos 
3. AL.7238 Pos Pos Neg Neg 
4. W.368 Pos Pos Pos Neg 
5. Am.22 Pos Pos Neg - 
6. A.m.825 Pos Pos Pos Neg 
7. Am.1838 Pos Pos Neg Neg 
8. 1846 Pos  Pos Pos Neg 
9. AN.5285 Pos  Pos  Neg Neg 
10. Am.777 Neg Neg Pos Neg 
11. O.5893 Neg Neg Pos Pos 
TABLE ILLUSTRATES THE IMPROVEMENT OF HEAMOGLOBIN & ESR:
IN PATIENTS: 
S. 
N
O
IP.NO
Haemoglobin                    ESR 
Before 
treat
ment 
After 
treat
ment 
   Before 
treatment 
After 
treatment 
   ½ 
hour 
1 hour ½ 
hour 
1 hour
1 1074 10.8 12.1  18 25 04 12 
2 1103 09.0 09.7  22 46 26 50 
3 1095 09.7 08.2  20 44 08 16 
4 1097 08.2 08.2  08 16 20 40 
5 1631 11.1 13.7  14 30 11 22 
6 1627 09.7 10.2  14 28 6 18 
7 1675 09.6 13.1  18 36 12 24 
8 1195 11.5 12.2  16 32 08 16 
9 1628 13.1 15.5  06 12 06 12 
10 1202 09.4 11.0  18 36 12 24 
11 1216 10.8 12.0  30 60 30 60 
12 1221 08.5 08.0  10 20 06 14 
13 1224 12.0 12.2  26 52 12 24 
14 1205 11.3 13.5  10 22 20 40 
15 1211 08.5 10.5  120 200 70 152 
16 1697 14.0 11.1  16 32 20 40 
17 1622 08.2 09.0  42 90 28 60 
18 1289 09.4 10.0  60 124 45 92 
19 1290 12.6 09.0  02 04 07 14 
20 1212 09.4 09.5 15 30 10 20 
TABLE ILLUSTRATES THE IMPROVEMENT OF HEAMOGLOBIN & ESR:
OUT PATIENTS: 
S.
N
O
OP. 
NO 
Haemoglobin                   ESR 
Before 
treatme
nt 
After 
treatme
nt 
   Before 
treatment 
After 
treatment 
   ½ 
hour 
1
hour 
½
hour 
1
hour
1 AL.9173 12.1 10.6  04 10 06 12 
2 AL.8950 09.2 09.2  15 30 08 16 
3 Am.48 08.7 10.6  10 22 04 08 
4 Am.191 11.2 10.7  12 24 08 16 
5 Am.732 08.7 08.2  12 25 06 12 
6 AL.7238 06.8 08.2  50 100 20 40 
7 Ak.271 09.7 15.0  48 82 04 08 
8 W.368 09.7 10.7  25 50 10 20 
9 Am.22 12.1 10.2  08 16 20 40 
10 Am.777 10.2 10.8  30 60 20 40 
11 Am.825 12.2 11.6  30 60 35 72 
12 Am.1838 10.7 11.0  16 32 08 16 
13 Am.4364 11.0 11.2  22 46 04 08 
14 O.5893 09.7 10.0  15 30 30 60 
15 O.2447 10.6 12.1  24 48 14 28 
16 AN.1856 11.6 11.8  08 16 04 08 
17 1846 12.6 13.0  22 44 12 28 
18 AN.1150 13.6 13.4  14 28 12 24 
19 AN.4353 10.3 11.2  16 32 06 12 
20 AN.5285 14.5 14.5  30 60 20 40 
DISCUSSION
DISCUSSION:
 The main aim of treatment is to keep the Trithodam in equilibrium state, and to keep the 
inflammatory process at a minimum there by preserving joint motion, reducing constitutional 
symptoms, maintaining healthy muscles, preventing joint stiffness, restricted movements and the 
development of deformity, 
 40 cases (20 Out-Patients and 20 In-Patients) were selected from the patients reporting in Pothu 
maruthuvam department, Ayothidoss pandithar hospital of NIS, satisfying inclusion and exclusion 
criteria will be eligible for admission to the trial. To balance the altered three thathus purgative was 
given on previous day to start the treatment. Hence all the patients were given Merugulli thylam 10 ml 
with warm water and were put on diet to take only butter milk.   
          The patients were treated for a period of 20 days with the trial drugs such as Rasapralaya 
chenthuram was given internal at the dose of 100 mg b.i.d with the vehicle of thirikaduku chooramam 
and adjuvant of honey and Navanatha siddhar thylam applied externally over affected joints. Out-
Patients were reviewed once in seven days. Clinical and assessments of In-Patients were reviewed 
daily. 
         Before starting the treatment, instructed the patients to stop if any medicines taken internally. All 
the patients were advised to follow strict diet restriction and peaceful life style to normalize the 
immune mechanism. Advised the patient to take warm water bath and hot fermentation therapy to 
reduce the stiffness. Ottradam was done over the inflammatory joints using Vatha Narayanan leaves, 
Erukku leaves, Notchi leaves, Neem leaves and Thazhuthalai leaves.
Mild exercises advised to reduce the stiffness and restricted movements. Savasana, breathing 
excercise also advised to relief stress and sleeplessness. The triggering factors were also studied. Daily 
observation was made during this study.  
The observations discussed below:
Sex Distribution:
 From this study it is clear that the incidence was higher in females than in males. In this study 
male and female ratio occur in 1:4. It indicates Udhiravatha Suronitham is predominant in females. 
Age Distribution: 
 The study reveals that the incidence of disease was more predominant in 4th, 5th decades of 
life.  Further it was concluded that majority of cases (70 %) were affected in their Pitha kaalam (i.e. 
Middle 33 years and 4 months). 
Thinai: 
In this study most of the cases comes from Neithal nilam.
                                  “ntö¾É¢Ä§Á ¾íÌ Å£¼¡Ìõ"
    
According to siddha literature Pathartha guna chinthamani mentioned vatha diseases occurs  
more in Neithal nilam.  
Paruva kaalam:
Siddha literature Yugi vaithya chinthamani mentioned  
            "¬¾¨Äô Àº¢§Â¡Î ¸¡÷ò¾¢ ¾ýÉ¢ø 
            «¼Õ§Á ÁüÈ Á¡¾í¸û ¾ýÉ¢ø" 
In this study most of the cases admitted in Karkaalam, Koothirkaalam.
Occupational status:
   Most of the cases are (45 %) coolies and non workers (32.5%). Mostly coolies belongs to 
poor socio economical status, their poverty and stress induce this disease. Most of the non workers are 
house wife. 
Diet reference: 
           Most of the cases (95 %) were non vegeterian and Non vegeterian diet may aggravates the 
disease process.  
Socio-Economic Status: 
Majority of the cases (50 %) belongs to poor socio-economical condition. It indicates 
malnutrition, lowered immune responses and emotional stress made them more prone to this disease. 
Etiological Factors:
From this study the etiology of the disease remains unknown. However changes in food habits 
and life style predisposes to the derangement of three humors resulting in the causation of disease.
Mode of Onset: 
In my observation most of the patients comes with gradual onset. Failure to follow medical 
advice regarding dietary restrictions, stress and strain, changes in life style all accounts for the disease 
to become chronic.  
Duration of Illness: 
 Most of the cases (27.5 %) were affected with the duration of illness between 6 – 12 months.
25% of cases were affected with duration of illness 1 – 2 years. 
Clinical Manifestations:
  In this study, joint pain and major joint swelling relieved in some of the cases and reduced in 
most of the cases. 
 Minor joint swelling relieved in 30 % of cases and reduced in 70 % of cases and Restricted 
movement reduced in 60 % of cases. 
 Sleeplessness and Loss of appetite are relieved in some cases only and reduction of some 
degree in most of the cases. 
 After treatment, the early morning stiffness which occured for a period of >1 hr has been 
reduced to 10 – 20 min. 
Systemic Examination: 
 Out of 40 cases, minimal cases only had subcutaneous nodules, muscle wasting and peripheral 
neuritis. After this treatment there are no changes in subcutaneous nodules. There was mild 
improvement in muscle wasting and peripheral neuritis. 
Deformity:
In this study there is no improvement in deformity. 
Changes in functional ability: 
.
S.
NO
Grading of Restricted 
movement 
Before treatment After treatment 
No. of 
Cases
Percent
age
No. of 
Cases
Perce
ntage 
1
I – no restriction in normal 
activities
6 15 10 25 
2 II – moderate restriction 18 45 19 47.5 
3 III – marked restriction 15 37.5 10 25 
4 IV – confined to bed 1 2.5 1 2.5 
 Among the 40 cases, before treatment 37.5 % of cases belongs to G III and after treatment 12 .5 
% of cases were reducing their restriction. 
 After to treatment 25 % of cases had no restriction in their normal activities. 
 Before to treatment 2.5 % of cases belong to G IV and after to treatment there is no changes 
occur.
MUKKURAM BASIS: 
A. Disturbances in Vatham:
 During the treatment Abanan affected (constipation) in some cases and advised to take more 
greens, vegetables and water. Most of the cases relieved from Constipation and for some cases only 
prescribed nilavagai chooranam. 
 In most of the cases devathathan affected due to sleeplessness and advised to do savasana and 
breathing exercise; in my study due to these patients get some relief.  
B. Disturbances in Kabham:
 Santhigam affected in all cases due to pain, swelling and restricted movement. After the 
treatment moderate improvement occurs in pain and swelling, mild reduction occurs in restricted 
movement. 
Involvement of Seven Udhal Thathukkal: 
Among 20 In-Patients and 20 Out-Patients, Saaram, Senneer, Oon, Kozhuppu and Enbu were 
affected in all the cases. 
Affected Saaram produces fatigue in patients. After the treatment it releives in some patients, it 
may be due to medicine and advised to take nutricious diet. 
Affected Senneer produces variation in the level of Hb, increased ESR, and positive CRP & 
Rheumatoid factor. After the treatment from the statistical analysis moderate improvements occur in 
Hb level (B V A – P < 0.05 – Moderately significant) and ESR level (P + 0.0007 – Highly 
significant).
Affected Kozhuppu produces restriction of movements in joints and after the treatment 25 % of 
cases had no restriction in their normal activities. 12 .5 % of cases were reduce their restriction from 
GIII restricted movement. 
Affected Enbu produces joint pain, joint deformity. After to this treatment there is no changes 
occur in deformity and pain reduced in most of the cases. 
Envagai Thervugal: 
Among 40 cases Naa was affected in most (65 % of IP & 75 % of OP) the cases due to coated 
tongue. After reducing constipation, coated tongue was disappearing in most cases.  
Pallor of the tongue and pallor of palpabral conjuctiva (due to vizhi affected) occur in minimal 
cases only and after to treatment paleness was reduced. 
Mozhi was affected in 10 % of OP cases due to hoarseness of voice and after to this treatment 
horseness persist in one case. 
Malam was affected in 60% of In-Patients and 45% of Out-Patients having constipation, advised to 
take more greens, vegetables and water. Most of the cases relieved from Constipation and for some of 
the cases only prescribed nilavagai chooranam. 
Sparisam was affected in all the cases producing swelling and warmth in the painful joints and 
after to treatment swelling relived in some cases and reduced in most of the cases. 
   Regarding Moothiram, neerkuri was normal in all the cases.  
¾ Neikuri showed Vatha Neer (Spread likes snake) in 40% of In-Patients and 45% of Out-
Patients. 
¾ 15% of In-Patients and out-Patients showed pitha neer. 
¾ 45 % of In-patients and 40 % of out patients showed kaba neer. 
After to the treatment there is no significant changes occur in neikuri. 
Investigations:
After to this treatment most of the cases had some improvement in their Hb level, CRP & RA 
factor.  Statistical analysis in serological report indicates significant changes occur in Hb and ESR 
level. 
S.NO Out patients In patients No of 
negative
cases No of cases No of cases 
BT AT BT AT AT 
RA 9 8 8 6 3 
CRP 6 3 12 7 8
Out of 40 cases 17 had RA factor positive and after to the treatment 3 cases only had negative 
result. 
 Out of 40 cases 18 cases had CRP positve and 8 cases had negative result in after the treatment
Biochemical analysis: 
 Qualitative analysis of Rasapralaya chenthuram done in C.L. Beid metha college of Pharmacy, 
Thoraippakkam reveals Rasapralaya chenthuram contains Calcium, Iron, Magnesium, Zinc etc.
 Quantitative analysis done in Mettex laboratory by Atomic absorbtion method, Rasapralaya 
chenthuram conatains 622 mg/ kg of Magnesium, 0.49 % of Calcium, 946 mg/kg of Iron and 
13.1 mg/ kg of Zinc. 
 Zn plays a vital role in immunity and it prevents infection. It also acts as an antioxidant. Iron is 
essential for transport of oxygen to the tissues. In Uthiravatha suronitham, anemia is one of the 
features. Statistical analysis from laboratory reports showed Moderate significant in 
haemoglobin level. Calcium is necessary for the regulation of acid base balance and water 
balance in the body and it also prevents the development of osteoporosis.
Toxicity study: 
 Toxicological study of Rasapralaya chenthuram were done in C.L.Beid Metha college of 
Pharmacy, Thoraippakkam, Acute oral toxicity study on RPC did not exihibit any mortality in 
rat at the dose of 2000 mg/kg/po. 
 In repeated oral toxicity study for 15 days at the dose of 500 mg/kg/poin rats, did not exhibit 
toxicity in Haematopoetic system and Liver. However the drug exhibited an increase in uric 
acid level after the administration for 15 days.  
 Did not exhibit any significant changes in RBC count and Hb%. The bio markers of liver 
function tests did not show the evidence of liver toxicity. There were no significant changes in 
Haematological parameters like cholesterol, body weight, food, water intake and behavioural 
parameters. 
 Pharmacological studies done in C.L.Beid Metha college of Pharmacy, Thoraippakkam reveals 
Rasapralaya chenthuram bears significant analgesic and Anti inflammatory actions in rats.The 
test drug showed maximum anti inflammatory activity at the end of 4 th hour to compared 
diclofinac sodium and Navanatha siddhar thylam had significant acute anti inflammatory 
activity. 
 Anti arthritic study done in S.S.N.college reveals Rasapralaya chenthuram have moderate anti 
arthritic activity. 
SUMMARY
SUMMARY
 The aim of the study is to evaluate the efficacy and safe chemotherapy for Uthiravatha 
suronitham. 
 For the clinical study, 40 cases were selected based on the inclusion and exclusion criteria. Out 
of this 20 cases were treated in OPD and 20 cases were treated in IPD of Ayothidoss Pandithar 
Hospital of National Institute of Siddha, Chennai. 
 Clinical diagnosis of Uthiravatha suronitham was done by Siddha and modern methodology. 
  Investigations carried out before and after treatment and data were recorded in the proforma. 
  A day before starting the trial drug treatment, purgation was given to correct the elevated 
mukkurams 
 The trial medicines selected for both internal and external treatment were Rasapralaya 
chenthuram – 100 mg b.i.d with the adjuvant of honey, vehicle of thirikaduku chooranam and 
Navanatha siddhar thylam respectively. 
 During the period of the treatment all the patients were put under pathiyam. 
 The improvement of the patients was observed from the second day of the treatment itself in 
general and clinical assessments noted in daily progress chart. Observation made during the 
clinical study showed that the trial drug was clinically effective.  
 It is more prevalent in Kaarkalam and Koothir kalam. Most of the patients are female and most 
of the patients were belongs to poor socio-economical status. 
 Most of the patients had vatha pitha naadi and pitha vatha naadi. In neikkuri, vatha neer and 
kaba neer showed in most of the cases. 
 In my observation stress, malnutrition and poor socio-economical status is aggravates this 
disease.  
 During the study period, there was no drug reactions occur. 
 In these studies out of 40 cases, 21 cases were good improvement, 10 cases were moderate 
improvement and 7 cases were mild improvement in clinical as well as laboratory investigation 
procedure also. 
 As per our Siddha Materia medica the ingredients of the trial drugs were found to have the 
property of controlling vatha diseases. 
 From the Acute toxicity study, the trial drug is safe even at higher dose of 2000 mg/kg/po. 
 Repeated oral toxicity study for 15 days exhibited, alteration in uric acid level and the trial drug 
did not exhibit any alteration in the normal architecture of the kidney at the end of 15 days. Since 
there is no report on the kidney function test done in clinical study, it can be resonably assumed 
that the drug is safe for humans. 
 The formulation exhibited significant anti oxidant activity and no change in the LPO activity in 
rat treated for 15 days. 
 Pharmacological study showed the trial drug contains significant anti arthritic, anti-
inflammatory and analgesic activity. 
CONCLUSION
                CONCLUSION 
Acute toxicity study reveals that the trial drug is safe even at higher dosage of 2000 mg/kg/po 
but in repeated toxicity study there was a mild variation only in uric acid level at the dosage of 500 
mg/kg/po. Since there are no reports on the kidney function test done in clinical study, it can be 
resonably assumed that the drug is safe for human. 
Clinical study reveals that the trial drug shows good improvement (55 %, moderate, 25 %, mild 
and 17.5%) and No improvement in 2.5% of cases. There were no adverse effects found during the 
course of the treatment. 
Because of the encouraging clinical results, if the study may be undertaken with the same drug 
for a prolonged period of time with more number of cases, it may become one of the milestones in 
treating Uthiravatha suronitham successfully. 
ANNEXURES
Preparations and 
Properties of the 
Trial drugs 
,urgpusa nre;J}uk; 
§¾¨ÅÂ¡É ºÃìÌ¸û: 
Rj;jp nra;j ,urk; 3 gyk; (105 fpuhk;)> Rj;jp nra;j ney;ypf;fha;f; nfe;jfk; 2.½
gyk; (87.½ fpuhk;)> nrk;Ks;spapiyr; rhW> nrk;guj;jk;g+r;rhW> kpsFj;jf;fhspr;rhW> 
nrUg;gbr;rhW> khJis ,iyr;rhW> khJsk;g+r;rhW> ,it tiff;F nry;yj;jf;f msT. 
nra;Kiw:- Nkw;gb ,uz;L ruf;ifAk; njhe;jpj;jiuj;J ed;whff; fWj;jgpd;G 
Nkw;fz;lgb MWtifr; rhWfspdhYk; xt;nthU ehs; cyh;j;jp Kbthfr; nrk;ikahf 
cyh;j;jpg; nghbj;J VO rPiykz; nra;j nfq;fhryf; Fg;gpapy; miuthrpapl;Lf; Fg;gptha;f;F 
khf;fy; %bapl;Lr; rPiynra;Jyh;j;jpr; nre;J}ug; ghidapy; ehYtpuw;fpil kzypl;L Njd; Nky; 
Fg;gpia itj;Jg; ghid epiwa kzypl;L tl;lLg;gpNyw;wpj; jhd; topgLk; flTisj;Jjpj;J> 
xUrhjpr; rpWtpwfhy; xUrhkk; jPghf;fpdpahfTk; ,uz;L rhkk; fkyhf;fpdpahfTk;> ,Ugj;njhU 
rhkk; fhlhf;fpdpahfTk; vhpj;Jf;Fspu Mwtpl;L> jhd; topgLk; flTisg; g+irnra;J 
ViofSf;F md;dkpl;L> Fg;gpia cilj;Jg; ghh;j;jhy; KUf;fk;g+g; Nghd;w tz;zKs;s 
nre;J}ukha; ,Uf;Fk,; ,jidg; nghbnra;J Gl;bapy; gj;jpug;gLj;jTk;. 
mDghdKk;> jPUk;Neha;fSk;:- jphpfLif ,stWg;ghf tWj;J ,bj;jj;J}s; tiff;F 3 
Fd;wpkzpnail (3.½ fpuhk;) Njd; 1 tuhfd; vil> Nkw;fz;l nre;J}uj;ij msTg;gb Nrh;j;J 
,uz;L NtisAk; ,UgJ ehs; cl;nfhs;s #iyfs;> thAf;fs;> thjNeha;fs; Mfpait 
jPUk;. 
etehjrpj;ju; ijyk;: 
rPk;kKfp jOjhio ahh;f;Fkj; jq;FlQ; 
rpj;jpuk; tpahf;fphpifahd; 
rpe;Jth uQ;rlf; fiunjhb kzpg;gyQ; 
Nrh;fhhp aq;Fthjk; 
ntk;ikNah nll;bnyhd; whapnwz; Nzuz;lk; 
Ntk;gpit nea;tpLgbgb 
Nth;f;nfhk;G gJkeh sq;fLF fl;lkfpy; 
nts;trk; Gf;fpufe;ij 
nrk;ikjU ghspj kuj;ijg+z;be;J 
jpg;gpyp ak;%ykJue; 
jphpgiy KRf;if rq;fPj Kah;NfhsQ; 
nrg;Gkf kpitfisnayhq; 
fk;nkd kzg;ngoj; Jfs;Ghpnaht; nthd;wdpU 
f/nrd tpshtped;whf; 
fha;r;rptb etehj rpj;jh;Ghp ijykpJ 
fskkpL kzpthuNk 
nghUs;
MlhNjhil> jOjhio> vUf;F> Ckj;ij> rJuf;fs;sp> Mkzf;F> fz;lq;fj;jphp> 
ifahe;jfiu> nehr;rpy; vd;Dk; Nth;fs; (9-k;) tif 1-f;F (gyk;-20) Mf epWj;jpbj;Jg; 
ghz;lj;jpw; Nrh;j;J (4-kuf;fhy;) ryk;tpl;Lf; fha;r;rp (8-y;) xU gq;fhfr; RLifAld; ,Wj;j 
f\haj;jpy; vs;Snea;> Mkzf;F nea;> Ntg;gnea; ,it %d;Wk; tif 1-f;F (gb-1) 
Mftpl;L> Rf;F> jhkiutisak;> fLF> Nfhl;lk;> mfpy;fl;il> nts;trk;G> trk;G> 
nrQ;re;jdk;> rpw;wuj;ij> nts;isg;g+z;L> ,e;Jg;G> Nfhiuf;fpoq;F> jpg;gpyp %yk;> 
mjpkJuk;> fLf;fha;> ney;ypf;fha;> jhd;wpf;fha;> KRKRf;ifNth;> fpr;rpypf;fpoq;F> 
tha;tpsq;fk;> vd;Dk; fw;fjputpak; (21-Ak;) thrid naOk;Gk;gb ed;whf ,bj;J 
t];jpufhaQ;nra;j J}is tif 1-f;F (gyk; 1/2) Mf vLj;J Nkw;gb vz;nzapypl;Lf; 
fyf;fp rpwpa jPapdhy; vhpj;Jg; gf;Ftj;jpy; tbj;J mf;flj;jpw;Fr; rPiykz; nra;J 
new;Glj;jpy; (9 ehs;); itg;ghahf. ,JNt etehjrpj;jh; ijykhk;. 
,jd; kfpik: 
kzpehl;l ze;njLj;jk; khjth;nghw; gjk;gutpg; 
gpzpahsh; jq;fUkg; gPilawr; nra;tdnra; 
jdpahU lytyj;je; nea;apl;lg; gpg;gpbf;fpw; 
wzpahg; gykUj;Je; jhtKZe; jhtkNuh 
(9) ehSq; fopj;njLj;J ,jw;F mjpfhhpfshfpa etehjh; jpUtbfis tzq;fp> 
NehAw;whh; tpidf;Fj; jf;f gbfUkrhe;jp nra;J ifyj;ijj; njhl;L mofpa rhPuj;jpy; 
NehapUf;Fk; ,lq;fspy; g+rpg; gpbg;igghahfpy;> rpfpr;irfSf;F trg;glhj gw;gy k`h
thjNuhfq;fSk; mf;fpdpahy; jfpf;fg;gl;l fhLfisg;NghyFk;. 
        TRIAL MEDICINES 
   Rasapralaya chenthuram Navanatha siddhar thylam              
ADJUVANT                 VEHICLE                  
§¾ý                                       ¾¢Ã¢¸ÎÌ 
ÝÃ½õ
                 INGREDIENTS OF RASAPRALAYA CHENTHURAM
Hybiscus rosa sinensis                Punica granatum                   Solanum nigrum 
  Barleria Prionitis                           Mollugo lotoidus 
Sulphur                                                             Mercury 
,urk; (Mercury)
NtWngah;: ,dpik, rptd;tpe;J, #jk,; Mjp. 
Rit: mWRitAk; rpwg;gha; ,dpg;igAk; cilaJ. 
tPhpak;: rPj> ntg;g tPhpak;. 
gphpT: JizkUe;jp;d; ghpitNa milfpwJ. 
nra;if: cly; Njw;wp. 
 clYukhf;fp. 
 tPf;fKUf;fp. 
 Nkfehrdp. 
 ckpo;ePh; ngUf;fp. 
 rpWePh; ngUf;fp. 
nghJ Fzk;: ~tpopNeha; fpue;jp Fd;kk;nka;r;#iy 
Gz;Fl;lopfhypy; tpe;Jtpdhy; mj;ij  
topaha GhpAtpjp ahJk; GhprNdh
nay;yhk; ,hpA tpjp ahJ kpiy|| 
,urj;jpdhy; fz;Neha;> fpue;jp> Fd;kk;> #iy> Gz;> Fl;lk;> Nghd;w Njhw;gpzpfs;> tsp 
Neha;fs; FzkhFk;. 
fe;jfk; (SULPHUR)
NtW ngah;: fhhpioapd; ehjk;, nry;tptpe;J, rf;jprf;jp, gPrk,; nre;J}uj;jhj, NjtpAuk.; 
Rit: ifg;G> Jth;g;G. 
nra;if: gpj;jePh; ngUf;fp. 
 kykpsf;fp. 
 fpUkpehrdp. 
 cly;Njw;wp> tpah;it ngUf;fp. 
Fzk;: 'ney;ypf;fha; fe;jpf;F ePs;gjpndd; Fl;l ke;jk; 
 ty;iy ftpir Fd;k thA fz;Nzha; 
 nghy;yhtpbf;fbtd; NkfNeha; tPW Ruk; Ngjp  
  jplf;fpufzp fgk; Nghf;Fk;"
 ney;ypf;fha; fe;jpapdhy; gjpnzd;Fl;lk;> ke;jk;> Fd;kthA> fz;Nzha;> 
tplf;fbtd;> NkfNeha;> Ruk;> Ngjp> fyk; NghFk;. 
kzj;jf;fhsp (Solanum nigrum) 
NtW ngah:; cyfkhjh> kpsjf;fhsp> fhfkrP 
Rit: ,dpg;G 
jd;ik: jl;gk; 
gphpT: ,dpg;G 
nra;if: clw;Nww;wp – Alternative
 rpWePh;ngUf;fp – Diuetic
nghJFzk:; kzj;jf;fhspf;fha; kykpsFe; jhNd kfhfgKk; NghFk; 
 gykpFe;j thjk;Nghk; ghh;f;Fs; - kiyNghw; 
 gizj;Jg;g+ hpj;jKiyg; ghtha;Nfs;! ey;y 
 kzj;jf;fh spf;fhia tho;j;J 
kyj;i;j ,sfp fopa nra;Ak;> Iaj;ijak; tspNehiaAk; Nghf;Fk;.
nrUg;gil (Mollugo lotoidus) 
NtW ngah:; nrUg;gb 
Rit: fhh;g;G 
jd;ik: ntg;gk; 
gphpT: fhh;g;G 
nra;if: ntg;gKz;lhf;fp Stimulant 
nghJFzk;: nrUg;gilf;F thjke;jQ; Nrh;thd Nkfk; 
 ,Og;gbnfhs; nghy;yh ,rpTk; - tpUg;gbf;FQ; 
 #iynahL thjFz;kQ; Njhw;wh njhOehSk; 
 Ntiynahj;j fz;zha; tpsk;G 
tsp> Iaf;Fw;wj;jhy; gpwf;Fk; Neha;fs; ke;jk;> #iy Fd;kk;> nts;is ,tw;iw 
ePf;Fk;.
khJisk;g+ (Punica granatum) 
NtW ngah:; jhbkk;> khJsq;fk;> gPrGuk; 
Rit: Jth;g;G 
jd;ik: jl;gk; 
gphpT: fhh;g;G 
nra;if: Jth;g;gp Astringent 
 grpj;J}z;b Stomachtic 
nghJFzk;: the;jpgpj;j NjhlnkhL khwhf; fLg;giyQ; 
 Nrh;e;Jdpd;w %yuj;je; jPh;f;Fq;fhd; - khe;jsph;f;if 
 khNj! apue;jG\;b ty;ygyd; cz;lhFk; 
 g+jyj;Js; khJisapd;g+ 
(Meaning) FUjp the;jp> tapw;Wf;fLg;G> ntg;gk;> ,Ujp%yk; ,it NghFk; 
FUjpiag;ngUf;Fk;. td;ikiaj; jUk;. 
nrk;guj;ij (Hybiscus rosa sinensis) 
NtW ngah:; rg;ghj;J> nrk;gUj;jp 
Rit: ,dpg;G  
jd;ik:      jl;gk;  
gphpT: ,dpg;G 
nra;if:  kykpsf;fp Laxative
 twl;rpafw;wp Emolient
 cs;sosw;wp Demelcant
 Fsph;r;rpAz;lhf;fp Refrigerant 
nghJFzk;: nrk;guj;ij Nkfntl;il jPuhg; gpukpnahL
 tk;gpuj;j nts;is tOtOg;Gk; - ntk;Gk; 
 ngUk;ghL uj;jgpj;j Ngjk; mfw;Wk; 
 fUk;gh nkhopapNy! fhz; 
,jdhy; nts;is FUjp nts;is> ngUk;ghL FUjpaoy; ,it ePq;Fk;. 
SEMMULLI (Barleria prionitis) : 
Part used : Whole plant, Root, Leaf, Bark, Flower.
Action : 
             Hypoglycemic 
             Diuretic 
            Spasmogenic 
            Hypotensive 
            Hypothermic. 
Use : 
 The plant has antiseptic properties, its decoction is used as a wash in dropy. The leaves and 
flowering tops are rich in soluble potassium salts and are valued as diuretic. 
STATISTICAL ANALYSIS 
HAEMOGLOBIN BEFORE AND AFTER TREATMENT COMPARISION: 
Paired t test 
------------------------------------------------------------------------------
Variable |     Obs        Mean Std. Err.   Std. Dev.  [95% Conf. Interval] 
---------+--------------------------------------------------------------------
    hbbt |      40       10.55    .2753087    1.741205    9.993136    11.10686 
    hbat |      40     11.0675    .3027944     1.91504    10.45504    11.67996 
---------+--------------------------------------------------------------------
    diff |      40      -.5175     .253182    1.601264   -1.029609   -.0053911 
------------------------------------------------------------------------------
                   Ho: mean(hbbt - hbat) = mean(diff) = 0 
  Ha: mean(diff) < 0         Ha: mean(diff) ~= 0        Ha: mean(diff) > 0 
       t =  -2.0440                t =  -2.0440              t =  -2.0440 
   P < t =   0.0239          P > |t| =   0.0477          P > t =   0.9761 
ESR 1/2 Hour - BEFORE AND AFTER COMPARISION: 
Paired t test 
------------------------------------------------------------------------------
Variable |     Obs        Mean Std. Err.   Std. Dev.  [95% Conf. Interval] 
---------+--------------------------------------------------------------------
  esrhbt |      40        22.4    3.194707     20.2051    15.93809    28.86191 
  esrhat |      40        15.3    2.079879    13.15431    11.09305    19.50695 
---------+--------------------------------------------------------------------
    diff |      40         7.1     2.04055    12.90557    2.972597     11.2274 
------------------------------------------------------------------------------
                 Ho: mean(esrhbt - esrhat) = mean(diff) = 0 
  Ha: mean(diff) < 0         Ha: mean(diff) ~= 0        Ha: mean(diff) > 0 
       t =   3.4795                t =   3.4795              t =   3.4795 
   P < t =   0.9994          P > |t| =   0.0013          P > t =   0.0006 
ESR 1 Hour - BEFORE AND AFTER COMPARISION: 
Paired t test 
------------------------------------------------------------------------------
Variable |     Obs        Mean Std. Err.   Std. Dev.  [95% Conf. Interval] 
---------+--------------------------------------------------------------------
  esr1bt |      40       43.85     5.62601    35.58201    32.47032    55.22968 
  esr1at |      40       31.45    4.371814    27.64978    22.60717    40.29283 
---------+--------------------------------------------------------------------
    diff |      40        12.4    3.358838    21.24316    5.606108    19.19389 
------------------------------------------------------------------------------
                 Ho: mean(esr1bt - esr1at) = mean(diff) = 0 
  Ha: mean(diff) < 0         Ha: mean(diff) ~= 0        Ha: mean(diff) > 0 
       t =   3.6918                t =   3.6918              t =   3.6918 
   P < t =   0.9997          P > |t| =   0.0007          P > t =   0.0003 
Comparision of RA facto before and after treatment: 
           |         RAAT 
      RABT |         N          P |     Total 
-----------+----------------------+---------- 
         N |        20          0 |        20
         P |         3         17 |        20
-----------+----------------------+---------- 
     Total |        23         17 |        40
Comparision of CRP before and after treatment
           |         CRPAT 
     CRPBT |         N          P |     Total 
-----------+----------------------+---------- 
         N |        17          0 |        17
         P |         7         12 |        19
-----------+----------------------+---------- 
     Total |        24         12 |        36
Due to adequate sample size, the significance of treatment 
could not be statistically determined. 
Bio – Chemical Analysis 
NATIONAL INSTITUTE OF SIDDHA, TAMBARAM SANATORIUM, CH-47. 
       BIO CHEMICAL ANALYSIS 
S.NO EXPERIMENT OBSERVARTION INFERENCE 
1. Appearance of the sample Dark brown in 
colour.
2. Solubility
a. A little of the sample is 
shaken well with distilled 
water. 
b. A little of the sample is 
shaken well with con. 
HClL / Con. H2So4. 
Sparingly soluble. Presents of Silicate 
3. Action of Heat 
      A small amount of the sample 
is taken in a dry test tube and 
heated gartly at first and then 
strong.
White fumes 
evolved.
.
Presence of 
Carbonate. 
4. Flame Test 
     A small amount of the sample is 
made into a pasted with con. HCL 
in a watch glass and introduced 
into non – luminous part of the 
bunsen flame. 
Blush green flame 
not appeared. 
Absence of copper. 
5. Ash Test  
     A filter is soaked into a mixture 
of sample and cobalt nitrate 
solution and introduced into the 
bunsen flame and ignited 
 Yellow colour flame Presents of sodium. 
Preparation of Extract
5 gm of Panchalavana Mezhugu is weighed accurately and placed in a 250 ml clean beaker and 
added with 50 ml of distilled water. Then it is boiled well for about 10minutes. Then it is cooled and 
filtered in a 100ml volumetric flask and made up to 100ml with distilled water. 
S.NO EXPERIMENT OBSERVARTION INFERENCE 
I Test for Acid Radicals
1. Test for Sulphate 
2 ml of the above prepared 
extract is taken in a test tube to 
this added 2 ml of 4% 
ammonium oxalate solution. 
Cloudy appearance 
present. 
Presence of sulphate 
2. Test of Chloride 
2 ml of the above prepared 
extract is added with 2ml of dil 
– Hcl is added until the 
effervescence ceases off. 
Cloudy appearance 
presents. 
Presents of 
Chloride. 
3. Test for Phosphate: 
2ml of the extract is treated with 
2 ml of ammonium molybdate 
solution and 2 ml of con.Hno3 
Mild yellow 
appearance. 
Phosphate mildly 
present. 
4. Test for Carbonate 
2 ml of the extract is treated 
with 2 ml magnesium sulphate 
solution.
 No cloudy 
appearance. 
Absence of 
carbonate
5. Test for Fluoride & Oxalate 
2 ml of extract is added with dil. 
Acetic acid and 2 ml calcium No cloudy Absence of fluride 
chloride solution and heated. appearance and Oxalate. 
6. Test for Nitrate 
3 drops of the extract is placed 
on a filter paper, on that – 
2drops of acetic acid and 2 
drops of Benzidine solution is 
placed.
No characteristic 
changes 
Absence of borate 
7. Test for Lead 
2 ml of the extract is added with 
2 ml of potassium iodide 
solution.
No yellow precipitate 
is obtained 
Absence of lead 
8. Test for Copper 
a. One pinch of substance 
is made into paste with con. 
Hcl in a watch glass and 
introduced into the non 
luminous part of the flame 
No colour precipitate 
formed 
Absence of copper. 
9. Test for Aluminium  
To the 2 ml of the extract  
sodium hydroxide is added in 
drops to excess. 
No characteristic 
changes 
Absence of 
aluminium 
10. Test for Iron 
a. To the 2 ml of extract 
add 2ml of ammonium 
thiocyanate solution. 
b. To the 2 ml of extract 
2ml ammonium thiocyanate 
solution and 2 ml of con. 
HN03 is added. 
Blood red colour 
appeared 
Presence of Iron 
11 Test for Zinc 
To 2ml of the extract sodium 
hydroxide solution is added in 
drops to excess. 
White precipitate is 
formed 
Presence if Zinc 
12 Test for Calcium 
2ml of the extract is added with 
2ml of 4% ammonium oxalate 
solution.
Cloudy appearance 
and white precipitate 
is obtained 
 Presence of calcium 
13 Test for Magnesium 
To 2ml of extract sodium 
hydroxide solution is added in 
drops to excess. 
White precipitate is
not obtained 
Presence of 
Magnesium 
14 Test for Ammonium 
To 2ml of extract few ml of 
Nessler’s reagent and excess of 
sodium hydroxide solution are 
added.
No Brown colour 
obtained 
Absence of 
ammonium 
15 Test for Sodium 
2 pinches of the substance is 
made into paste by using HCL 
and introduced into the blue 
flame of Bunsen burner. 
Yellow colour flame 
appeared 
Presents of 
sodium 
16 Test for Mercury 
2ml of the extract is treated with 
2ml of sodium hydroxide 
solution.
No yellow precipitate is 
obtained 
Presents of 
mercury 
17 Test for Arsenic 
2ml of the extract is treated with 
2ml of sodium hydroxide 
No brownish red 
precipitate is obtained 
Absence of 
arsenic 
solution.
III Miscellaneous 
18 Test for Starch 
2ml of extract is treated with 
weak iodine solution. 
No blue colour 
developed 
Presence of starch 
19 Test for Reducing Sugar 
5ml of Benedict’s qualitative 
solution is taken in a test tube 
and allowed to boil for 2 
minutes and added 8 to 10 drops 
of the extract and again boil it 
for 2 minutes. The Colour 
changes are noted. 
Brick red colour 
developed 
Absence of 
reducing sugar 
20 Test for the Alkaloids 
a. 2ml of the extract is 
treated with 2ml of 
potassium iodide solution 
b. 2ml of extract is treated 
with 2ml of picric acid 
No red colour developed Absence of 
alkaloid. 
21 Test for Amino Acid 
2 drops of the extract is placed 
on a filter paper and dried well. 
No violet colour 
developed 
Absence of amino 
acids
22. Test for Tannic Acid 
2ml of extract is teated with 2ml 
of ferric chloride solution. 
No black precipitate is 
obtained 
Presence of 
Tannic acid 
23 Test for type of Compound 
2ml of the extract is teated with 
2ml of ferric chloride solution. No colour change 
Absence of oay 
quinole
pinephrine and 
pyro catechol 
24 Test for Unsaturated 
Compound
2ml of Biuret reagent is added 
to the 2ml of extract of 
potassium permanganate 
solution is added. 
Potassium permanganate 
is not decolourised 
Absence of 
unsaturated 
compound 
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1.0 MATERIALS AND METHODS
1.1 Test Drugs 
The following medicine was used in the study was processed by the methods prescribed in 
standard text books of siddha medicines. 
Rasapralya chenthuram (RPS) was prepared by the method prescribed in the text book of 
Anuboga vaithya navaneetham.
1.2 Preparation of drug for dosing 
 All drugs used for the study was suspended each time with 1% (w/v) solution of sodium 
carboxy methyl cellulose before administration. 
1.3 Drugs and chemicals 
 Standard Drugs and fine chemicals used in these experiments were obtained from Sigma 
Chemicals Company, U.S.A. Other analytical grade chemicals were obtained from S.d. Fine 
Chemicals Ltd., Mumbai. 
1.4 Experimental animals
 Colony inbred animals strains of wistar rats of either sex weighing 200 - 250 g were used for 
the pharmacological and toxicological studies. The animals were kept under standard conditions 12:12 
(day/night cycles) at 220C room temperature, in polypropylene cages. The animals were fed on 
standard pelleted diet (Hindustan Lever Pvt Ltd., Bangalore) and tap water ad libitum. The animals 
were housed for one week in polypropylene cages prior to the experiments to acclimatize to laboratory 
conditions. The experimental protocol was approved by the Institutional Animal Ethical Committee 
(IAEC). 
1.5 Acute oral toxicity study
Acute oral toxicity was conducted as per the OECD guidelines (Organization of Economic 
Cooperation and Development) 423 (Acute Toxic Class Method). The acute toxic class method is a 
stepwise procedure with 3 animals of a single sex per step. Depending on the mortality and /or 
moribund status of the animals, on the average 2-4 steps may be necessary to allow judgment on the 
acute toxicity of the test substance. This procedure results in the use of a minimal number of animals 
while allowing for acceptable data based scientific conclusion. 
The method uses defined doses (5, 50, 300, 2000 mg/kg body weight) and the results allow a 
substance to be ranked and classified according to the Globally Harmonized System (GHS) for the 
classification of chemicals which cause acute toxicity. 
1.5 Acute oral toxicity study
Acute oral toxicity was conducted as per the OECD guidelines (Organization of Economic 
Cooperation and Development) 423 (Acute Toxic Class Method). The acute toxic class method is a 
stepwise procedure with 3 animals of a single sex per step. Depending on the mortality and /or 
moribund status of the animals, on the average 2-4 steps may be necessary to allow judgment on the 
acute toxicity of the test substance. This procedure results in the use of a minimal number of animals 
while allowing for acceptable data based scientific conclusion. 
The method uses defined doses (5, 50, 300, 2000 mg/kg body weight) and the results allow a 
substance to be ranked and classified according to the Globally Harmonized System (GHS) for the 
classification of chemicals which cause acute toxicity 
Wistar albino rats of either sex weighing 200-250 g were fasted overnight, but allowed water 
ad libitum. Since the formulation is relatively non toxic in  clinical practice the highest dose of 2000 
mg/kg/p.o (as per OECD guidelines “Unclassified”) was used in the acute toxicity study.   
The animals were observed closely for behavioral toxicity, if any by using FOB (Functional 
observation battery). 
1.6 Repeated oral toxicity study
Repeated oral toxicity studies can be used to get additional information regarding the toxicity 
profile of a chemical. Repeated oral toxicity studies are defined as those studies where the chemical is 
administered to the animal for a period covering approximately 10% of the expected life of the animal. 
Usually, the dose levels are lower than for acute studies and allow chemicals to accumulate in the body 
before lethality occurs, if the chemical possess this ability. 
Experimental procedure 
The following experimental procedure was followed to evaluate the repeated oral toxicity study 
of RPC.
Group I : Control animals received 1%CMC, 2 ml/kg/p.o. for 15days  
Group II : Rasapralya chenduram (RPS) inCMC at the dose Level of 500mg/kg/p.o. was given to 
rats for 15days 
 Body weight, food intake and water intake was recorded at two intervals with simultaneous 
observation for toxic manifestation and mortality, if any. At the end of 15days treatment all the 
animals were sacrificed by over dosage of ether anaesthesia. Blood was collected and used for 
hematological studies. Section of liver, kidney, and heart were dissected out and kept in 10% formalin 
for histopathological studies. 
1.7 Biochemical studies 
 Estimation of glucose 
Glucose was estimated using commercial Glucose estimation kit (Span Diagnostics) by 
the method of Barham et al., (1972) and Tenscher. et al., (1971). 
Aspartate aminotransferase (AST)
 Aspartate aminotransferase was estimated using commercial AST kit (Span Diagnostics) by the 
method of Reitman and Frankel (1957). 
Alanine aminotransferase (ALT) 
 Alanine aminotransferase was estimated using commercial AST kit (Span Diagnostics) by the 
method of Reitman and Frankel (1957). 
Alkaline phosphatase (ALP) 
 Alkaline phosphatase was assayed using commercial ALP kit (Span Diagnostics)  by the method 
of King (1934). 
Cholestrol
Cholestrol was estimated using the commercial kit (Span diagnostics) 
Urea and Uric acid  
 Urea and Uric acid were assayed using the commercial kit (Span Diagnostics)  
1.8 Haematological studies 
Erythrocyte count 
 Erythocyte count was estimated by Hemocytometer method of Ghai (1995). 
Total Leukocyte Count (WBC) 
Total Leukocyte Count was estimated by Hemocytometer method of John (1972). 
Haemoglobin  
 Haemoglobin was estimated by method of Ghai (1995). 
1.9 Histopathological studies  
 Animals were sacrificed at the end of repeated oral toxicity and tissues were processed for 
histopathological studies.
1.10 Analgesic, Antiinflammatory studies 
Analgesic activity
Tail Flick method 
Wistar rats of either sex (200-250g) were divided into different groups with 6 animals in each 
group
Group-1. Control animals received 1% CMC 10ml/Kg/po 
Group 2. Test drug at the dose of 500mg/kg/po 
 Withdrawal of tail (Tail Flick) for noxious thermal (radiant heat) can be used for screening 
drugs with analgesic activity. Radiant heat can be generated by passing electrical current through 
nichrome wire mounted in an analgesiometer. 
 The base of the tail of the test rats is placed on a nicrome wire. The tail withdrawal for the 
radiant heat (flicking response) is taken as the end point. Normally the rats and mice withdraw their 
tails within 3 – 5 secs. A cutoff time of 10 – 12 secs is used to prevent damage to the tail. Any animal 
failing to withdraw its tail in 3-5 secs is rejected from the study.  
 The reaction time of test drug, standard and control are taken at intervals of 30, 60 and 120 mts. 
A reaction time (withdrawal time) increment of 2-5 secs more than the control animals can be 
considered for analgesic activity of the drug.  
Anti inflammatory activity  
 Anti inflammatory activity was evaluated in acute model of inflammation. Wistar rats either 
sex weighing 200-250g were divided into different groups with 6 animals in each group 
Group-1. Control group received CMC 10ml/kg/po 
Group-2.  Received Carrageenan (0.1% solution) and served as positive control 
Group-3 Received test drug (RPS) at the dose of 500mg/kg/po 
Group-4 received standard drug Diclofenac sodium (5mg/kg/po) 
Acute model 
Carrageenan induced hind paw edema  
 The carrageenan assay procedure was carried out according to the method of Wintar et al.
(1962). Edema was induced by injecting 0.1 ml of 1% solution of carrageenan in saline into the plantar 
aponeurosis of the left hind paw of the rats.  The extracts, reference drug and the control vehicle 
(distilled water) were administered 60 min prior to the injection of the carrageenan. The volumes of 
edema of the injected and contra lateral paws were measured at +1, 3 and 5 hrs after induction of 
inflammation using a plethysmometer (Bhatt et al., 1977) and percentage of anti-inflammatory activity 
was calculated.
1.11 In Vivo Antioxidant study 
Samples of serum collected from rats treated with test drugs were assayed for GSH (Moron et
al , 1979)  and LPO (Yagi, 1976)  and the results were compared with  control group.  
2.0 Results 
2.1 Preliminary basic, acidic radicals and phytochemical studies
The qualitative chemical analysis and acidic, basic radicals assay of the drugs showed the 
presence of phytoconstituents and minerals as depicted in (Table 1). 
2.2 Acute oral toxicity study: 
RPS at the dose of 2000mg/kg/po did not exhibit any mortality in rats. As per OECD 423 
guidelines the dose is said to be “Unclassified” under the toxicity scale. Hence further study with 
higher doses was not executed 
2.3 Repeated oral toxicity for 15 days: 
Test drug RPS at the dose of 500 mg/kg/po when administered orally for 15 days in rats did not  
exhibit toxicity in haematopoeitic system and liver. However the drug exhibited an increase in uric 
acid level after the administration for 15 days (Tables 2 and 3) 
2.4 Histopathological study: 
RPS at the dose of 500 mg/kg/po daily administered for 15days did not show evidence of 
pathological lesions in the tissues tested (Plate 1). 
2.5 Analgesic, Antiinflammatory studies:
RPS at the dose of 500 mg/kg/p.o showed significant analgesic activity in rats(Table-3). RPS  
also exhibited significant anti-inflammatory activity in carrageenan induced hind paw edema (acute 
inflammation model) in rats. The results of present study was comparable to that of the standard 
NSAID Diclofenac sodium (5 mg/kg/p.o) (Table4). 
2.6 Antioxidant activity:  
At the end of 15 days repeated oral toxicity study when the plasma of drug treated animals was 
examined for GSH activity, the level of GSH activity was increased significantly (p>0.001) in test 
groups. On the other hand there was no difference in the LPO activity of treated animals when 
compared to control(Table-5)  
Discussion
The siddha formulation Rasapralya chenduram (RPC) was tested for its reverse 
pharmacological and toxicological profiles in the experimental rats. The drug did not exhibit mortality 
at the highest dose of 2000 mg/kg/p.o, As per OECD 423 guidelines the dose is said to be 
“Unclassified” under the toxicity scale. Hence further study with higher doses was not executed 
The preliminary phytochemical study revealed the absence of alkaloids and saponins in the test 
drug. The test drug answered for the presence of calcium,ferrous iron,sulphate,chloride,carbonate and 
absence for alkaloids and saponins.Repeated oral toxicity study conducted for15days with the drug did 
not  exhibit significant changes in RBC count and in Hb%.The biochemical markers of liver function 
tests did not show evidence of liver toxicity..However ther uric acid level showed an upward trend that 
may be due to the probable toxic effect on the kidney functioin after the drug treatment There was no 
significant changes in Haematological parameters like blood Cholesterol, body weight, food, water 
intake and behavioural parameters.. 
The test drug exhibited significant analgesic, and anti-inflammatory activity in acute 
experimental inflammatory conditions in rats.. A significant anti-inflammatory activity was obtained 
with the test drug in carrageenan induced hind paw edema model. The test drug showed maximum 
anti-inflammatory activity at the end of 4th hour after carrageenan challenge. The result of test drug 
(500 mg/kg/p.o) was comparable to that of Diclofenac Sodium (5 mg/kg/p.o). Since the maximum 
anti-inflammatory activity (reduction in the paw edema volume) was observed at the end of 4th hour, 
the mechanism of anti-inflammatory activity of test drug may be attributed for its inhibitory activity on 
cyclooxygenase (COX) enzymes. 
The present study on the reverse pharmacological and toxicological profiles of the drug may be 
summarized as follows: 
1. The drug is safe even at the highest dose of 2000mg/kg/po.  According to OECD 
classification for toxicity scale this drug comes under the “unclassified” scale.  
However caution should be taken to prevent overdosing with the drug since it contains 
mercury 
2. Though the repeated drug treatment for 15 days exhibited alteration in theuric acid 
level, the test drug did not exhibit any alterations in the normal architecture of the 
kidney at the end of 15 days. Since there is no report on the kidney function tests done 
in clinical study, it can be reasonably assumed that the drug is safe for humans unless 
and otherwise proved with clinical data generated on  kidney function 
3. The formulation exhibited significant antioxidant activity  and no change in the LPO 
activity in rats treated for 15 days 
Table 1
Effect of Siddha Formulations(RPC) on Haematological parameters after 15 days repeated oral 
dosing (500 mg/kg) 
Groups Hb 
(gm/10
0ml)
RBC
(millions/cu.
mm)
WBC
(cells/cu.mm) 
Differential leucocyte count (%) 
Lympho 
cytes 
Mono 
cytes 
Granulo 
cytes 
Normal 14.00.  
r 0.34 
5.18 r 0.35 ns 6500r 491.44 76.06 r 3.89
ns
5.30 r 1.04 16.50 r
4.27
RPS 
(500mg/
kg. p.o.,)
14.50 r
0.60ns
5.28 r 0.70 ns 6686.66 r
3.323ns
76.67 r 3.32
ns
6.16 r 1.7
ns
18.66 r 3.44
ns
N=6; Values are expressed as mean r S.D followed by Students Paired ‘T’ Test 
Ns – non significant when compared to control groups. 
Table 2
Effect of Siddha formulation (RPC) on Biochemical markers of liver and kidney after 15 days 
repeated oral dosing (50 mg/kg/po) in rats
Groups AST  
(IU/L)
ALT
(IU/L)
Cholestrol
(mg/dl) 
Creatinin
(mg/dl) 
Urea 
(mg/100ml)
Uric acid 
(mg/dl) 
Normal 70.24r0.23  30.70 r
0.81
45.84 r 0.58 1.26r
0.64
13.86 r 0.37 1.83 r 0.58 
RPS 
(500mg/kg.p.o.,) 
76.45r5.92
ns
35.43 r
2.67 ns
39.6 r 0.92ns 2.15
r0.72ns 
14.60 r 0.69
ns
4.26r
0.84*** 
N=6; Values are expressed as mean r S.D followed by Students Paired ‘T’ Test 
Ns – non significant when compared to control groups  
***P<0.001 as compared with control 
    
Table 3
Analgesic activity of (RPC) using Tail flick Method:
Groups Paw licking response  (Sec) 
0 min 
( Sec) 
30 min 
( Sec ) 
60 min 
(Sec ) 
120 min 
(Sec) 
Control 2.266r 0.396 2.293r 0.96 2.46r0.367 2.582r 0.653 
RPS 
(500mg/kg.p.o.,) 
2.811 r  0.361 3.427 r 0.450 
*** 
4.921r 0.077 
*** 
2.762r 1.213ns
n=6,  Values are expressed as mean r S.D using followed by paired T – test  
***P<0.001 as compared with control. ns - Non significant as compared with control; 
 Table 4
Anti inflammatory activity of RPC in carrageenan induced hind paw edeama in rats:
Groups Paw volume ( ml) by mercury Displacement at regular interval of time 
0min 30min 60min 120min 240min 4th hrs 
Control 1.483 r
0.1915
1.766 r
0.1366
2.06 r
5.164
2.195 r
7.7619
2.33 r 0.136 2.23 r
0.4612
RPS  
(500mg/kg. 
p.o.,)
1.356 r
0.1402
ns
1.358 r
0.213
ns
1.536 r
0.404
ns
2.168 r
0.302
ns
2.43 r 0.326 
ns
1.43 r 0.133 
*** 
Standard
(Dic.Sodium 
5 mg/kg/po) 
0.835 r
0.065 ns
1.315 r
0.069ns
1.128 r
0.049**
1.011 r
0.056***
0.896 r
0.048***
0. 85 r
0.054*** 
n=6; Values are expressed as mean r S.D followed by paired T – test. 
ns - Non significant as compared with control; 
P< 0.001 (***),P <0.003(**)as compared with control.Table 6:
Anti oxidant activity of Siddha Formulation (RPC)  
after 15 days repeated oral dosing (500 mg/kg) 
Groups LPO GSH 
Control 0.60 r 1.37 45.48 r 2.31 
RPS (500mg/kg. p.o.,) 0.70 r 4.90ns 80.65 r 0.35*** 
N=6; Values are expressed as mean r S.D followed by Student T- Test. 
***P<0.001 as compared with control. ns - Non significant as compared with control; 
RASAPRALAYACHENTHURAM 
ANTIARTHRITIC ACTIVITY
Formaldehyde-induced arthritis in rats 
The animals were divided into three groups of five rats. A sub plantar injection of 0.1 ml of 2% 
(v/v) formaldehyde was administered to the right hind paw on the first and third days of the 
experiment. The test drug (200 mg/kg body wt.), nalfon (standard) or vehicle (1 ml/kg body wt.) were 
administered orally once daily for 10 days. The paw volumes were measured using plethysmometer, 
before the formaldehyde injection (day 0) and repeated every day, for 10 days. 
EFFECT OF RASAPRALAYACHENTHURAM ON FORMALDEHYDE INDUCED 
ARTHRITIS IN HIND PAW OF RATS 
Groups Changes in paw size (cm) 
1 day 5 days 10 days 
Arthritis  0.40 ± 0.03 0.73 ± 0.05 0.67 ± 0.07 
Arthritis +drug (200mg/kg) 0.41 ± 0.03 0.58 ± 0.04* 0.49 ± 0.05*
Arthritis + Nalfon (standard) 0.42 ± 0.02 0.42 ± 0.03** 0.31 ± 0.01**
Values are expressed as mean ± SEM of 5 rats. **P<0.01; *P<0.05 Vs arthritis group. 
Interference: The drug (Rasapralaya Chenthuram) showed moderate antiarthritic effect.
NAVANATHA SIDDHAR THYLAM
ACUTE ANTI-INFLAMMATORY ACTIVITY 
EFFECT OF NAVANATHA SIDDHAR THYLAM ON CARRAGEENAN- INDUCED HIND 
PAW EDEMA IN RATS 
Drug Paw volume (ml) Inhibition (%) 
1hr 3hr 
Control (water) 2.22 ± 0.2       5.42 ± 0.4 - 
Navanatha siddhar thylam 2.65 ± 0.1 3.28 ± 0.2** 80.3 
Diclofenac sodium gel 
(standard)
2.20 ± 0.2 2.01 ± 0.2** 93.7 
Values are expressed as mean ± SEM of 5 rats. **P<0.01Vs control group. 
Interference: The drug (Navanatha Siddhar Thylam) showed significant anti-inflammatory effect 
when applied externally. 
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 In Vitro antimicrobial activity of Rasapralaya chenthuram as screened against bacteria and 
Yeast strains. The results are depicted in table. In 50, 100 and 150 μl/ disc concentration of RPC were 
exhibited high antimicrobial activity in streptococcus  mutans, S. aureus, Klebsilla and Pseudononas 
when compared to standard drugs ciprofloxacin. 
Organism Standard 
drug 
Ciprofloxacin 
50 mg/disc 
             TEST DRUG (µl/disc) 
           Zone of Inhibition in mm 
 50 µl 100 µl 150 µl 
Strepto.mutans   29.0 mm  13.0 mm  15.0 mm 19.0 mm 
Klebsilla   29.0 mm  14.0 mm  16.0 mm 18.0 mm 
Staphylo.aureus   33.0 mm  21.0 mm  27.0 mm  30.0 mm 
Pseudomonas 
aeroginosa
  29.0 mm  14.0 mm  17.0 mm  19.0 mm 
ANTIMICROBIAL ACTIVITY OF RASAPRALAYA CHENTHURAM
The tested microorganisms 
;
The strain used in this work was Staphylococcus aureus, Streptococcus mutans, Pseudomonas 
aeroginos and Klebsiella were provided from the Culture Stock. The bacteria was maintained by 
weekly transfer in a chemically defined medium and tryptic soy broth (TSB) and distributed in 
5ml volumes in screw-capped tubes. Cells were grown at 37°C for 48h and cultures were kept at 
4°C.
Method:
The antibacterial action of the RPC was tested on the test bacteria using the agar-gel diffusion 
inhibition test. In the agar-gel diffusion inhibition test 0.2ml of a 24h broth culture (106cfu/ml) of 
the bacteria was aseptically introduced and evenly spread using bent sterile glass rod on the 
surface of gelled sterile Mueller-Hinton agar plates. Four wells of about 4.0mm diameter were 
aseptically punched on agar-plate using a sterile cork borer allowing at least 30mm between 
adjacent wells and between peripheral wells and the edge of the petri dish. Fixed volumes (0.1ml) 
of the RPC in different concentration like 50 µl, 100 µl, 150 µl were then introduced into the 
wells in the plates. A control well was loaded with 0.1ml of the solvent. The plates incubated at 
37°C for 24h for the test bacteria. The plates were duplicated in all the experiments. 
Results and discussion: 
The RPC exhibited highly sensitive against staphylococcus aureus, Streptococcus mutans, 
Pseudomonas and Klebsilla microorganisms used in the study from the zone of inhibition 
produced by the RPC. None of the negative control exhibited anti microbial activity but when it 
compared with Ciprofloxacin it doesn’t exhibited highly sensitive. The solvent used for 
solubilisation of drug had no anti microbial activity.  
 Thus it is confirmed that the RPC exhibited antimicrobial activity against above four 
organisms. Higher diameter zones of inhibition (30 mm) was obtained on the test organism 
Staphylococcus aureus. 
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OVERALL IMPROVEMENT TABLE FOR OUT PATIENTS:
S.No Op. No Age/Sex Date of 
Treatment
Starting 
 End  
of The
Treatment 
Improvement     Duration 
of illness  
1. A.L.9173    37/F       09.08.08       02.09.08 Good 3 month 
2. A.L.8950    31/F       09.08.08       02.09.08 Good 3 month 
3. A.m.48    55/F       13.08.08       04.09.08 Good > 1 yr 
4. A.m.732    29/F       18.08.08       08.09.09 Mild > 1 yr 
5. A.L.7238    42/F       11.09.08       02.10.08 Mild > 6 month 
6. A.K.271    39/F       17.08.08       08.10.08 Good 3 month 
7. W.368    44/F       20.08.08       11.09.08 Good 1 yr 
8. A.m.22    38/F       13.08.08       04.09.08 Good 1 1/2 yr  
9. A.m.777    33/F       17.08.08       09.09.09 Good > 6 month 
10. A.m.825    29/F       17.08.08       09.09.08 Good > 6 month 
11. A.m.1838    38/F       10.9.08       02.10.08 Moderate 8 month 
12. A.m.4364    46/F        09.09.08       29.09.08 Moderate 3 month 
13. O.5893    32/F        11.09.08       03.10.08 Moderate 6 month 
14. O.2447    40/F        04.09.08       24.09.08 Good > 3 month 
15. A.N.1856    42/F        13.10.08       04.10.08 Good 1 1/2 yr 
16. A.N.1846    55/M        04.10.08       25.10.08 Moderate 1  yr 
17. A.m.191    48/M        14.08.08       05.09.08 Good > 6 month 
18. A.N.1150    38/F        10.10.08       01.11.08 Moderate 4 month 
19. A.N.4353    45/F        11.10.08       02.11.08 Good 5 month 
20. A.N.5285    32/F         22.10.08       13.11.08 Mild 8 month 
OVERALL IMPROVEMENT FOR IN PATIENT DEPARTMENT: 
S.N
o
IP. No Age/S
ex 
Date of 
Admissi
on
Date of 
Discharge 
Treatment 
days in IP Improvement 
Duration of 
illness    
1. 1074  34/F 08.08.08   29.08.08        20       Good < 1 yr 
2. 1103 30/F 21.08.08   12.09.08        20        Mild < 1 yr 
3. 1095 43/F 19.08.08   11.09.08      20      Moderate > 1 yr 
4. 1097 40/F 20.08.08   12.09.08      20       Good > 5 yr 
5. 1631 25/M 16.09.08   29.09.08      12       Good < 3month 
6. 1627 47/M 16.09.08     04.10.08      18       Good < 1 yr 
7. 1675 52/M 04.10.08   13.10.08      08       Good > 6 month 
8. 1195 55/F 29.09.08     10.10.08      10       Good  > 6 month 
9. 1628 32/M 16.09.08    14.10.08      28       Moderate > 4 yr 
10. 1202 50/F 04.10.08     24.10.08      20       Moderate > 2 yr 
11. 1216 36/F 10.10.08   19.10.08      08       Moderate > 3 yr 
12. 1221 48/F 15.10.08    24.10.08      08       Good > 1 yr 
13. 1622 30/M 15.09.08     22.09.08      07       Moderate 2 ½ yr 
14. 1224 36/F 16.10.08   31.10.08      15       Moderate > 4yr 
15. 1205 55/F 06.10.08   31.10.08      24       Moderate > 1 yr 
16. 1211 50/F 07.10.08    31.10.08      22        Mild  < 5 month 
17. 1212 36/F 09.10.08     31.10.08      20        Mild > 5 yr 
18. 1697 36/F 13.10.08  31.10.08      18       Good 1 yr 
19. 1289 40/F 18.11.08    08.12.08      19       Good > 2 yr 
20. 1290 38/F    18.11.08  10.12.08      20        Mild  2 yr 
Ayothidhasar Pandithar Hospital, National Institute of Siddha, Tambaram sanatorium. 
IN PATIENTS SEROLOGICAL IMPROVEMENT REPORT: 
S.NO IP .NO             RA factor                   CRP 
  Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
1. 1103 Pos Pos Pos - 
2. 1095 Pos Pos Pos Neg 
3. 1097 Pos Pos Pos Pos 
4. 1631 Neg Neg Pos Pos 
5. 1195 Pos Neg Pos  Pos 
6. 1202 Pos  Pos Pos  Neg 
7. 1216 Neg Neg Pos  Neg 
8. 1221 Neg Neg Pos  Pos  
9. 1224 Pos  Pos  Pos  Pos  
10. 1205 Pos  Neg  Pos  Pos  
11. 1211 Pos Pos Pos Pos 
12. 1212 Neg Neg Pos  Pos  
13. 1697 Pos  Neg Neg Neg 
14. 1622 Neg Neg Pos Pos 
15. 1289 Pos Pos Pos Pos 
16. 1290 Pos Pos Neg Neg 
Ayothidhasar Pandithar Hospital, National Institute of Siddha, Tambaram sanatorium. 
OUT PATIENTS SEROLOGICAL IMPROVEMENT REPORT: 
S.NO OP .NO             RA factor                   CRP 
  Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
1. AL.9173 Pos Pos Neg Neg 
2. Am.732 Pos Pos Pos Pos 
3. AL.7238 Pos Pos Neg Neg 
4. W.368 Pos Pos Pos Neg 
5. Am.22 Pos Pos Neg - 
6. A.m.825 Pos Pos Pos Neg 
7. Am.1838 Pos Pos Neg Neg 
8. 1846 Pos  Pos Pos Neg 
9. AN.5285 Pos  Pos  Neg Neg 
10. Am.777 Neg Neg Pos Neg 
11. O.5893 Neg Neg Pos Pos 
TABLE ILLUSTRATES THE IMPROVEMENT OF HEAMOGLOBIN & ESR:
IN PATIENTS: 
S. 
N
O
IP.NO
Haemoglobin                    ESR 
Before 
treat
ment 
After 
treat
ment 
   Before 
treatment 
After 
treatment 
   ½ 
hour 
1 hour ½ 
hour 
1 hour
1 1074 10.8 12.1  18 25 04 12 
2 1103 09.0 09.7  22 46 26 50 
3 1095 09.7 08.2  20 44 08 16 
4 1097 08.2 08.2  08 16 20 40 
5 1631 11.1 13.7  14 30 11 22 
6 1627 09.7 10.2  14 28 6 18 
7 1675 09.6 13.1  18 36 12 24 
8 1195 11.5 12.2  16 32 08 16 
9 1628 13.1 15.5  06 12 06 12 
10 1202 09.4 11.0  18 36 12 24 
11 1216 10.8 12.0  30 60 30 60 
12 1221 08.5 08.0  10 20 06 14 
13 1224 12.0 12.2  26 52 12 24 
14 1205 11.3 13.5  10 22 20 40 
15 1211 08.5 10.5  120 200 70 152 
16 1697 14.0 11.1  16 32 20 40 
17 1622 08.2 09.0  42 90 28 60 
18 1289 09.4 10.0  60 124 45 92 
19 1290 12.6 09.0  02 04 07 14 
20 1212 09.4 09.5 15 30 10 20 
TABLE ILLUSTRATES THE IMPROVEMENT OF HEAMOGLOBIN & ESR:
OUT PATIENTS: 
S.
N
O
OP. 
NO 
Haemoglobin                   ESR 
Before 
treatme
nt 
After 
treatme
nt 
   Before 
treatment 
After 
treatment 
   ½ 
hour 
1
hour 
½
hour 
1
hour
1 AL.9173 12.1 10.6  04 10 06 12 
2 AL.8950 09.2 09.2  15 30 08 16 
3 Am.48 08.7 10.6  10 22 04 08 
4 Am.191 11.2 10.7  12 24 08 16 
5 Am.732 08.7 08.2  12 25 06 12 
6 AL.7238 06.8 08.2  50 100 20 40 
7 Ak.271 09.7 15.0  48 82 04 08 
8 W.368 09.7 10.7  25 50 10 20 
9 Am.22 12.1 10.2  08 16 20 40 
10 Am.777 10.2 10.8  30 60 20 40 
11 Am.825 12.2 11.6  30 60 35 72 
12 Am.1838 10.7 11.0  16 32 08 16 
13 Am.4364 11.0 11.2  22 46 04 08 
14 O.5893 09.7 10.0  15 30 30 60 
15 O.2447 10.6 12.1  24 48 14 28 
16 AN.1856 11.6 11.8  08 16 04 08 
17 1846 12.6 13.0  22 44 12 28 
18 AN.1150 13.6 13.4  14 28 12 24 
19 AN.4353 10.3 11.2  16 32 06 12 
20 AN.5285 14.5 14.5  30 60 20 40 
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FORM I – SELECTION PROFORMA/CASE SHEET
1. OP/ IP No:   __________ 2. BED NO: ____________ 3. SI.NO: _________ 
4. NAME: ________________
5. AGE (YEARS)                              6. GENDER: M                F
7. OCCUPATION: __________________ 
8. INCOME: ________________ 
9. ADDRESS:  _____________________
                         _____________________
                         _____________________ 10. DATE OF ADMISSION:
                         _____________________ 
11. DATE OF DISCHARGE:
12. COMPLAINTS AND DURATION: ____________________________________________ 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
13. HISTORY OF PRESENT ILLNESS: ___________________________________________ 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
14. PAST HISTORY: ___________________________________________________________ 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
15. MENSTRUAL HISTORY (If applicable): _______________________________________ 
______________________________________________________________________________
______________________________________________________________________________
16. Family history:                1. No  2. Yes       If any: ---------------------
17. Socio economical status:  1.Low                2. Middle                3. Upper
18. Habits:
                                                                        1. Yes               2.  No 
1. Betel nut chewer:                                                                           
2. Alcoholic:                                              
3. Smoker:                             
4. Drug addiction:                          
5. Food habits:                    V                    NV                  M   
19. GENERAL EXAMINATION:
1. Body weight (kg):                                                    
2. Temperature (°F):        . 
3. Pulse rate / minute:                                          
4. Heart rate / minute:        
5. Respiratory rate / minute:        
6. Blood pressure (mmHg):                               / /
                                                      1. Yes                   2. No 
7. Pallor:                        
8. Jaundice:                                                         
9. Cyanosis:                                                            
           
10. Lymphadenopathy:                                    
11. Pedal edema:                                                
12. Clubbing:
13. Jugular venous pulsation:         
20. VITAL ORGANS EXAMINATION: 
                                         1. Normal         2. Affected 
1. Heart                                                                    ________________ 
2. Lungs                                                                   ________________ 
3. Brain                                        _______________ 
4. Liver                     ________________ 
5. Kidney                                       ________________
5. Spleen                               ________________
6. Stomach                                   ________________
21. CLINICAL EXAMINATION: 
I. INSPECTION:
1. Attitude:            Normal                         Affected   
                                                                               Present                             Absent 
2. Muscle spasm:                      
3. Muscle wasting of the upper limbs:         
4. If yes,                                        Proximal                                         
                                                      Distal 
5. Joint swelling:                        Major joints
                                                   Minor joints
6. Skin over the joints:                    Normal                                          Reddish 
7. Muscle wasting of the lower limbs: 
8. Nodules:
9. Deformities:  
1. Swan neck deformity:                              1.Yes                                       2. No           
 2. Button hole deformity:                            1. Yes                                      2. No 
3. Z Shaped thumb                                       1. Yes                     2. No 
4. Ulnar deviation of hand                           1. Yes                                      2. No 
5. Ulnar deviation of foot             1. Yes                                       2. No 
6. Hallus valgus                                           1. Yes                                       2. No
II. PALPATION:
Present                             Absent 
1. Tenderness
2. Muscle spasm 
3. Local heat 
 4.  Local Lymphadenopathy:                                            
 5.  Pitting edema:                                                             
6.  Joint stiffness 
7. Nodules:
III. MOVEMENTS:
1. Pain:
 i. Onset: Sudden                                Gradual 
 ii. Early morning stiffness:  Present                                 Absent 
 iii. Nature of pain:                  Mild                   Moderate               Severe
 iv. Aggravating factor – Movement:                              Yes                               No
 v. Relieving factor – Rest:                                               Yes                              No 
 vi. Stiffness Yes                              No
 vii. Tenderness: Yes                              No 
2. Restriction:  Fully                        Partial                No
A. Neck :
B. Shoulder joints:
                   C. Elbow joints:
D. Knee joints: 
                   E. Ankle joints: 
F. Phalangeal joints:  
                  I. Hip joints:
3. Grading of function:
                  Grade I                     Grade II                       Grade III              Grade IV   
4. Excess mobility:                    Yes                                       No
22. CLINICAL FEATURES: 
                                                                                             Yes                            No 
1. Arthritis and soft tissue swelling of three or more  
       joints present for at least 6 weeks   
 2.   Arthritis of hand joints present for at least 6 weeks 
3. Morning stiffness > 1 hr     
4. Symmetrical arthritis      
5. Restricted movements                       
 6.   Spindled appearance of fingers   
7.   Anemia 
 8.   Anorexia 
9.    Low grade fever 
10.  Sub cutaneous nodules in specific places 
11.  Broadening of the forefoot  
23. AUTONOMIC NERVOUS SYSTEM:
                                                                                            Normal                   Affected 
  1. Bladder
   2. Bowel 
24. SIDDHA SYSTEM OF EXAMINATON: 
1. Nilam: 
1. Kurinji                2. Mullai              3. Marutham                  4.Neithal            5. Palai 
2. Kaala Iyalbu: 
   1. Kaarkaalam                              2. Koothirkaalam                          3. Munpanikaalam 
    4. Pinpanikaalam                        5. Ilavenilkaalam                          6. Muduvenirkaalam 
3.Yaakkai:
1. Vali                      2.Azhal                       3. Iyyam 
     4. Valiazhal 5.Valiiyyam                6. Azhalvali    
7. Azhaliyam       8. Iyavali           9. Iyaazhal
4. Gunam:
    1. Sathuva gunam                  2. Rajo gunam             3. Thamo gunam 
5.Poripulangal:
                                      1. Normal        2. Affected 
1. Mei                      
2. Vaai                  
3. Kan             
4. Mookku
5. Sevi                   
                         
                  
6. Kanmenthirium:
1. Kai               
2. Kaal                       
3. Vaai              
4. Eruvai       
5. Karuvaai       
7. Uyir Thathukkal:
 A.Vali:
  1. Normal       2. Affected
1. Pranan                                         
2. Abanan                                         
3. Samanan                                          
4. Udhanan                                         
5. Viyanan                                         
6. Nagan                                         
7. Koorman                                          
8. Kirukaran                                        
9. Devathaththan                                     
10. Thananjeyan                  
B. Azhal: 
                                           1. Normal          2. Affected 
1. Anal pittham             
2. Prasaga pittham             
3. Ranjaga pittham                        
4. Aalosaga pittham              
5. Sathaga pittham  
                  
   C. Iyam: 
                                          1. Normal          2. Affected                                     
1. Avalambagam        
2. Kilethagam                                                          
3. Pothagam                 
4. Tharpagam              
5. Santhigam        
8. Udal Thathukkal: 
                                          1. Normal         2. Affected 
1. Saaram                      
2. Senneer
3. Oon                            
4. Kozhuppu                  
5. Enbu                     
6. Moolai               
7. Suronitham or Sukkilam 
9. Envagai Thervukal:
                                    1. Normal        2. Affected 
1. Naa               
2. Niram           
3. Mozhi                             
4. Vizhi                                                             
              
5.Malam:     1. Normal   2. Affected
i. Niram             
ii.Nurai                   
iii. Thanmai:              Erugal           Elagal 
iv. Kirumi: 
6. Moothiram:
A. Neerkuri:
i. Niram                          ______________________ 
ii. Eadai                                   _____________________
                             
iii. Manam                             ______________________
iv. Nurai                          ______________________
v. Enjal                                 ______________________ 
B.Neikuri:  1.Vatha neer                   2. Pitha neer                    3. Kaba neer      
7. Naadi:
   
8. Sparisam:     1. Mithaveppam         2. Miguveppam                  3. Thatpam 
25. INVESTIGATION:        
A. Blood: 
1. TC (cells /cumm): 
2. DC (%):    1. P                         2.L                    3. E                      4. B                  
  5. M
3. Hb (gms %):                  .
4. ESR (mm/hr):        1. 1/2hr                           2.1hr 
5. Blood Sugar (R) (mg %): 
6. Blood Urea (mg %): 
7. Serum Creatinine (mg %):               
8. Serum Cholesterol (mg %):    
9. Triglycerides (mg %)    
10. Total Bilirubin 
11. Direct Bilirubin 
12. Indirect Bilirubin
10. SGOT
11. SGPT 
12. Alkaline phosphatase 
13. ASO titer                       1. Positive                             2. Negative 
14. CRP                               1. Positive                             2. Negative 
15. RA Factor                      1. Positive                            2. Negative 
16. VDRL                            1.  Positive                            2.  Negative 
B. Urine: 
1. Albumin:   1.   Present                        2.    Absent
2. Sugar:        1.   Present                        2.   Absent
3. Deposit:                           1. Yes          2. No 
i. Pus cells
ii. Epithelial cells     
iii. RBC                
iv. Crystals
C. Motion:
                                      1. Yes         2.No    
i. Ova
ii. Cyst                   
iii. Occult blood      
26. INCLUSION CRITERIA: 
Yes                   No 
1. Age between 25 to 55 yrs   
2. Arthritis of three or more joints                                                           
3. Arthritis of hand joints: 
4. Morning stiffness > 1 hr
5. Symmetrical arthritis 
6. Restricted movements 
7. Sub cutaneous nodules in specific places
 8.   Spindled appearance of fingers 
9. Fever 
10. Anemia 
11. Anorexia
12. Broadening of the forefoot
 13. RA Factor positive 
 27. EXCLUSION CRITERIA: 
                                                                                            Yes                    No 
 1. Cardiac disease 
 2. Hypertension 
 3. Use of narcotics 
 4. Pregnancy 
 5. Lactation 
6. Other joint diseases 
7. History of trauma 
8. Diabetic mellitus 
 9. Neurological disorder 
28. ADMITTED TO TRIAL:                                  1.Yes 2. No
 29. If yes
 1. I.P / O.P        1. I.P 2. O.P
 2. IP/ OP No 
30. Drug issued for OP/ IP patient
        Rasapralaya chenthuram (mg):  
        Thirikaduku chooranam (g): 
        Navanatha siddhar thylam (ml): 
Station:
Date:
Signature of Medical Officer: 
Signature of HOD:
      NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 47. 
 POST GRADUATE DEPARTMENT OF POTHU MARUTHUVAM 
    AN OPEN TRIAL OF SIDDHA DRUGS RASAPRALAYA CHENTHURAM AND                                   
NAVANATHA SIDDHAR THYLAM FOR THE TREATMENT OF UTHIRAVATHA
        SURONITHAM (RHEUMATOID ARTHRITIS) 
                                                            BY 
                                                  Dr.S.SUNITHA 
                                FORM II – ASSESSMENT PROFORMA
1. O.P/ I.P.No:   ________    2. Bed No: ___________           3. S.I.No: ______________ 
4. Name: ________________ 5. Age (years):            6. Sex: M                F       
7. Address: _________________________             8. Occupation: _______________ 
                    _________________________ 
                    _________________________ 
9. Date of admission: 10. Date of discharge:
I. INSPECTION: 
                                                                  Present                                  Absent 
    1. Attitude:
    2. Muscular spasm 
    3. Muscle wasting – proximal 
    4. Muscle wasting – distal 
    5. Major joint swelling 
    6. Minor joint swelling 
    7. Nodules 
    8. Deformity 
    9. Skin over the joints    Normal                               Reddish 
II. PALPATION: 
                                                                       Present                           Absent 
1. Swelling
2. Tenderness 
3. Joint stiffness 
4. Muscle wasting 
5. Local heat 
6. Local lympadenopathy 
7. Pitting edema 
8. Nodules 
III. MOVEMENTS: 
    1. Restriction of joint movements:                Yes                            No 
              i. Neck                                                 Full                         Partial 
              ii. Shoulder joints             Full                         Partial 
              iii. Elbow joints                                   Full                         Partial 
              iv. Knee joints               Full                         Partial 
              v. Ankle joints                                     Full                         Partial 
              vi. Hip joints                Full                         Partial 
              vii. Minor joints                                  Full                          Partial 
2. Excess mobility:                                      Yes                          No 
     3. Pain                                                           Yes                         No 
IV. PAIN: 
     i. Onset                                             Sudden                         Gradual 
     ii. Early morning stiffness             Present                           Absent 
     iii. Nature of pain                           Mild                             Moderate                  Severe 
     iv. Aggravating factor – Movements                        Yes                        No 
     v. Relieving factor – Rest                                         Yes                        No 
     vi. Stiffness                                                               Yes                        No 
     v. Tenderness                                                            Yes                        No 
V. CLINICAL ASSESSMENTS: 
Yes                  No 
1. Arthritis and soft tissue swelling of three or more  
      joints at least 6 weeks 
2. Arthritis of hand joints at least 6 weeks 
3. Morning stiffness > 1 hr 
4. Symmetrical arthritis 
5. Restricted movements 
6. Spindled appearance of fingers 
7. Rheumatoid nodules 
8.  Fever 
9. Anemia 
10. Anorexia
11. Broadening of forefoot 
8. RESULT: 
1. Good improvement              2. Mild improvement                 3. Moderate improvement                                   
4. No improvement 
9. INVESTIGATION:    
A. BLOOD: 
1. TC (cells /cumm): 
2. DC (%):    1. P                         2.L                    3. E                      4. B                  
          5. M
3. Hb (gms %): 
4. ESR (mm/hr):        1. 1/2hr                           2.1hr 
5. Blood Sugar (R) (mg %): 
6. Blood Urea (mg %): 
7. Serum Creatinine (mg %):               
8. Serum Cholesterol (mg %):    
9. Triglycerides (mg %)     
10. Serum total billirubin 
11. Direct billirubin 
12. Indirect billirubin 
13. SGOT
14. SGPT 
15. Alkaline phosphatase 
16. Total protein 
17. Albumin 
18. Globulin 
19. CRP                               1. Positive                            2. Negative 
20. RA Factor                      1. Positive                            2. Negative 
B. URINE: 
1. Albumin:      Present                        Nil 
2. Sugar:          Present                         Nil
3. Deposit:                           1. Yes          2. No 
i. Pus cells
ii. Epithelial cells     
iii. RBC                
iv. Crystals
13. Date: _____________________ 
14. Station: __________________             15. Signature of Doctor: ___________________ 
16. Signature of HOD: ____________________ 
LAB INVESTIGATIONS CHART 
S.NO INVESTIGATIONS DATE OF 
ADMISSION 
DATE OF 
DISCHARGE 
I.
1.
      2. 
      3. 
      4. 
      5. 
       6. 
       7. 
       8. 
       9. 
      10. 
      11. 
      12. 
      13. 
      14. 
      15.
      16. 
      17. 
      18. 
      19. 
      20. 
      21. 
      22. 
BLOOD:
TC (Cells/ Cumm) 
DC (%) 
ESR (mm): ½ hr & 1 hr 
Hb (gm %) 
Blood sugar (mg %) 
    Fasting: 
    Postprandial: 
Serum cholesterol 
Serum Trigliceride 
Serum Total Bilirubin 
Serum Indirect Bilirubin 
Serum Direct Bilirubin 
Alkaline phosphatase 
SGOT 
SGPT 
Serum Creatinine 
Blood Urea 
Total Protein 
Albumin 
Globulin
Calcium 
Special Investigations: 
ASO Titre 
RA Factor (Dilution) 
CRP 
   II. URINE: 
Albumin 
Sugar
Deposits: 
    Epithelial  cells: 
    Pus cells 
    Red blood cells: 
    Cast/ Crystals: 
   III. NEIKURI: 
N
A
TI
O
N
A
L 
IN
ST
IT
U
T
E 
O
F 
SI
D
D
H
A
 A
Y
O
D
H
ID
O
SS
 P
A
N
D
ID
H
A
R
 H
O
SP
IT
A
L
, C
H
E
N
N
A
I –
 4
7.
A
N
 O
PE
N
 T
R
IA
L
 O
F 
R
A
SA
PR
A
LA
Y
A
 C
H
EN
TH
U
R
A
M
 A
N
D
 N
A
V
A
N
A
T
H
A
 S
ID
D
H
A
R
 T
H
Y
LA
M
 F
O
R
 T
H
E 
TR
E
A
TM
EN
T 
O
F 
U
TH
IR
A
V
A
TH
A
 
SU
R
O
N
IT
H
A
M
 (R
H
EU
M
A
T
O
ID
 A
R
TH
R
IT
IS
)
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  F
O
R
M
 II
I –
 P
A
T
IE
N
T
S 
D
A
IL
Y
 P
R
O
G
R
E
SS
 C
H
A
R
T
1.
 O
P/
 IP
 N
O
:  
    
   
   
   
   
   
2.
 B
ed
 n
o:
   
   
   
   
   
 3
. S
l. 
N
o:
   
   
   
   
   
   
4.
 N
am
e:
   
    
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 5
. A
ge
: 
 6
. G
en
de
r:
 
7.
 D
at
e 
of
 A
dm
is
si
on
:  
   
   
   
   
   
   
   
   
   
   
   
 8
. D
at
e 
of
 P
ur
ga
tio
n:
   
   
   
   
   
   
   
   
   
   
   
   
  9
. D
at
e 
of
 D
is
ch
ar
ge
:  
   
   
   
   
   
  
Sl
. 
N
o 
D
at
e 
Pa
in
 in
 
sm
al
le
r 
jts
 
Pa
in
 
in
 
m
aj
or
 
jts
 
Sw
el
lin
g 
in
 
sm
al
le
r 
jt
s 
Sw
el
lin
g 
in
 
m
aj
or
 jt
s 
Sy
m
m
et
r
ic
al
 
in
vo
lv
em
en
t 
R
es
tr
ic
te
d 
m
ov
em
en
t 
St
iff
ne
ss
 
+ 
af
te
r 
re
st
 
M
or
ni
ng
 
st
iff
ne
ss
 
L
os
s o
f 
ap
pe
tit
e 
T
en
de
r
ne
ss
 
sle
ep
le
ss
ne
ss
 
N
aa
di
 
Sp
ar
is
m
M
al
am
 
N
ei
ku
ri
 
1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 2
 
   
  L
ec
tu
ru
er
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
H
O
D
 
- 2
 - 
Sl
. 
N
o 
D
at
e 
Pa
in
 
in
 
sm
al
le
r 
jt
s 
Pa
in
 in
 
m
aj
ot
 jt
 
Sw
el
lin
g 
in
 
sm
al
le
r 
jt 
Sw
el
lin
g 
in
 m
aj
or
 
jt 
Sy
m
m
et
ri
c
al
 
in
vo
lv
em
en
t
R
es
tr
ic
te
d 
m
ov
em
en
t 
St
iff
ne
ss
 +
 
af
te
r 
re
st
 
m
or
ni
ng
 
St
iff
ne
ss
 
L
os
s o
f 
ap
pe
tit
e 
Te
nd
er
n
es
s
Sl
ee
pl
es
ne
ss
 
N
aa
di
 
Sp
ar
is
m
M
al
am
 
N
ei
ku
ri
 
9.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  L
ec
tu
ru
er
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  H
O
D
 
A PILOT OPEN CLINICAL TRIAL OF SIDDHA DRUGS RASAPRALAYA 
CHENTHURAM AND NAVANATHA SIDDHAR THYLAM IN THE TREATMENT 
OF UTHIRAVATHA SURONITHAM (RHEUMATOID ARTHRITIS)
CONSENT FORM 
Certificate by Investigator 
          I certify that I have disclosed all details about the study in the terms readily understood by 
the patient. 
Date: ______________                                                    Signature: ______________ 
                                                                                          Name: _________________ 
                                                     
Consent of Patient
          I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial, and the nature of drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my body functions. 
          I am aware of my right to opt out of the trial at any time during the course of the trial 
without having to give the reasons for doing so. 
         I, exercising my free power of choice, hereby give my consent to be included as a subject 
in the clinical trial of Rasapralaya chenthuram and Navanatha siddhar thylam for the 
management of Uthiravatha suronitham (Rheumatoid arthritis). 
Date:  ____________________                                Signature_____________________ 
                                                                                  Name: ________________________ 
Date:  _____________________                              Signature of witness:  ___________    
                                                                                                               
                                                                                   Name:  ______________________ 
                 
                                                                                   Relationship: __________________ 
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